Global Clinical Development - General Medicine  
AIN457/Secukinumab 
Clinical Trial Protocol CAIN457H2315 / [STUDY_ID_REMOVED]
A randomized, double -blind, placebo- controlled multicenter 
study o f secukinumab 15 0 mg in patients w ith active non -
radiographic axial spondyloarthritis to evaluate the safety, 
tolerability and efficacy up to 2 years, followed by [CONTACT_884141] 150 m g or 3 00 mg randomized 
dose escalation for up to another 2 years 
Document type:  Clinical Trial Protocol  
EUDRACT number:  2015 -001106 -33 
Version number:  v02 Clean  
Development phase:  III 
Release date:  11-Jul-[ADDRESS_1236736] of abbreviations ............................................................................................................ 7 
Glossary of terms  ............................................................................................................... 11 
Protocol summary .............................................................................................................. 15 
1 Introduction ....................................................................................................................... 22 
1.1 Background ............................................................................................................ 22 
1.2 Purpose .................................................................................................................. 23 
2 Study objectives ................................................................................................................. 24 
2.1 Primary objective(s)  ............................................................................................... 24 
2.2 Secondary objectives ............................................................................................. 24 
  26 
3 Investigational plan  ........................................................................................................... 28 
3.1 Study design........................................................................................................... 28 
3.2 Rationale of study design ....................................................................................... 31 
3.3 Rationale of dose/regimen, route of administration and duration of treatment ..... 32 
3.4 Rationale for choice of comparator ....................................................................... 33 
3.5 Purpose and timing of interim analyses/design adaptations .................................. [ADDRESS_1236737]-study tr eatment  .......................................... 52 
5.5.14  Early study termination  ......................................................................... 52 
6 Visit schedule and assessments  ......................................................................................... 53 
6.1 Information to be collected on screening failures .................................................. 61 
6.2 Patient demographics/other baseline characteristics  ............................................. 61 
6.3 Treatment exposure and compliance  ..................................................................... 61 
6.4 Efficacy  .................................................................................................................. 61 
6.4.1  Assessment of SpondyloArthritis International Society criteria (ASAS)  .................................................................................................. 62
 
6.4.2  Patient’s global assessment of disease activity (VAS)  ......................... 63 
6.4.3  Patient’s assessment of back pain intensity (VAS)  ............................... 63 
6.4.4  Bath Ankylosing Spondylitis Functional Index (BASFI) ..................... 63 
6.4.5  Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ........ 63 
  64 
 
 64 
6.4.8  High sensitivity C -reactive protein (hsCRP)  ......................................... [ADDRESS_1236738] X -ray or MRI .............................................................................. 67 
6.5.3  Physical examination  ............................................................................ 67 
6.5.4  Vital signs .............................................................................................. 68 
6.5.5  Height and weight ................................................................................. 68 
6.5.6  Laboratory evaluations  .......................................................................... 68 

[COMPANY_001]  Confidential  Page 4 
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
   69 
6.5.8  Electrocardiogram (ECG)  ..................................................................... 69 
6.5.9  Pregnancy and assessments of fertility  ................................................. 69 
6.5.10  Local tolerability (Injection site reactions)  ........................................... 70 
6.5.11  Tolerability of secuki numab  ................................................................. 70 
6.5.12  Appropriateness of safety measurements  .............................................. 70 
6.6 Other assessments  .................................................................................................. 70 
6.6.1  Health -related Quality of Life and Patient Reported Outcome  ............. 70 
  73 
6.6.3  HLA-B27............................................................................................... 73 
  73 
  74 
  74 
7 Safety monitoring .............................................................................................................. 75 
7.1 Adverse events  ....................................................................................................... 75 
7.2 Serious adverse events  ........................................................................................... 77 
7.2.1  Definition of SAE ................................................................................. 77 
7.2.2  SAE reporting........................................................................................ 78 
7.3 Liver safety monitoring ......................................................................................... 79 
7.4 Renal safety monitoring ......................................................................................... 79 
7.5 Pregnancy reporting ............................................................................................... 79 
8 Data review and database management  ............................................................................. 79 
8.1 Site monitoring  ...................................................................................................... 80 
8.2 Data collection  ....................................................................................................... 80 
8.3 Database management and quality control  ............................................................ 80 
8.4 Data Monitoring Committee  .................................................................................. 81 
8.5 Adjudication Committee  ........................................................................................ 81 
9 Data analysis  ...................................................................................................................... 82 
9.1 Analysis sets .......................................................................................................... 82 
9.2 Patient demographics and other baseline characteristics  ....................................... 82 
9.3 Treatments  ............................................................................................................. 83 
9.4 Analysis of the primary variable(s) ....................................................................... 84 
9.4.1  Variable(s)  ............................................................................................. 84 
9.4.2  Statistical model, hypothesis, and method of analysis .......................... 84 
9.4.3  Handling of missing values/censoring/discontinuations ....................... 85 
9.4.4  Supportive analyses ............................................................................... 86 

[COMPANY_001]  Confidential  Page 5 
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 9.5 Analysis of secondary variables ............................................................................ 86 
9.5.1  Secondary efficacy variables ................................................................. 86 
  96 
9.5.3  Safety variables  ..................................................................................... 98 
  99 
  101 
  101 
  102 
  102 
9.6 Interim analyses  ................................................................................................... 102 
9.7 Sample size calculation  ........................................................................................ 102 
9.8 Power for analysis of secondary variables ........................................................... 104 
9.9 Analysis of extension phase................................................................................. 106 
10 Ethical considerations ...................................................................................................... 106 
10.1  Regulatory and ethical compliance ...................................................................... 106 
10.2  Informed consent procedures ............................................................................... 107 
10.3  Responsibilities of the investigator and IRB/IEC ................................................ 107 
10.4  Publication of study protocol and results............................................................. 108 
11 Protocol adherence  .......................................................................................................... 108 
11.1  Protocol Amendments ......................................................................................... 108 
12 References  ....................................................................................................................... 108 
13 Appendices ...................................................................................................................... 111 
13.1  Appendix 1: Clinically notable laboratory values ............................................... 111 
  112 
13.3  Appendix 3: Modified [LOCATION_001] criteria ........................................................... 114 
13.4  Appendix 4: ASAS Classification Criteria for Axial Spondyloarthritis (axSpA) ................................................................................................................ 115
 
13.5  Appendix 5: Assessment of SpondyloArthritis International Society criteria (ASAS)  ................................................................................................................ 115
 
13.5.1  Bath Ankylosing Spondylitis Functional Index (BASFI) ................... 115 
13.5.2  Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ...... 116 
  116 
13.6  Appendix 6: Definition of Sacroiliitis on MRI .................................................... 117 
  118 
13.8  Appendix 8: Guidelines for administering the questionnaires for patient reported outcomes ................................................................................................ [ADDRESS_1236739] of tables 
Table 5 -1 Prohibited treatment .............................................................................. 49 
Table 6 -1 Assessment schedule: Core phase  ......................................................... 54 
Table 6 -2 Assessment schedule: Extension phase ................................................. 59 
Table 9 -1 Summary of power for binary primary endpoint ................................ 103 
Table 9 -2 Summary of power for binary primary endpoint  ................................ 104 
Table 9 -3 Power for binary secondary variables at Week 16 .............................. 104 
Table 9 -4 Power for continuous secondary variables at Week 16 ...................... 104 
Table 9 -5 Power for binary secondary variables ................................................. 105 
Table 9 -6 Power for continuous secondary variables .......................................... 105 
Table 13 -1 Safety Analyses: Expanded Limits and Notable Criteria  .................... [ADDRESS_1236740] of abbreviations  
AE adverse event  
ALT/SGPT  alanine aminotransferase/serum glutamic pyruvic transaminase  
ANCOVA  analysis of covariance  
AS Ankylosing Spondylitis 
ASAS  Ankylosing SpondyloArthritis International Society 
ASDAS  Ankylosing Spondylitis Disease Activity Score 
ASQoL  Ankylosing Spondylitis Quality of Life  
AST/SGOT  aspartate aminotransferase/serum glutamic oxaloacetic transaminase  
axSpA Axial Spondyloarthritis 
BASDAI  Bath Ankylosing Spondylitis Disease Activity Index  
BASFI  Bath Ankylosing Spondylitis Functional Index 
BASMI  Bath Ankylosing Spondylitis Metrology Index 
BSL baseline  
BOCF  Baseline observation carried forward 
CFR  Code of Federal Regulation  
COX Cyclooxygenase CPO  country pharma organization 
(e)CRF  electronic case report form  
CRO  contract research o rganization  
CRP (hsCRP)  (high sensitivity) C- reactive protein  
CRP+  Patient with a CRP value above the ULN at screening  
DMARD disease modifying anti- rheumatic drug  
DNA  deoxyribonucleic acid  
DS&E  Drug Safety and Epi[INVESTIGATOR_884124]- tetraacetic acid  
EEA  European Economic Area 
ELISA  enzyme-linked immuno sorbent assay 
EMA/EMEA  European Medical Agency 
  

[COMPANY_001]  Confidential  Page 8 
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 EU European Union 
eSource  electronic Source Data Capturing Tool 
  
  
FDA  Food and Drug Administration 
FAS full analysis set 
GCP  good clinical practice 
GDPR  General Data Protection Regulation 
GGT  gamma -glutamyl- transferase  
hCG human chorionic gonadotropin 
HIV human immunodeficiency virus 
HLA  human leukocyte antigen 
IB Investigator’s Brochure 
ICF informed consent form 
ICH International Conference on Harmonization of Technical Requirem ents for 
Registration of Pharmaceuticals for Human Use 
IEC/EC  Independent Ethics Committee 
IFU Instructions for Use 
IQS Integrated Quantitive Sciences  
IL interleukin  
IN Investigator Notification  
IRB Institutional Review Board  
IRT interactive response techn ology 
i.v. intravenous(ly) 
LLN  lower limit of normal 
LLOQ  lower limit of quantification  
LOCF  last observation carried forward 
MAR  missing at random 
  
MedDRA  Medical Dictionary for Regulatory Activities  
MMRM  mixed -effects model repeated measures  
MRI  magnetic resonance imaging  

[COMPANY_001]  Confidential  Page 9 
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 MRI+  Patient with a MRI considered positive for sacroiliitis at screening  
  
MTX  methotrexate  
nr-axSpA non-radiographic axial spondyloarthritis 
NSAID  non- steroidal anti-inflammatory drug 
PCS Physical Component Summary  
  
PFS pre-filled syringe 
  
  
PoC proof of concept 
[COMPANY_003] purified protein derivative 
PRN  pro re nata  
PRO  patient reported outcome 
PsA psoriatic arthritis  
OC/RDC  Oracle clinical/remote data capture  
QoL quality of life  
RA rheumatoid arthritis  
RoW Rest of World  
SAE  serious adverse event  
SCR  screening  
s.c. subcutaneous(ly) 
SD Standard Deviation 
SF-36 Short Form-36 
SIJ/SI Joint Sacroiliac Joint  
SpA Spondyloarthritis 
STIR  Short tau inversion recovery 
S[LOCATION_003]R  suspected unexpected serious adverse reaction  
t.i.d. ter in die , three times a day  
TB Tuberculosis 
TNF/TNFα  Tumor Necrosis Factor 
TNF -IR TNFα i nhibitor inadequate responder 

[COMPANY_001]  Confidential  Page [ADDRESS_1236741]  upper limit of normal 
[LOCATION_003] [LOCATION_002] of America  
VAS  visual analog scale  
WBC  White Blood Cell 
  

[COMPANY_001]  Confidential  Page 11  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 Glossary of terms 
 
Assessment  A procedure used to generate data required by [CONTACT_263593]/time of patient entry into the study at which informed consent 
must be obtained (i.e. prior to starting any of the procedures 
described in the protocol)  
Epoch  A portion of the study which serves a specific purpose. Typi[INVESTIGATOR_540294]: screening  / wash -out, treatment, and follow -up 
Investigational drug  The drug whose properties are being tested in the study; this 
definition is consistent with US CFR 21 Section 312.3 and is 
synonymous with “investigational new drug” or “investigational 
medicinal product.”  
Investigational treatment  All investigational drug(s) whose properties are being tested in the 
study as well as their associated treatment controls.  
This includes  any placebos, any active controls,  as well as approved 
drugs used outside of their indication/approved dosage or tested in a fixed combination.  
Investigational treatment generally does not include protocol -
specified concomitant background therapi[INVESTIGATOR_884125] t hat indication  
Medication number  A unique identifier on the label of each investigational/study drug 
package in studies that dispense medication using an IRT system  
Protocol  A written account of all the procedures to be followed in a trial, which describes all the administrative, documentation, analytical and 
clinical processes used in the trial.  
Part  A single component of a study which contains different objectives or 
populations within that single study. Common parts within a study 
are: a single dose part and a multiple dose part, or a part in patients 
with established disease and in those with newly -diagnosed 
disease.  
Period  A subdivision of a cross -over study  
Premature subject/patient 
withdrawal  Point/time when the patient exits from the study prior to the planned completion of all study treatment administration and/or assessments; at this time all study treatment administration is discontinued and no further assessments are planned, unless the 
patient will be followed for progression and/or survival  
Randomization number  A unique identifier assigned to each randomized patient, 
corresponding to a specific treatment arm assignment  
Study drug/ treatment  Any single drug or combination of drugs administered to the patient as part of the required study procedures; includes investigational 
drug (s), active drug run -ins or background therapy  
Study/investigational 
treatment discontinuation  Point/time when patient permanently stops taking study/investigational treatment  for any reason; may or may not also 
be the point/time of premature patient withdrawal  
Subject Number  A number assigned to each patient who enrolls into the study  
Variable  A measured value or assessed response that is determined in 
specific assessments and used in data analysis to evaluate the drug 
being tested in the study  
[COMPANY_001]  Confidential  Page 12  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 Amendment 1  
Amendment rationale 
This protocol amendment is issued for the following reasons: 
Based on a meta -analysis from unpublished studies with secukinumab, the powering of the 
study was re -evaluated. This new evaluation triggered a changed order in the testing hierarchy 
as well as adjustments of the population for the primary endpoint to TNF naïve patients only. 
These changes ensure that the placebo population will remain the same size and the randomization will continue to be 2:[ADDRESS_1236742] for HLA -B27 is moved from the baseline visit  to screening visit 2 to facilitate the 
screening process for the sites . 
The maximally allowed proportion of TNF -IR patients was changed from 30% to 20% , based 
on the aforementioned meta -analysis from unpublished studies with secukinumab and due to 
the changes in the statistical hierarchy , as well as the unavailability of response rates for 
biologics in TNF -IR patients to validate power calculation assumptions . Additionally, due to 
the long wash out required for some TNF -IR patients, enrolment of TNF -IR patients will end 
two months prior to the projected end of the screening period. Historic MRI will be accepted, if taken within [ADDRESS_1236743]  the data for the study in 
OC/RDC in all countries. This process change will be reflected in the respect ive sections where 
eSource is mentioned.  None of the changes made are due to evidence- based safety concerns . 
Changes to the protocol 
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font deletions and red underlined for insertions. 
The wording of various sub- sections to “Study objectives” (Section 2) , “Investigational Plan” 
(Section 3), “Population” (Section 4), “Treatment” (Section 5), “Visit schedule and 
assessments” (Section 6), “Safety Monitoring” (Section 7), “Data review and database management ” (Section 8), and “Data analysis” (Section 9)  have been amended to reflect the 
rationale given above. 
[COMPANY_001]  Confidential  Page [ADDRESS_1236744] 
(IRBs)/Independent Ethics Committee (IECs) and  Health Authorities.  
The changes described in th is amended protocol require IRB/IEC  approval prior to 
implementation.  
  
[COMPANY_001]  Confidential  Page [ADDRESS_1236745] patient has reached 
the end of the 16- week dose escalation treatment period. B efore a patient will be able to 
participate in this additional 16 -week treatment escalation period, a new  informed consent form 
(ICF) has to be signed.  
The order of the secondary endpoints of the analysis plan B in the hierarchy was updated to 
elevate several Load regimen endpoints to reflect their clinical relevance.  
The wording for the Withdrawal of Consent  section  was updated to align with the Europea n 
Economic Area (EEA) General Data Protection Regulation (GDPR) requirements.  
Changes to the protocol 
Changes to specific sections of the protocol are shown in the track changes version of the protocol using strike through red font deletions and red underlined for insertions. 
The wording of various sub- sections to  “Introduction” (Section 1),  “Study objectives” (Section 
2), “Investigational Plan” (Section 3), “Population” (Section 4), “Treatment” (Section 5), “Visit schedule and assessments” (Section 6), “Data analysis” (Section 9) , “References” (Section 12), 
and “Appendices” (Section 13) have been amended to reflect the rationale given above.  
Additionally, this protocol amendment includes the correction of typographical and formatting errors and minor editorial changes for increased clarity of the text. Consequently, a small number of changes were implemented throughout the protocol. 
None of the changes described in this amended protocol are made due to newly emerged safety 
considerations.  
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
The changes described in this amended protocol require IRB/IEC approval prior to implementation.  
[COMPANY_001]  Confidential  Page 15  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 Protocol summary  
Protocol number  CAIN457H2315  
Title A randomized, double- blind, placebo- controlled multicenter study of 
secukinumab 150 mg in patients with active non- radiographic axial 
spondyloarthritis  to evaluate the safety, tolerability and efficacy up to 2 
years , followed by [CONTACT_884142] 150 mg or 300 mg 
randomized dose escalation for up to another 2 years  
Brief title  
 Study of efficacy and safety of secukinumab in patients with non-
radiographic axial spondyloarthritis   
Sponsor and Clinical Phase  [COMPANY_001]  
Phase III  
Investigation type  Drug; Biologic  
Study type  Interventional  
Purpose and rationale  To demonstrate the clinical efficacy, safety and tolerability of secukinumab compared to placebo in patients with nr -axSpA at Week 
16 as well as Week 52 and long term efficacy and safety up to Week 
104 followed by [CONTACT_410497]  16-week randomized dose escalation 
treatment period and a contin uous treatment period for up to Week 208.  
Primary Objective(s)  ANALYSIS PLAN A - EU and other non- [LOCATION_003] Regions  
To demonstrate superiority of secukinumab 150 mg s.c. with loading over placebo at Week 16, based on the proportion of TNF naïve patients 
achieving an ASAS40 response (Assessment of SpondyloArthritis International Society criteria).  
ANALYSIS PLAN B - [LOCATION_003]  
To demonstrate superiority of secukinumab 150 mg s.c. without loading over placebo at Week 52, based on the proportion of  TNF naïve patients 
achieving an ASAS40 response (Assessment of SpondyloArthritis 
International Society criteria)  
Secondary Obj ectives  
 ANALYSIS PLAN A  
1. To demonstrate that the efficacy of secukinumab 150 mg s.c., with or without loading, at Week 16 is superior to placebo based on the proportion of all patients achieving an ASAS40 response 
2. To demonstrate that the efficacy of secukinumab 150 mg s.c., without loading, at Week 16 is superior to placebo based on the proportion of TNF naive patients achieving an ASAS40 response  
3. To demonstrate that the efficacy of secukinumab 150 mg s.c. with or without loading at Week 16 is superior to placebo based on the proportion of patients meeting the ASAS 5/6 response criteria  
4. To demonstrate that the efficacy of secukinumab 150 mg s.c. with or without loading at Week 16 is superior to placebo based on the change from baseline in total Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)  
5. To demonstrate that the efficacy of secukinumab 150 mg s.c. with or without loading at Week 16 is superior to placebo based on the 
proportion of patients achieving BASDAI 50  
[COMPANY_001]  Confidential  Page 16  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 6. To demonstrate that the efficacy of secukinumab 150 mg s.c., with 
or without loading, at Week 16 is superior to placebo based on the 
change from baseline of high sensitivity C -Reactive Protein (hsCRP)  
7. To demonstrate that the efficacy of secukinumab 150 mg s.c. with or 
without loading at Week 16 is superior to placebo based on the change from baseline in total Bath Ankylosing Spondylitis Functional Index (BASFI)  
8. To demonstrate that the efficacy of secukinumab 150 mg s.c. with or without loading at Week 16 is superior to placebo based on the change from screening in sacroiliac ( SI) joint edema on MRI  
9. To demonstrate that the efficacy of secukinumab 150 mg s.c., with or without loading, at Week 16 is superior to placebo based on the proportion of subjects achieving an ASAS20 response  
10. To demonstrate that the efficacy of secukinumab 150 mg s.c. with or without loading at Week 16 is superior to placebo based on the change from baseline in Short Form- 36 Physical Component 
Summary (SF -36 PCS)  
11. To demonstrate that the efficacy of secukinumab 150 mg s.c., with 
or without loading, at Week 16 is superior to placebo based on the 
change from baseline in Ankylosing Spondylitis Quality of Life 
(ASQoL)  scores  
12. To demonstrate that the efficacy of secukinumab 150 mg s.c. with or  
without loading at Week 16 is superior to placebo based on the proportion of patients achieving ASAS partial remission 
13. Overall safety and tolerability of secukinumab  
 
ANALYSIS PLAN B  
1. To demonstrate that the efficacy of secukinumab 150 mg s.c., with 
or wit hout loading, at Week 52 is superior to placebo based on the 
proportion of all patients achieving an ASAS40 response 
2. To demonstrate that the efficacy of secukinumab 150 mg s.c., with loading, at Week 52 is superior to placebo based on the proportion of TNF  naive patients achieving an ASAS40 response  
3. To demonstrate that the efficacy of secukinumab 150 mg s.c., with or without loading, at Week 16 is superior to placebo based on the proportion of subjects achieving an ASAS40 response  
4. To demonstrate that the efficacy of secukinumab 150 mg s.c. with or without loading at Week 16 is superior to placebo based on the 
change from baseline in total Bath Ankylosing Spondylitis Disease 
Activity Index (BASDAI)  
5. To demonstrate that the efficacy of secukinumab 150 mg s.c. w ith 
or without loading at Week 16 is superior to placebo based on the proportion of patients achieving BASDAI 50  
6. To demonstrate that the efficacy of secukinumab 150 mg s.c. with or without loading at Week 52 is superior to placebo based on the proportion of patients achieving BASDAI 50  
7. To demonstrate that the efficacy of secukinumab 150 mg s.c., with or without loading, at Week 16 is superior to placebo based on the change from baseline of high sensitivity C -Reactive Protein 
(hsCRP)  
8. To demonstrate that the efficacy of secukinumab 150 mg s.c. with 
or without loading at Week 16 is superior to placebo based on the 
[COMPANY_001]  Confidential  Page 17  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 change from baseline in Short Form -36 Physical Component 
Summary (SF -36 PCS)  
To demonstrate that the efficacy of secukinumab 150 mg s.c., with or 
without loading, at Week 16 is superior to placebo based on the change 
from baseline in Ankylosing Spondylitis Quality of Life (ASQoL)  scores  
9. To demonstrate that the efficacy of secukinumab 150 mg s.c. with 
or without loading at Week 16 is superior to placebo based on the 
proportion of patients meeting the ASAS 5/6 response criteria  
10. To demonstrate that the efficacy of secukinumab 150 mg s.c., with or without loading, at Week 16 is superior to placebo based on the proportion of subjects achieving an ASAS20 response  
11. To demonstrate that the efficacy of secukinumab 150 mg s.c. with or without loading at Week 16 is superior to placebo based on the change from baseline in total Bath Ankylosing Spondylitis Functional Index (BASFI)  
12. To demonstrate that the efficacy of secukinumab 150 mg s.c. with or without loading at Week 16 is superior to placebo based on the change from screening in SI joint edema on MRI  
13. To demonstrate that the efficacy of secukinumab 150 mg s.c. with or without loading at Week 52 is superior to placebo based on the proportion of patients achieving Ankylosing Spondylitis Disease Activity Score (ASDAS) -C-Reactive Protein (CRP) inactive disease 
as defined by [CONTACT_884143] < 1.3  
14. To demonstrate that the efficacy of secukinumab 150 mg s.c. with or without loading at Week 52 is superior to placebo based on the change from screening in SI joint edema on MRI  
15. To demonstrate that the efficacy of secukinumab 150 mg s.c. with or without loading at Week 52 is superior to placebo based on the change from baseline in Ank ylosing Spondylitis Quality of Life 
(ASQoL)  scores  
16. Overall safety and tolerability of secukinumab  
Study design  This is a randomized, double -blind, placebo -controlled study  
Population  The study population will consist of 555 male and female patients (≥ 18 
years old at the time of consent) fulfilling the ASAS classification criteria for axSpA, with no radiographic evidence of changes in the sacroiliac 
joints that would meet the modified [LOCATION_001] criteria for AS.  
Inclusion criteria  • Patient must be able to understand and communicate with the investigator and comply with the requirements of the study and must give a written, signed and dated informed consent before any study assessment is p erformed  
• Male or non- pregnant, non- nursing female patients at least 18 
years of age  
• Diagnosis of axSpA according to ASAS axSpA criteria:  
• Inflammatory back pain for at least 6 months  
• Onset before 45 years of age  
• Sacroiliitis on MRI with ≥ 1 SpA feature OR HLA -B-27 
positive with ≥2 SpA features  
• Objective signs of inflammation at screening , evident by  
[CONTACT_884144] > ULN (as defined by [CONTACT_6626])  
[COMPANY_001]  Confidential  Page 18  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 • Active axSpA as assessed by [CONTACT_884145] ≥ 4 cm (0 -10 cm) 
at baseline  
• Spi[INVESTIGATOR_90150] #2 ≥ 4 cm (0- 10 
cm) at baseline  
• Total back pain as measured by [CONTACT_8298] ≥ 40 mm (0- 100 mm) at 
baseline  
• Patients should have been on at least [ADDRESS_1236746] 4 weeks in total prior to randomization with an inadequate response or failure to 
respond, or less if therapy had to be withdrawn due to 
intolerance, toxicity or contraindications  
• Patients who are regularly taking NSAIDs (including  COX -2 
inhibitors) as  part of their axSpA therapy are required to be on 
a stable dose for at least 2 weeks before randomization 
• Patients who have been on a TNFα inhibitor (not more than 
one) must have experienced an inadequate response to previous or current treatment given at  an approved dose for at 
least [ADDRESS_1236747] one administration of an anti- TNFα agent  
• Patients who have previously been on a TNFα inhibitor will be allowed entry into study after an appropriate wash- out period 
prior to randomization:  
• 4 weeks for Enbrel® (etanercept) – with a terminal half -life 
of 102 ± 30 hours (s.c. route)  
• 8 weeks for Remicade® (infliximab) – with a terminal half -
life of 8.0- 9.5 days (i.v. infusion)  
• 10 weeks for Humira® (adalimumab) – w ith a terminal 
half-life of 10- 20 days (average 2 weeks) (s.c. route)  
• 10 weeks for Simponi® (golimumab) – with a terminal half -
life of 11- 14 days  
• 10 weeks for Cimzia® (certolizumab) – with a terminal 
half-life of 14 days   
• Patients taking MTX (≤ 25 mg/week)  or sulfasalazine (≤ 3 
g/day) are allowed to continue their medication and must have taken it for at least [ADDRESS_1236748] 4 weeks prior to randomization  
• Patients on MTX must be on stable folic acid supplementation before randomization  
• Patients who are on a DMARD other than MTX or sulfasalazine must discontinue the DMARD 4 weeks prior to randomization, except for leflunomide, which has to be discontinued for 8 weeks prior to randomization unless a cho lestyramine washout 
has been performed  
• Patients taking systemic corticosteroids have to be on a stable dose of ≤ 10 mg/day prednisone or equivalent for at least 2 weeks before randomization 
For extension phase:  
• Written informed consent must be obtained before any assessment is performed.  
• Patients who have completed the full study treatment period 
(104 weeks) in the core phase on study treatment.  
[COMPANY_001]  Confidential  Page 19  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
  
Exclusion criteria  • Patients with radiographic evidence for sacroiliitis, grade  ≥ 2  
bilaterally or grade ≥ 3 unilaterally (radiological criterion 
according to the modified [LOCATION_001] diagnostic criteria for AS) as assessed by [CONTACT_39582]  
• Inability or unwillingness to undergo MRI (e.g., patients with 
pacemakers, aneurysm clips or metal fragments / foreign 
object s in the eyes, skin or body)  
• Chest X -ray or MRI with evidence of ongoing infectious or 
malignant process, obtained within 3 months of screening and evaluated by a qualified physician  
• Patients taking high potency opi[INVESTIGATOR_2467] (e.g., methadone, hydromor phone, morphine)  
• Previous exposure to secukinumab or any other biologic drug directly targeting IL- 17 or IL -17 receptor  
• Use of any investigational drug and/or devices within 4 weeks of randomization, or a period of 5 half -lives of the 
investigational drug, whichever is longer  
• History of hypersensitivity to the study drug or its excipi[INVESTIGATOR_201021]  
• Any therapy by [CONTACT_90169]- articular injections (e.g., corticosteroid) 
within 4 weeks before randomization  
• Any intramuscular corticosteroid injection within 2 weeks before randomization  
• Patients previously treated with any biological immunomodulating agents, except those targeting TNFα  
• Patients who have taken more than one anti -TNFα agent  
• Previous treatment with any cel l-depleting therapi[INVESTIGATOR_250307] -CD20 or investigational agents (e.g., 
CAMPATH, anti -CD4, anti -CD5, anti -CD3, anti -CD19)  
• Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test  
• Women of child- bearing potential, defined as all women 
physiologically capable of becoming pregnant, unless they are using effective methods of contraception during entire study  or longer if required by [CONTACT_109016].  
• Active ongoing inflammatory diseases other than axSpA that 
might confound the evaluation of the benefit of secukinumab 
therapy, including inflammatory bowel disease or uveitis  
• Underlying metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal conditions, which in the opi[INVESTIGATOR_90157]/or places the patient  at 
unacceptable risk for participation in an immunomodulatory therapy  
• Significant medical problems or diseases, including but not 
limited to the following: uncontrolled hypertension (≥  160/95 
mmHg), congestive heart failure ([LOCATION_001] Heart Association 
[COMPANY_001]  Confidential  Page 20  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 status of class III or IV), uncontrolled diabetes, or very poor 
functional status unable to perform self -care 
• History of clinically significant liver disease or liver injury as 
indicated by [CONTACT_884146] (AST), SGPT (ALT), alkalin e phosphatase, or serum bilirubin.  
• History of renal trauma, glomerulonephritis, or patients with one kidney only, or a serum creatinine level exceeding 1.5 mg/dL (132.6 µmol/L)  
• Screening total WBC count <3,000/µL, or platelets <100,000/µL 
or neutrophils < 1,500/µL or hemoglobin <8.5 g/dL (85 g/L)  
• Active systemic infections during the last two weeks prior to 
randomization (exception: common cold)  
• History of ongoing, chronic or recurrent infectious disease or evidence of tuberculosis infection as defined by [CONTACT_5640] a 
positive purified protein derivative ([COMPANY_003]) skin test (the size of 
induration will be measured after 48- 72 hours, and a positive 
result is defined as an induration of ≥ 5 mm or according to 
local practice/guidelines) or a positive QuantiFERON TB -Gold. 
Patients with a positive test may participate in the study if 
further work up (according to local practice/guidelines) 
establishes conclusively that the patient has no evidence of active tuberculosis. If presence of latent tuberculosis is established, then treatment according to local country guidelines must have been initiated  
• Known infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C at screening or randomization  
• History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system within the past 5 
years (except for basal cell carcinoma or actinic keratoses that have been treated with no evidence of recurrence in the past [ADDRESS_1236749] been removed)  
• Current severe progressive or uncontrolled disease which in the judgment of the clinical investigator renders the patient unsuitable for the trial  
• Inability or unwillingness to undergo repeated venipuncture (e.g., because of poor tolerability or lack of access to veins)  
• Inability or unwillingness to receive injections with PFS  
• Any medical or psychiatric condition which, in the Investigator’s opi[INVESTIGATOR_1649], would preclude the participant from adhering to the protocol or completing the study per protocol  
• Donation or loss of 400 mL or more of blood within 8 weeks before dosing  
• History or evidence of ongoing alcohol or drug abuse, within the last six months before randomization  
• Plans for administration of live vaccines during the study period 
or 6 weeks prior to randomization  
Investigational and 
reference therapy  Secukinumab 150 mg s.c.  
Matching placebo  
[COMPANY_001]  Confidential  Page 21  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 Efficacy assessments • Assessment of SpondyloArthritis International Society criteria 
(ASAS)  
• Patient’s global assessment of disease activity (VAS)  
• Patient’s assessment of back pain intensity (VAS)  
• Bath Ankylosing Spondylitis Functional Index (BASFI)  
• Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)  
  
  
• hsCRP  
• , ASDAS- CRP  response categories  
  
• MRI of spi[INVESTIGATOR_884126]  
 
 
• X-ray of the sacroiliac joints  
Safety assessments  • QuantiFERON TB -Gold test or [COMPANY_003] skin test  
• Chest X -ray or MRI  
• Physical examination  
• Vital signs  
• Height and weight  
• Laboratory evaluations  
  
• Electrocardiogram  
• Pregnancy and assessment of fertility  
• Local tolerability (Injection site reactions ) 
• Tolerability of secukinumab  
Other assessments  • Health- related Quality of Life 
SF-36 
ASQoL  
 
 
 
  
• HLA-B27 
  
  
  
Data analysis  The statistical hypothesis for ASAS40 being tested is that there is no 
difference in the proportion of patients fulfilling the ASAS40 criteria at 
Week 16 (analysis plan A) or 52 (analysis plan B), respectively  in the 
secukinumab regimen s versus placebo regimen  
Key words  Non- radiographic spondyloarthritis, chronic inflammatory disease, 
inflammatory back pain, secuki numab, AIN457  

[COMPANY_001]  Confidential  Page 22  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 1 Introduction 
1.1 Background 
Axial Spondyloarthritis (axSpA) is a group of rheumatic disorders with spi[INVESTIGATOR_884127]. axSpA is among the most common chronic inflammatory joint disorders, with re cent estimates of prevalence in Caucasian 
populations in the range of 1–2% (Baraliakos and Braun 2011). Patients with chronic back pain (onset before 45 years of age) are classified according to the Assessment of Spondyloarthritis international Society (ASAS) classification criteria ( Rudwaleit et al 2009 ) for axSpA if they 
fulfill either the clinical arm or the imaging arm of the criteria.  
Based o n the presence or absence of sacroiliitis on conventional X -ray radiographs, axSpA 
patients are sub -grouped into non- radiographic axSpA (nr -axSpA) and ankylosing spondylitis 
(AS). Patients with evidence for sacroiliitis on X -ray fulfilling the 1984 modifie d [LOCATION_001] 
diagnostic criteria ( van der Linden et al 1984) are classified AS whereas patients who do not 
show sacroiliitis on X -ray but may show evidence of sacroiliitis on magnetic resonance imaging  
(MRI ) are classified as having nr -axSpA. 
The 2009 ASAS classification criteria for axSpA were introduced to establish standards that apply to patients with or without radiographic sacroiliitis by [CONTACT_884147] X -ray and MRI as 
imaging modalities. The diagnosis of nr -axSpA based on imaging can achieve up to 88% 
specificity and 67% sensitivity whilst diagnosis based on clinical parameters only achieve approximately 83% specificity and 57% sensitivity when based on clinical parameters only (Sieper and van der Heijde 2013). In addition to the differential identification of AS and nr -
axSpA patients, the ASAS criteria allow for the implementation of clinical trials in the treatment of nr-axSpA, a disease entity for which there is an unmet medical need ( Sieper 2012).  
Studies and registry data have shown that nr -axSpA patients have similar levels of disease 
activity, pain, and health- related quality of life impairment as do AS patients ( Wallis et al 2013 ). 
Commonality of etiopathogenic characteristics and natural history of AS and nr -axSpA is the 
subject of ongoing research. Disease parameters and response rates to treatment with tumor necrosis factor (TNF) antagonists are similar in patients with AS and nr -axSpA, supporting the 
concept that axSpA is a disease with distinct stages ( Song et al 2013). Progression from nr -
axSpA to AS was observed in about 12% of nr- axSpA patients over the course of 2 years 
(Poddubnyy et al 2011). However, it is estimated that 10 -15% of nr -axSpA patients do not 
develop radiographic sacroiliitis ( Sieper and van der Heijde 2013 ). 
Non-steroidal anti- inflammatory drugs (NSAIDs) are considered first -line therapy for all 
patients with axSpA. Traditional disease -modifying antirheumatic drugs (DMARDs) such as 
methotrexate and sulfasalazine are not effective in the treatment of axSpA. Anti -TNF agents 
are approved therapi[INVESTIGATOR_884128]. In Europe, several anti -TNF agents are also approved for nr -axSpA. However, more 
than 60% of nr -axSpA patients treated with adalimumab or etanercept did not achieve an 
ASAS40 response in randomized clinical trials ( Sieper et al 2013 , Dougados et al 2014). 
Moreover, TNF blockade does not result in long term remission in AS and responders usually relapse within a few weeks after interruption of treatment ( Baraliakos et al 2005). Whilst 
effective in treating the inflammatory symptoms, TNF antagonists do not prevent structural 
[COMPANY_001]  Confidential  Page 23  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 damage of the joints in AS ( van der Heijde et al 2008a , van der Heijde et al 2008b). Currently, 
there is no experimental evidence that early therapy wi th approved treatment options in patients 
with nr -axSpA can prevent or delay the occurrence of structural alterations of the axial skeleton, 
which usually develop over a period of up to 10 years ( Robinson et al 2013 ). 
Secukinumab (AIN457) is a high- affinity recombinant, fully human monoclonal anti -human 
Interleukin- 17A antibody of the IgG1/κ -class. Secukinumab binds to human IL -17A and 
neutralizes the bioactiv ity of this cytokine. IL -17A is the central lymphokine of a newly defined 
subset of inflammatory T cells (Th17) which appear to be pi[INVESTIGATOR_884129]. IL -17A is mainly produced by [CONTACT_53437]4+ 
and CD8+ T lymphocytes and is being recognized as one of the principal pro- inflammatory 
cytokines in immune mediated inflammatory diseases. Assuming a potential role of Th17 cells in the inflammatory infiltrate in spondyloarthritides, it can be speculated that  the activity of 
inflammation in early disease stages, such as nr -axSpA and the ensuing structural changes in 
axial joints over the longer term, characteristic of axSpA may be amenable to modulation via IL-17 antagonism. 
AS (one of the Radiographic axial SpAs) Phase III studies showed an ASAS40 response rate of 36.1% at Week 16 to secukinumab (150 mg s.c. at Weeks 0, 1, 2, and 3, followed by [CONTACT_209768] 4 weeks). A statistically significant difference in ASAS40 response between the secukinumab 150 m g group and placebo was evident as early as at Week 2. In the Phase II study 
in AS, MRI imaging performed at baseline and at Weeks 6 and 28 showed a reduction of inflammation after 6 weeks which was maintained up to Week 28. Early improvements were especially noted in patients with higher baseline MRI scores ( Baraliakos et al 2011).  
As of 12-Jul- 2015, approximately [ADDRESS_1236750] included various indications (Rheumatoid Arthritis (RA), AS, Psoriatic Arthritis (PsA), psoriasis, multiple sclerosis, uveitis, Crohn’s disease, dry eye syndrome, polymyalgia rheumatica) at doses ranging from single and multiple doses of 0.1 mg/kg to 30 mg/kg i.v. and 25 mg t o 300 mg subcutaneous(ly) ( s.c.). As of March 
2015, Secukinumab is now approved for the treatment of psoriasis in the European Union (EU) , 
the US, and Japan. Full safety results from completed studies for PsA, AS and psoriasis show that secukinumab general ly is safe and well tolerated. Please refer to the Investigator’s Brochure 
(IB) for a more detailed review of the risk : benefit profile of secukinumab which supports the clinical development for the treatment of nr -axSpA patients with secukinumab. 
As most  studies for currently marketed biologic treatments for axSpA (with and without 
radiologic evidence) have failed to show evidence of slowing- down or even stoppi[INVESTIGATOR_884130], there is an unmet medical need for new therapi[INVESTIGATOR_014] b eing 
able to stop this structural damage. 
1.2 Purpose 
The purpose of this study is to demonstrate the clinical efficacy, safety and tolerability of two different regimens of secukinumab, with loading and without loading, compared to placebo in patients with nr -axSpA at Week 16 as well as Week 52. Additionally, 1 year progression of 
structural changes as evidenced by [CONTACT_884148]  52. This study will also 
observe the long- term efficacy, safety, and tolerability of secukinumab and the evolution of 
[COMPANY_001]  Confidential  Page 24  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 radiographic correlates of inflammation and structural progression based on the MRI and X -ray 
results up to Week  104. 
At the end of the core phase, an optional 16- week randomized dose escalation treatment period 
will assess if a treatment escalation from 1 50 mg to 300 mg secukinumab is of further benefit 
to patients , as compared to continuous treatment with 150 mg secukinumab. Additionally, long-
term efficacy, safety and tolerability of the 300 mg dose will be assessed in a treatment follow -
up phase.  
2 Study objectives  
2.1 Primary objective(s) 
There are two primary objectives based on regional regulatory precedent and feedback. These 
objectives will be tested in separate analysis plans.  
ANALYSIS PLAN A - EU and other non- [LOCATION_002] of America ( [LOCATION_003] ) Regions 
To demonstrate superiority of secukinumab 150 mg s.c. with loading over placebo at Week 16, based on the proportion of TNF na ïve patients achieving an ASAS40 response (Assessment of 
SpondyloArthritis International Society criteria).  
ANALYSIS PLAN B - [LOCATION_003] 
To demonstrate superiority of secukinumab 150 mg s.c. without loading over placebo at Week 
52, based on the proportion of TNF naïve  patients achieving an ASAS40 response (Assessment 
of SpondyloArthritis International Society criteria) 
2.2 Secondary objectives 
ANALYSIS PLAN A 
1. To demonstrate that the efficacy of secukinumab 150 mg s.c., with or without loading, at Week 16 is superior to placebo based on the proportion of all patients  achieving an 
ASAS 40 response 
2. To demonstrate that the efficacy of secukinumab 150 mg s.c., without loading, at Week 16 is superior to placebo based on the proportion of TNF naïve patients  achieving an 
ASAS 40 response 
3. To demonstrate that the efficacy of secukinumab 150 mg s.c., with or without loading, at Week 16 is superior to placebo based on the proportion of patients meeting the ASAS 5/6 response criteria  
4. To demonstrate that the efficacy of secukinumab 150 mg s.c., with or without loading, at 
Week 16 is superior to placebo based on the change from baseline in total Bath 
Ankylosing Spondylitis Disease Activity Index (BASDAI) 
5. To demonstrate that the efficacy of secukinumab 150 mg s.c., with or without loading, at Week 16 is superior to placebo based on the proportion of patients achieving BASDAI 50 
6. To demonstrate that the efficacy of secukinumab 150 mg s.c., with or without loading, at Week 16 is superior to placebo based on the change from baseline of high sensitivity C-Reactive Protein (hsCRP)  
[COMPANY_001]  Confidential  Page 25  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 7. To demonstrate that the efficacy of secukinumab 150 mg s.c., with or without loading, at 
Week  16 is superior to placebo based on the change from baseline in total Bath 
Ankylosing Spondylitis Functional Index (BASFI)  
8. To demonstrate that the efficacy of secukinumab 150 mg s.c., with or without loading, at 
Week 16 is superior to placebo based on the change from screening in SI joint edema on 
MRI  
9. To demonstrate that the efficacy of secukinumab 150 mg s.c., with or without loading, at Week 16 is superior to placebo based on the proportion of subjects achieving an ASAS20 response 
10. To demonstrate that the efficacy of secukinumab 150 mg s.c., with or without loading, at Week 16 is superior to placebo based on the change from baseline in Short Form-36 Physical Component Summary (SF-36 PCS) 
11. To demonstrate that the efficacy of secukinumab 150 mg s.c., with or without loading, at 
Week 16 is superior to placebo based on the change from baseline in Ankylosing 
Spondylitis Quality of Life ( ASQoL ) scores  
12. To demonstrate that the efficacy of secukinumab 150 mg s.c., with or without loading, at Week 16 is superior to placebo based on the proportion of patients achieving ASAS partial remission  
13. Overall safety and tolerability of secukinumab 
ANALYSIS PLAN B  
1. To demonstrate that the efficacy of secukinumab 150 mg s.c., with or without loading, at Week 52 is superior to placebo based on the proportion of all patients  achieving an 
ASAS 40 response 
2. To demonstrate that the efficacy of secukinumab 150 mg s.c., with loading, at Week 52 is superior to placebo based on the proportion of TNF na ïve patients  achieving an ASAS 40 
response 
3. To demonstrate that the efficacy of secukinumab 150 mg s.c., with or without loading, at Week 16 is superior to placebo based on the proportion of subjects achieving an ASAS40 response 
4. To demonstrate that the efficacy of secukinumab 150 mg s.c., with or without loading, at Week 16 is superior to placebo based on the change from baseline in total Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 
5. To demonstrate that the efficacy of secukinumab 150 mg s.c., with or without loading, at Week 16 is superior to placebo based on the proportion of patients achieving BASDAI 50 
6. To demonstrate that the efficacy of secukinumab 150 mg s.c., with or without loading, at 
Week 52 is superior to placebo based on the proportion of patients achieving BASDAI 50 
7. To demonstrate that the efficacy of secukinumab 150 mg s.c., with or without loading, at 
Week 16 is superior to placebo based on the change from baseline of high sensitivity C-Reactive Protein (hsCRP)  
8. To demonstrate that the efficacy of secukinumab 150 mg s.c., with or without loading, at Week 16 is superior to placebo based on the change from baseline in Short Form-36 Physical Component Summary (SF-36 PCS) 
[COMPANY_001]  Confidential  Page 26  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 9. To demonstrate that the efficacy of secukinumab 150 mg s.c., with or without loading, at 
Week 16 is superior to placebo based on the change from baseline in Ankylosing Spondylitis Quality of Life ( ASQoL ) scores  
10. To demonstrate that the efficacy of secukinumab 150 mg s.c., with or without loading, at 
Week 16 is superior to placebo based on the proportion of patients meeting the ASAS 5/6 
response criteria  
11. To demonstrate that the effic acy of secukinumab 150 mg s.c., with or without loading, at 
Week 16 is superior to placebo based on the proportion of subjects achieving an ASAS20 response 
12. To demonstrate that the efficacy of secukinumab 150 mg s.c., with or without loading, at Week 16 is superior to placebo based on the change from baseline in total Bath Ankylosing Spondylitis Functional Index (BASFI)  
13. To demonstrate that the efficacy of secukinumab 150 mg s.c., with or without loading, at Week 16 is superior to placebo based on the change from screening in SI joint edema on MRI  
14. To demonstrate that the efficacy of secukinumab 150 mg s.c., with or without loading, at Week 52 is superior to placebo based on the proportion of patients achieving Ankylosing Spondylitis Disease Activity Score (AS DAS) -C-Reactive Protein (CRP) inactive disease 
as defined by [CONTACT_884143] < 1.3 
15. To demonstrate that the efficacy of secukinumab 150 mg s.c., with or without loading, at Week 52 is superior to placebo based on the change from screening in SI joint edema on MRI  
16. To demonstrate that the efficacy of secukinumab 150 mg s.c., with or without loading, at 
Week 52 is superior to placebo based on the change from baseline in Ankylosing 
Spondylitis Quality of Life ( ASQoL ) scores  
17. Overall safety and tolerability of secukinum ab 

[COMPANY_001]  Confidential  Page 27  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 

[COMPANY_001]  Confidential  Page 28  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 3 Investigational plan 
3.1 Study design 
This is a randomized, double -blind, placebo- controlled study. Approximately 555 analyzable  
patients will be randomized to one of three treatment groups (secukinumab 150 mg Load, secukinumab 150 mg No Load or placebo in a ratio of 1:1:1):  
• Group 1 (secukinum ab 150 mg Load) : secukinumab 150 mg (1 mL, 150 mg/mL)  s.c. pre -
filled syringe (PFS) at  baseline  (BSL), Weeks 1, 2 and 3, followed by [CONTACT_884149] 4  
• Group 2 (secukinumab 150 mg No Load) : secukinumab 150 mg (1 mL, 150 mg/mL)  s.c. 
PFS at BSL, placebo at Weeks 1, 2 and 3, followed by [CONTACT_37234] 150 mg PFS 
administration every four weeks starting at Week 4 
• Group 3 (placebo ): placebo (1 mL) s.c. PFS at BSL, Weeks 1, 2, 3 , followed by 
[CONTACT_884150] 4  
At Week 104, patients can continue in an optional randomized dose escalation treatment 
extension phase. The patients will be assessed based on their ASAS20 response at Week 104. 
Secukinumab 150 mg responders at W eek 104 (Core Phase Responders) will be randomized to 
the following treatment groups in a blinded manner: 
• Group 4 (Core Phase Responder 150 mg): secukinumab 150 mg (1 mL, 150 mg/mL)  s.c. 
pre-filled syringe (PFS) and placebo (1 mL) s.c. PFS every four weeks  

[COMPANY_001]  Confidential  Page 29  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 • Group 5 (Core Phase  Responder 300 mg): 2 injections with secukinumab 150 mg (1 mL, 
150 mg/mL)  s.c. PFS every four weeks  
Secukinumab 150 mg incomplete -responders at Week 104 (Core Phase Non-Responders) will 
be escalated to secukinumab 300 mg in an open- label manner  
• Group 6 (C ore Phase Non- Responder 300 mg): 2 injections with secukinumab 150 mg (1 
mL, 150 mg/mL)  s.c. PFS every four weeks open- label  
Based on the clinical judgment of disease activity by [CONTACT_23298], 
background medications, such as NSAIDs and DMARDs, may be modified or added to treat signs and symptoms of nr-axSpA from Week 16 on . Furthermore, patients who are repeatedly  
(e.g. at two or more consecutive visits)  considered to be inadequate responders based on the 
clinical judgment of disease activity by  [CONTACT_23298], may receive 
secukinumab [ADDRESS_1236751] of care treatment as outlined in Section 
5.5.6 from Week 20 on.  
Changes in concomi tant medications used to treat nr -axSpA  will not be allowed before the  
completion of all Week 16 assessments (see Section 5.5.6). Efficacy will be assessed in detail 
at every study visit, and patients wh o are deemed not to be benefiting from the study treatment 
based upon safety and efficacy assessments as defined in Section 5.5.[ADDRESS_1236752] will be free to discontinue participation in the study at any time. Patients will be stratified at randomization according to the subgroup of objective signs of 
inflammation they belong to (based on their CRP and MRI status at screening). The only condition that will be placed on enrollment is that no less than 15% of patients should belong to either of the three subgroups of objective signs of inflammation: CRP+ and MRI+, CRP+ 
and MRI -, CRP - and  MRI+.  
Additionally, it is planned to enroll no more than approximately 20% TNF -IR patients in the 
study. Due to the long wash out required for some TNF -IR patients, enrolment of TNF -IR 
patients will end two months prior to the projected end of screening period.   
Starting at Week 52, all patients will be assigned to receive secukinumab 150 mg s.c. in an 
open- label fashion except for those patients who discontinued blinded study treatment  
(secukinumab 150 mg or placebo) during the initial 52 weeks of the study.  The original ly randomized treatment assignment ( secukinumab 150 mg or placebo ) will remain 
blinded until all patients have completed the Week [ADDRESS_1236753] completed 
the Treatment Period 2 (Week 52) and the W eek [ADDRESS_1236754] discontinued study treatment. 
Starting at Week 104, all patients who finish the core phase according to the protocol on study 
medication will be asked to continue in an additional extension phase. A new Informed Consent 
form has to be signed before proceeding into the extension phase. The patients will be assessed 
as having been Core Phase Responders (i.e., achieving ASAS20 at W eek 104) or Core Phase  
Non-Responders (i.e., not achieving ASAS20 at Week 104). Core Phase Responders will be 
randomized 1:[ADDRESS_1236755] patient has finished the 16 -week dose escalation treatment period  
(i.e., continuous treatment period).  
Starting from Week [ADDRESS_1236756] administration of study treatment for all 
patients , regardless of whether they complete the entire study (either core or extension phase)  
as planned or discontinue prematurely. Subjects who complete the 2- year Core Phase are eligible to enter the extension phase.  
Figure 3-1 Study design  Core Phase 
 Week 4 20 8 12 16* 24 28 32 36 40 44 48 52* 56 60 -10 to BSL 104 100 F112
Group 2: No Load
Secukinumab 150 mg s.c. 
N=185
Group 3: Placebo
Placebo s.c.
N=185
Randomization Secukinumab 150 mg administration s.c.
Placebo to secukinumab administration s.c.Primary Endpoint at Week 16 (Analysis Plan A) 
and Week 52 (Analysis Plan B)*Escape treatment for 
inadequate responders
Secukinumab 150 mg s.cGroup 1: Load
Secukinumab 150 mg s.c. 
N=185
[COMPANY_001]  Confidential  Page 31  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 Figure 3-2 Study design Extension Phase 
 
3.2 Rationale of study design 
This phase III trial utilizes a double -blind, randomized, placebo- controlled design with two 
different loading regimens. The treatment duration of the placebo group will be 52 weeks. Starting at Week 20, all patients who are repeatedly  (e.g. two or more consecutive visits)  
considered t o be inadequate responders based on the clinical judgment of disease activity by 
[CONTACT_1755] /or the patient will receive secukinumab [ADDRESS_1236757] of care after observing the required wash out period as described in Section 5.5.6. This is in compliance with the EMA/EMEA (European Medicines Agency) guidelines for AS ( EMA 
2009), considered relevant for trials in nr -axSpA and in line with guidance provided by [CONTACT_1556]. All other patients will continue their original randomly assigned treatment. From Week [ADDRESS_1236758] 16 weeks of the extension phase, it will be assessed if a higher dose of treatment 
(secukinumab 300 mg) will provide further benefit to patients. The [ADDRESS_1236759] year 
of the extension phase. For patients  escalated to 300 mg open- label , no dose reduction can be 
performed at a later time point.  

[COMPANY_001]  Confidential  Page 32  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 Regular assessments of disease activity ensure that patients who are experiencing worsening of 
disease in any of the treatment groups can be discontinued from the study as described in Section [IP_ADDRESS]. Data up to 216 weeks ( 204 weeks of treatment plus 12 weeks of safety follow -
up) is being generated to evaluate the safety and the duration of response in this population. 
3.3 Rationale of dose/regimen, route of administration and duration 
of treatment 
The dosing regimen in this study is based upon dose-efficacy relationships observed in a proof of concept (PoC) trial (CAIN457A2209) and two phase III trials (CAIN457F2305, CAIN457F2310) in AS. The Phase III trials in AS, CAIN457F2305 and CAIN457F2310, assessed the efficacy of both 75 mg and 150 mg s.c. maintenance doses with loading regimens consisting of either intravenous doses (CAIN457F2305: 3 doses of 10 mg/kg given every 2 weeks at BSL, Weeks 2 and 4) or subcutaneous doses (CAIN457F2310: 4 weekly doses matching the maintenance dose o f either 75 mg or 150 mg given at BSL, Weeks 1, 2, and 3). 
Given the similarity of the ASAS20 and ASAS 40 response at the Week 16 primary endpoint for the 150 mg dose in each of these studies, regardless of whether the loading dosing was i.v. (CAIN457F2305: 60.8% for IV -150 mg vs 28.7% for placebo for ASAS20 and 41.6% for IV -
150 mg vs 13.1% for placebo for ASAS 40) or s.c. (CAIN457F2310: 61.1% for SC-150 mg vs 27.0% for placebo for ASAS20 and 36.1% for SC -150 mg vs 10.8% for placebo for ASAS 40), 
secukinuma b 150 mg s.c. is a sufficient dose to provide clinically and statistically significant 
efficacy, whereas higher loading doses of secukinumab do not appear to confer greater efficacy in AS. Of note, the 75 mg s.c. loading and maintenance regimen tested in CAIN457F2310 did not achieve statistically significant improvements in any of the efficacy endpoints tested in a pre-defined testing hierarchy, including ASAS20, ASAS 40, hsCRP, ASAS5/6, BASDAI, SF -
36 PCS and ASQoL. Therefore, there are currently no plans to further pursue the 75 mg dose in future studies. Furthermore, a meta -analysis of trials examining TNF -α inhibitors, 
demonstrated that nr-axSpA patients respond similarly well to biologic anti- TNF treatments as 
AS patients ( Callhoff et al 2014). There was no evidence that different axSpA populations (e.g. 
AS and nr -axSpA) could require different dose regimens ( Callhoff et al 2014, Landewe et al 
2014). As other phase III trials of TNF -α inhibitors in nr -axSpA also evaluated dosages that 
already proved to be efficacious in AS, this trial will use the secukinumab dose of [ADDRESS_1236760] of the s.c. loading regimen itself on efficacy by [INVESTIGATOR_3086] a treatment arm of 150 mg maintenance dosing without a s.c. loadi ng 
regimen. Thus, the loading regimen (150 mg Load) will assess initial weekly administration of 150 mg for 4 weeks (BSL, Weeks 1, 2, and 3) followed by [CONTACT_884151] [ADDRESS_1236761], with placebo dosing given during the loading phase to mask the two active treatment regimens. Both secukinumab regimens will be compared to a placebo arm whose dosing simulates the loading regimen, in order to blind placebo treatment compared to either active treatment arm.  
Notably, 300 mg s.c. administered monthly is an approved dose for secukinumab in both psoriasis and in PsA, and the safety profile for 300 mg s.c. every 4 weeks is comparable to 150 mg s.c. every 4 weeks ( Langley et al, 2014, McInnes et al, 2015). The higher dose of 
[COMPANY_001]  Confidential  Page 33  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 secukinumab confers an additional benefit in other disease conditions (e.g., psoriasis and PsA). 
This study will evaluate whether a higher dose of secukinumab will have an effect on subjects with nr -axSpA with respect to treatment response. The dose escalation will be done in a 
randomized and blinded manner for  responding patients  who achieve an ASAS20 response at 
the end of the core phase, whereas non- responders will all be escalated during the extension 
phase in open- label fashion to the [ADDRESS_1236762] year of randomized treatment in the extension  phase, patients whose overall 
therapeutic response is not fully achieved with the current dose  and may improve with a higher 
dose, as judged by [CONTACT_093], can escape to the open-label 300 mg dose. 
3.4 Rationale for choice of comparator 
A placebo arm up to Week 52 is included in this study. Due to the nature of the disease and the 
outcome measures  used (e.g., ASAS response criteria, MRI for inflammation), a placebo arm 
is necessary to obtain reliable efficacy measurements. As there is currently conflicting evidence as to whether biologic treatments for axSpA are able to slow down or halt the struct ural 
progression of the disease, there is a need to study whether secukinumab as a new treatment option targeting IL -17A has a positive effect on correlates of structural damage evident on MRI 
of the sacroiliac joint (SIJ) and the spi[INVESTIGATOR_884131]. A placebo controlled period of one year is considered the shortest possible timeframe to assess differences in effects on signs of structural damage (assessed by [CONTACT_9268]) between both treatment groups. In a similar population, the anti -TNF α agent etanercept failed to show a reduction or a stop in progression of fatty 
lesions over 1 year of treatment compared to sulfasalazine ( Song et al 2011). The continuation 
of the placebo group up to Week 52 can be supported from an ethical standpoint, as patients continue their treatment with NSAIDs and other concomitant treatments including MTX and sulfasalazine. I f the patient or investigator feels the level of disease activity requires an 
escalation in therapy, b ackground medications such as NSAIDs and DMARDs may be modified 
or added after Week 16 , and all patients repeatedly (e.g. two or more consecutive visits) 
considered to be not responding to treatment can be re -assigned to secukinumab [ADDRESS_1236763] of care from Week 20 on as described in Section 3.2. Moreover, the inclusion of a placebo group is in accordance with previously implemented methodology and in compliance with the EMA/EMEA (European Medicines Agency) guidelines for AS ( EMA 2009), 
considered relevant for trials in nr-axSpA and recommended by [CONTACT_1622]. 
3.5 Purpose and timing of interim analyses/design adaptations 
The first primary endpoint analysis will be performed after all patients complete the treatment period 1 of the study (Week 24 for analysis plan A) and again after all patients complete the treatment period 2 of the study (Week 52 for analysis plan B).  
Depending on health authority advice, group sequential testing, as described in the statistical 
analysis plan, might be done at the Week [ADDRESS_1236764] completed the treatment period 2 (Week 52)  and the Week 
[ADDRESS_1236765] the 24 W eek interim analysis and no access to the interim results or individual treatment 
assignments will be given to the study team conducting the ongoing trial until the Week 52 
database lock.  
3.6 Risks and benefits 
The risk to patients in this trial will be minimized by [CONTACT_178438], close clinical monitoring, and extensive guidance for the investigators provided in the Investigator ’s Brochure.  
As of July 2015, approximately [ADDRESS_1236766] been enrolled in both completed and ongoing studies with secukinumab, with over 9600 having received active drug at doses ranging from single and/or multiple doses of 0.1 mg/kg to 30 mg/kg i.v. and 25 mg to 300 mg s.c. across various indications (including psoriasis, RA, AS, PsA, multiple sclerosis and uveitis).  
The risk profile of secukinumab in nr -axSpA is informed by [CONTACT_884152]. Secukinumab has been studied most extensively in psoriasis, and side 
effects seen in psoriasis patients treated with secukinumab include upper respi[INVESTIGATOR_6014] (nasopharyngitis, rhinitis) (very common: in more than 1 in 10 patients); oral herpes, rhinorrhea , diarrhea and urticaria (common: in more than 1 in 100 but fewer than 1 in 10 
patients); oral candidiasis, tinea pedis, neutropenia, and conjunctivitis (uncommon: in more than 1 in 1,000 but fewer than 1 in 100 patients). Additionally, worsening of Crohn’ s disease, 
in some cases serious, was seen in studies of Crohn’s disease and psoriasis, in patients receiving secukinumab or placebo.  
In the phase III AS studies CAIN457F2305 and CAIN457F2310 in [ADDRESS_1236767] of male and female patients (≥ 18 years old at the time of consent) fulfilling the ASAS classification criteria for axSpA plus an abnormal CRP and/or 
[COMPANY_001]  Confidential  Page 35  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 MRI, with no radiographic evidence of changes in the sacroiliac  joints that would meet the 
modified [LOCATION_001] criteria for AS (described in Appendix 3).  
Patients included must report active disease despi[INVESTIGATOR_250306], non-biologic 
DMARD, and/or anti -TNFα therapy. Patients should have been on NSAIDs at the highest 
recommended dose for at least [ADDRESS_1236768] been on a TNFα inhibitor (not more than one) must have experienced an inadequate response to treatment given at an approved dose for at least [ADDRESS_1236769] one administration of an anti -TNFα agent. It is planned to limit the inclusion of patients that are TNF inadequate 
responders (TNF -IR) to n o more than 20% of the overall randomized population. Due to the 
long wash out required for some TNF -IR patients, enrolment of TNF -IR patients will end two 
months prior to the projected end of screening period.   
The study aims to randomize approximately 555 analyzable patients worldwide. Enrollment 
will stop as soon as the target number of randomized analyzable patients is reached.  
Patients can be re- screened only once, and no study- related re- screening procedure should be 
performed prior to written re -consent by [CONTACT_102]. Mis -randomization occurs when a patient 
who does not meet all eligibility criteria receives a randomization number nevertheless; mis -
randomized patients will not be re- screened.  
4.[ADDRESS_1236770] to fulfill all of the following criteria:  
1. Patient must be able to understand and communicate with the investigator and comply 
with the requirements of the study and must give a written, signed and dated informed consent before any study assessment is performed 
2. Male or non-pregnant, non- nursing female patients at least 18 years of age  
3. Diagnosis of axSpA according to ASAS axSpA criteria ( Appendix 4):  
a. Inflammatory back pain for at least 6 months  
b. Onset before 45 years of age 
c. Sacroiliitis on MRI with ≥ 1 SpA feature OR HLA -B-27 positive with ≥2 SpA 
features  
4. Objective signs of inflammation at screening , evident by [CONTACT_5640] 
• MRI with Sacroiliac Joint inflammation ( Appendix 6) 
AND / OR 
•  hsCRP > ULN (as defined by [CONTACT_6626])  
5. Active axSpA as assessed by [CONTACT_884145] ≥ 4 cm (0-10 cm) at baseline  
6. Spi[INVESTIGATOR_90150] #2 ≥ 4 cm (0-10 cm) at baseline  
7. Total back pain as measured by [CONTACT_8298] ≥ 40 mm (0-100 mm) at baseline  
8. Patients should have been on at least [ADDRESS_1236771] 4 weeks in total prior to randomization with an inadequate response or failure to respond, or less if therapy had to be withdrawn due to intolerance, toxicity or contraindications  
[COMPANY_001]  Confidential  Page 36  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 9. Patients who are regularly taking NSAIDs (including COX-1 or COX-2 inhibitors) as part 
of their axSpA therapy are required to be on a stable dose for at least [ADDRESS_1236772] been on a TNFα inhibitor (not more than one) must have experienced 
an inadequate response to previous or current treatment given at an approved dose for at 
least [ADDRESS_1236773] previously been on a TNFα inhibitor will be allowed entry into study after an appropriate wash -out period prior to randomization: 
• 4 weeks for Enbrel® (etanercept) – with a terminal half -life of 102 ± 30 hours (s.c. 
route) 
• 8 weeks for Remicade® (infliximab) – with a terminal half -life of 8.0-9.5 days (i.v. 
infusion) 
• 10 weeks for Humira® (adalimumab) – with a terminal half -life of 10 -20 days 
(average 2 weeks) (s.c. route)  
• 10 weeks for Simponi® (golimumab) – with a terminal half -life of 11 -14 days 
• 10 weeks for Cimzia® (certolizumab) – with a terminal half -life of 14 days   
12. Patients taking MTX (≤ 25 mg/week) or sulfasalazine (≤ 3 g/day) are allowed to continue their medication and must have taken it for at least [ADDRESS_1236774] to be on a stable dose of ≤ 10 mg/day prednisone or equivalent for at least 2 weeks before randomization. 
Inclusion criteria for extension phase: 
1. Written informed consent must be obtained before any assessment is performed.  
2. Patients  who have completed the full study treatment period (104 weeks) in the core 
phase on study treatment. 
4.2 Exclusion criteria 
Patients fulfilling any of the following criteria are not eligible for inclusion in this study. No 
additional exclusions may be applied by [CONTACT_093], in order to ensure that the study population will be representative of all eligible patients.  
1. Patients with radiographic evidence for sacroiliitis, grade  ≥ 2  bilaterally or grade ≥ 3 unilaterally (radiological criterion according to the modified [LOCATION_001] diagnostic criteria for AS; Appendix 3) as assessed by [CONTACT_39582]  
2. Inability or unwillingness to undergo MRI (e.g., pat ients with pacemakers, aneurysm 
clips or metal fragments / foreign objects in the eyes, skin or body that are not MRI compatible)  
[COMPANY_001]  Confidential  Page [ADDRESS_1236775] X -ray or MRI with evidence of ongoing infectious or malignant process, obtained 
within 3 months of screening and evaluated by a qualified physician 
4. Patients taking high potency opi[INVESTIGATOR_2467] (e.g., methadone, hydromorphone, 
morphine) 
5. Previous exposure to secukinumab or any other biologic drug directly targeting IL-17 or 
IL-17 receptor 
6. Use of any investigational drug and/or devices within 4 weeks of randomization, or a period of 5 half-lives of the investigational drug, whichever is longer 
7. History of hypersensitivity to the study drug or its excipi[INVESTIGATOR_201014]  
8. Any therapy by [CONTACT_90169]-articular injections (e.g., corticosteroid) within [ADDRESS_1236776] taken more than one anti- TNFα agent  
12. Previous treatment with any cell-depleting therapi[INVESTIGATOR_90156]-
CD20 or investigational agents (e.g., CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19) 
13. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a 
female after conception and until the termination of gestation, confirmed by a positive 
human chorionic gonadotropin (hCG) laboratory test  
14. Women of child- bearing potential, defined as all women physiologically capable of 
becoming pregnant, unless they are using effective methods of contraception during entire study or longer if required by [CONTACT_109016] (e.g. 20 weeks in EU). Effective co ntraception methods include: 
• Total abstinence, when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception  
• Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by [CONTACT_104]  
• Male sterilization (at least 6 months prior to screening). For female patients on the study, the vasectomized male partner should be the sole partner for that patient  
• Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository  
• Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficac y (failure rate <1%), for 
example hormone vaginal ring or transdermal hormone contraception 
• Placement of an intrauterine device or intrauterine system  
In case of use of oral contraception, women should have been stable on the same pi[INVESTIGATOR_6522] a 
minimum of [ADDRESS_1236777] 
had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by [CONTACT_6592].  
15. Active ongoing inflammatory diseases other than axSpA that might confound the 
evaluation of the benefit of secukinumab therapy, including inflammatory bowel disease 
or uveitis 
16. Underlying metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal conditions, which in the opi[INVESTIGATOR_90157]/or places the patient at unacceptable risk for participation in a n immunomodulatory therapy 
17. Significant medical problems or diseases, including but not limited to the following: uncontrolled hypertension (≥  160/95 mmHg), congestive heart failure ([LOCATION_001] Heart 
Association status of class III or IV), uncontrolled diabetes, or very poor functional status unable to perform self- care 
18. History of clinically significant liver disease or liver injury as indicated by [CONTACT_884153] (AST), SGPT (ALT), alkaline phosphatase, or serum 
bilirubin. The Investigator should be guided by [CONTACT_4868]: 
• Any single parameter may not exceed 2 x upper limit of normal (ULN). A single parameter elevated up to and including [ADDRESS_1236778] prior to enrollment/randomization, to rule out lab error. 
• If the total bilirubin concentration is increased above [ADDRESS_1236779] reacting bilirubin. 
19. History of renal trauma, glomerulonephritis, or patients with one kidney only, or a serum creatinine level exceeding 1.5 mg/dL (132.6 µmol/L) 
20. Screening total WBC count <3,000/µL, or platelets <100,000/µL or neutrophils 
<1,500/µL or hemoglobin <8.5 g/dL (85 g/L) 
21. Active systemic infections during the  last two weeks prior to randomization (exception: 
common cold) 
22. History of ongoing, chronic or recurrent infectious disease or evidence of tuberculosis 
infection as defined by [CONTACT_5640] a positive purified protein derivative ([COMPANY_003]) skin test (the size of indur ation will be measured after 48 -72 hours, and a positive result is defined as 
an induration of ≥ 5 mm or according to local practice/guidelines) or a positive QuantiFERON TB -Gold test as indicated in the assessment schedule in Table [ADDRESS_1236780] may participate in the study if further work up (according to local practice/guidelines) establishes conclusively that the patient has no evidence of active tuberculosis. If presence of latent tuberculosis is established, then treatment according to local country guidelines must have been initiated 
23. Known infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C at screening or randomization 
[COMPANY_001]  Confidential  Page [ADDRESS_1236781] 5 years (except for basal cell carcinoma or actinic keratoses that have been treated with no evidence of recurrence in the past [ADDRESS_1236782] been removed)  
25. Current severe progressive or uncontrolled disease which in the judgment of the clinical 
investigator renders the patient unsuitable for the trial 
26. Inability or unwillingness to undergo repeated venipuncture (e.g., because of poor 
tolerability or lack of access to veins) 
27. Inability or unwillingness to receive injections with PFS  
28. Any medical or psychiatric condition which, in the Investigator’s opi[INVESTIGATOR_1649], would 
preclude the participan t from adhering to the protocol or completing the study per 
protocol 
29. Donation or loss of [ADDRESS_1236783] six months before 
randomization 
31. Plans for ad ministration of live vaccines during the study period or 6 weeks prior to 
randomization  
Exclusion criteria for extension phase: 
No additional exclusion criteria apply for the extension phase 
5 Treatment  
5.1 Protocol requested treatment  
5.1.1  Investigational treatment  
[COMPANY_001]/CRO will supply the following study treatments: 
• Investigational Treatment: 
• Secukinumab 150 mg provided in a 1 mL PFS (one PFS for 150 mg dose) 
• Reference Therapy:   
• Secukinumab placebo (Placebo) provided in a [ADDRESS_1236784] completed the treatment period 2 (Week 52)  and the week [ADDRESS_1236785] the 24 week interim analysis and no access to the interim data will be given to the study team conducting the ongoing trial until Week 52. After the treatment period 2 ( Week 52) has been completed for all patients  and 
the Week [ADDRESS_1236786] discontinued study treatment. 
After the core phase of the study, patients can join the extension phase and will receive either double-blinded or open- label treatment consisting of two injections per treatment.  
Patients will be instructed by [CONTACT_144955]-administer the s.c. injection using the PFS 
containing the liquid formulation of secukinumab/placebo, based on the Instructions for Use 
(IFU). The s.c. investigational drug will be administered by [CONTACT_884154].  
Note: The Secukinumab/Placebo  PFSs are pack aged in double -blinded fashion until Week [ADDRESS_1236787] dose is given at Week 
100.  In the extension phase, the study medication will again be provided in a double -blinded fashion 
to mask the 150 mg and  300 mg doses. 
The core phase medication will be labeled as follows:  
• Double-blind Secukinumab and Placebo PFS will be labeled as AIN457 
150mg/1mL/Placebo. 
• Open -label Secukinumab PFS will be labeled as AIN457 150mg/1mL 
The extension study medication will be labeled as follows: 
• Double-blind Secukinumab and Placebo PFS will be labeled as AIN457 
150mg/1mL/Placebo. 
• Open -label Secukinumab PFS will be labeled as AIN457 150mg/1mL 
For detailed instructions on storage of the investigational treatments, please refer to Section  5.5.3. 
5.1.2  Additional study treatment  
No additional treatment beyond investiga tional treatment is required for this trial.  
5.2 Treatment arms 
Patients will be assigned to one of the following three treatment arms in a 1:1:1 ratio, with approximately 185 analyzable patients each in the following arms: 
• Group 1: Secukinumab 150 mg Load 
• Group 2: Secukinumab 150 mg No Load 
• Group 3: Placebo 
Patients will receive study treatment at BSL, Weeks 1, 2, 3, and 4 followed by [CONTACT_250343] 
4 weeks through Week 100. Patients who are repeatedly  (e.g. two or more consecutive visits)  
considered to be in adequate responders based on the clinical judgement of disease activity from 
Week [ADDRESS_1236788] 
discontinued study treatment. Blinding to the original treatment assignment will be maintained until the treatment period 2 (Week 52) is completed by [CONTACT_16983] . Patients will self -administer 
all secukinumab and placebo doses as described in Section 3.1 at the study site or at home, 
according to the assessment schedule in Table 6 -1.  
Patients in the extension phase will be assigned to one of the following three treatment arms:  
Core Phase Responders:  
• Group 4: Secukinumab 150 mg blinded 
• Group 5: Secukinumab 300 mg blinded 
Core Phase Non -Responders:  
• Group 6: Secukinumab 300 mg open- label  
At Week 104, patients will be assessed as being Core Phase Responders or Core Phase Non-
Responders. Core Phase Responders will be randomized to treatment group 4 or 5; Core Phase  
Non-Responders will receive treatment according  to group 6. Patients will self -administer all 
secukinumab and placebo doses as described in Section 3.[ADDRESS_1236789] year in the extension phase 
(Week 156), patients whose overall therapeutic response is not fully achieved with the current 
dose and may improve with a higher dose, as judged by [CONTACT_093] , can escape to open -
label secukinumab [ADDRESS_1236790] patient is completed and the database is locked after the completion of all follow -up visits.  
5.3 Treatment assignment, randomization 
At baseline, all eligible patients will be randomized to one of the treatment arms via Interactive Response Technology (IRT). The investigator or delegate will contact [CONTACT_579075]/exclusion criteria. The IRT will assign a randomization number to the patient, which will be used to link the patient to a treatment arm and will specify a unique medication number for the first package of investigational treatment to be dispensed to the patient.   
From Week 20 on, the patient’s responder status (responder / inadequate responder) which 
should be based on the clinical judgment of disease activity should be entered into IRT . Patients 
repeatedly  (e.g. two or more consecutive visi ts) considered  to be  inadequate responders may 
receive secukinumab [ADDRESS_1236791] will be produced by [CONTACT_884155] 42  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 Drug Supply Management using a validated system that automates the random assignment of 
medication numbers to packs containing the investigational drug(s).  
Patients will be stratified at randomization according to the subgroup of objective signs of 
inflammation they belong to (based on their CRP and MRI status at screening). The only condition that will be placed on enrollment is that no less than 15% of patients should belong to either of the three subgroups of objective signs of inflammation: CRP+ and MRI+, CRP+ 
and MRI -, CRP - and  MRI+.  
Additionally, it is planned to enroll no more than 20% TNF -IR patients in the  study.   
At the beginning of the extension phase, patients will be assessed as being Core Phase  
Responders or Core Phase Non-Responders at Week [ADDRESS_1236792] completed the treatment period 2 (Week 52) and the W eek [ADDRESS_1236793] the 24 Week interim analysis and no access to the interim data will be given to the study team conducting the ongoing trial until Week 52. The blind is kept by [CONTACT_331614]: (1) Randomization data are kept strictly confidential until the time of unblinding and will not be accessible by [CONTACT_884156]; (2) The identity of the original randomized treatments administered through Week [ADDRESS_1236794] completed the treatment period 2 (Week 52). For details regarding the 
planned Interim Analyses, refer to Section 3.5. 
The reading of MRI and X -ray will be performed in a blinded fashion by [CONTACT_884157]. Other unblinding of original randomized treatment assignment before Week 52 will only occur 
in the case of patient emergencies (see Section 5.5.12) and at the conclusion of the study.  
The extension phase will be conducted in double-blinded fashion (for Core Phase Responders) 
and will remain blinded for the duration of each individual patient’s participation in the study. 
At the end of the extension treatment phase, which may last up to [ADDRESS_1236795] Number will not be reused.  
Upon signing the informed consent form, the patient is assigned the next sequential number by 
[CONTACT_093]. The investigator or his/her staff will contact [CONTACT_884158]. The site should select the CRF book with a matching Subject Number from the electronic data capture tool (EDC) system 
to enter data.  
If the patient fails to be treated for any reason, the IRT must be notified within [ADDRESS_1236796] number assigned for 
the core phase.  
5.5.2  Dispensing the investigational treatment  
Each study site will be supplied by [CONTACT_144949].  
The investigational treatment packaging has a 2- part label. A unique randomization number is 
printed on each part of this label which corresponds to placebo or active treatment. Investigator 
staff will identify the investigational treatment package(s) to dispense to the patient by [CONTACT_105245](s). Immediately before dispensing the package to the patient, investigator staff will detach the outer part of the label from the packaging and affix it to the source document (Drug Label Form) for that patient’s unique subject number.  

[COMPANY_001]  Confidential  Page 44  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 After Week 52, if the patient opts for home administration (at protocol specified time points, 
see Table 6 -1 and Table 6 -2) the investigator will dis pense, via IRT, an appropriate number of 
investigational treatment packages for home administrations. The investigator will detach the outer part of the label and affix it to the source documentation (Drug Label Form). Detailed instructions on the self -administration of the study treatment will be described in the IFU 
provided to each patient and made available to the site staff and investigator. These instructions should be reviewed in detail by [CONTACT_884159].  
5.5.3  Handling of study treatm ent 
[IP_ADDRESS]  Handling of investigational treatment  
Investigational treatment must be received by a designated person at the study site, handled and 
stored safely and properly, and kept in a secured location to which only the investigator and designees have access. Upon receipt, all investigational treatment should be stored according to the instructions specified on the labels. Clinical supplies are to be dispensed only in accordance with the protocol. The investigator should educate the patient on how to properly store the study treatment if the patient is self -administering at home. 
Medication labels will be in the local language and comply with the legal requirements of each country. They will include storage conditions for the investigational treatment but no information about the patient except for the medication number. 
The investigator must maintain an accurate record of the shipment and dispensing of 
investigational treatment in a drug accountability log. Monitoring of drug accountability will be performed by [CONTACT_527651]. Patients will be asked to return all unused investigational treatment and packaging throughout the study or at the time of discontinuation of investigational treatment.  
At the conclu sion of the study, and as appropriate during the course of the study, the investigator 
will return all unused investigational treatment, packaging, drug labels, and a copy of the completed drug accountability log to the [COMPANY_001] monitor or to the [COMPANY_001] address provided in the investigator folder at each site.  
[IP_ADDRESS]  Handling of other study treatment  
Not applicable.  
5.5.4  Instructions for prescribing and taking study treatment  
Study treatment (150 mg secukinumab and placebo) will be administered s.c. by 1 mL PFS throughout the study as 150 mg / [ADDRESS_1236797] been completed. The PFS with the ready -to-use study treatment solution will be provided by 
[CONTACT_884160]. Detailed instructions on the self -administration of the study treatment 
will be described in the IFU for secukinumab and provided to each patient. After Week 52, 
patients will be allowed to self -administer the study treatment at home during the optional visits 
in which there are no scheduled assessments at the site (see T able 6 -1 and Table 6 -2 below). If 
[COMPANY_001]  Confidential  Page [ADDRESS_1236798] using a PFS. Patients will be asked to raise any questions and then to proceed with self -
injection. At the Week 1 visit, patients will be asked to refer to the IFU and to proceed direc tly 
with self -injection of the study drug (i.e., no prior retraining) for the remainder of the trial. 
However, if the patient is not comfortable self -injecting the study treatment, then the site staff  
may administer it for the patient.  
All study treatment kits assigned to the patient during the study will be recorded in the  IRT. 
 
T
he investigator should promote compliance by [CONTACT_884161]’s safety and the validity 
of the study. The patient should be instructed to contact [CONTACT_087]/she is unable for any reason to attend a study visit as scheduled or if he/she is unable for any reason to take the study treatment as prescribed.  
Home administration 
Up to Week 52, all doses of study treatment will be self -administered by [CONTACT_884162], aft er the study assessments for the visit have been completed. After Week 52, the patients 
will be allowed to self -administer the study treatment at home during the optional visits in which 
there are no scheduled site assessments. Optional site visits are inc luded in the assessment table 
of the study ( Table 6 -1), between visits in which trial- related procedures are to be conducted. 
Patients will be allowed to self -administer the study treatment by [CONTACT_884163] -administer study treatment under the supervision of the site 
staff. If the patient opts for home administration of study treatment and is unable or unwilling 
to self -administer the treatment via PF S, a caregiver may administer the study treatment after 
Week 52. Caregivers should be trained on the IFU prior to administering the study treatment to the patient. It should be recorded on the Dose Administration Record eCRF(s) whether the patient self -administered the study treatment at home or at the site and if a caregiver 
administered the treatment. In the extension phase of the study, the optional site visits for drug administration will continue to be possible, but will only be recorded in the source documents at the site.  
Prior to self -administration at home, patients should contact [CONTACT_093]/site staff in case  
they are experiencing any AE/SAEs, or have any concerns. 
All dates and times of self -administrations by [CONTACT_884164]. Immediately before dispensing the package to the patient, site staff will detach the outer part of the label from the packagi ng and affix it to the 
source document (Drug Label Form) for that patient’s unique subject number. 
5.5.5  Permitted dose adjustments and interruptions of study treatment  
Study treatment dose adjustments are not permitted. Study treatment interruption is also not 
permitted with the following exceptions: 

[COMPANY_001]  Confidential  Page [ADDRESS_1236799] of secukinumab on live vaccines is unknown; therefore live vaccines should not be administered during participation in the study.  In case a live vaccine has been administered due to a medical urgency, study treatment should be interrupted for [ADDRESS_1236800] be recorded in the eCRF page. 
From Week 20 on , based on the clinical judgment of disease activity by [CONTACT_884165], patients may be consider ed as inadequate responders. Patients who are repeatedly  
(e.g. two or more consecutive visits) considered to be inadequate responders will have the 
option to enter escape. Upon entering “escape”, patients have the option (at investigator /patient 
discretion) to continue to receive blinded study treatment  or switch to open- label locally 
applicable standard of care. Patients continuing with blinded study treatment will be assigned 
to receive secukinumab 150 mg s.c.  (patients originally assig ned to placebo) or continue to 
receive secukinumab 150 mg s.c.  (patients originally assigned to secukinumab). While the 
standard of care will be open- label,  the original ly randomized treatment assignment 
(secukinumab 150 mg or placebo ) will remain blinded . If the standard of care includes the use 
of a biologic such as a TNFα inhibitor , it should be  prescribed in accordance with investigator 
practice  and local treatment guidelines . Patients switching to a  biologic therapy (e.g. anti -TNF)  
other than secukinumab  must not receive any further study medication and will have to observe 
a [ADDRESS_1236801] , patients whose overall therapeutic response is not fully achieved 
with the current dose  and may improve with a higher dose, as judged by [CONTACT_093] , can 
escape to open -label secukinumab 300 mg. 
While nr -axSpA is a multifaceted disease and the assessment of responder status should be 
based on the global clinical pi[INVESTIGATOR_884132] a single efficacy parameter; repeatedly  (e.g. at 
two or more  consecutive visits) not achieving a clinically meaningful improvement in the 
BASDAI of ≥ 20% or ≥ 1 unit (0 – 10 scale) ( Pavy et al. 2005) may be considered  as a general 
guidance for considering a patient inadequate responder to study treatment.  
[COMPANY_001]  Confidential  Page 47  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 Although no patient will be restricted from receiving necessary medications for lack of benefit 
or worsening of disease, if treatment with prohibited biologics (as described in Section 5.5.8 ) 
occurs, patients may remain in the trial but must  discontinue study treatment. Efficacy will be 
assessed in detail at every study visit, and patients who are deemed not to be benefiting from the study treatment based on safety and efficacy assessments (see Section 5.5.9) or for any reason on their own accord will be free to discontinue participation in the study at any time. Changes in NSAID, non- biologic DMARDs and corticosteroid concomitant therapy are 
permitted as per investigator’s and patient’s clinical judgment after all Week [ADDRESS_1236802] be recorded in the 
Prior/Concomitant medications eCRF page. 
5.5.[ADDRESS_1236803] the patient to notify the study site about any new medications he/she takes after the patient was enrolled into the study. All medications, procedures and significa nt non- drug therapi[INVESTIGATOR_014] (including physical therapy and blood transfusions) administered 
after the patient was enrolled into the study must be recorded.  
Guidelines for the use of specific medications are provided below: 
Methotrexate  
Patients taking MTX (≤ 25 mg/week) must be on a stable dose for at least [ADDRESS_1236804] be recorded in the Prior/Concomitant medications eCRF page. 
Folic acid  
Patients on MTX must be taking folic acid supplementation before randomization and during 
the trial to minimize the likelihood of MTX associated toxicity.  
Sulfasalazine Patients taking sulfasalazine (≤ 3 g/day) must be on a stable dose for at least [ADDRESS_1236805] be recorded in the Prior/Concomitant medications eCRF page. 
Leflunomide wash-out with cholestyramine In case of leflunomide treatment, a drug wash- out of 8 weeks has to be performed. However, 
another wash -out procedure might be considered. Cholestyramine could be given orally to 
wash -out the drug at a dose of 8 g t.i.d. Cholestyramine reduced plasma levels of the active 
leflunomide metabolite by [CONTACT_3450] 40% in 24 hours and by 49 % to 65 % in 48 hours in 
three healthy volunteers. The administration of cholestyramine is recommended in patients who require a drug elimination procedure. If a patient receives the dose of 8 g t.i.d. for 11 days, he/she could be safely randomized [ADDRESS_1236806] be recorded in the Prior/Concomitant medications eCRF page. 
[COMPANY_001]  Confidential  Page 48  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 Systemic corticosteroids  
Treatment with systemic corticosteroids is permitted if the dose was stable within the 2 weeks 
preceding randomization, up to a maximum daily dosage of 10 mg prednisone equivalent. After  
Week 16, the dose and regimen of systemic corticosteroids may be modified as per investigator’s judgment and patient’s need, although the corticosteroid dose should not be reduced rapi[INVESTIGATOR_375]. Any change in the dose of systemic corticosteroids during the tria l must be 
recorded on the corresponding eCRF page. 
Intra -articular corticosteroids are not permitted within the 4 weeks preceding randomization 
and up to Week 16. No single injection should exceed 40 mg of triamcinolone (or equivalent) 
and the total dose of intra -articular corticosteroid may not exceed 80 mg of triamcinolone (or 
equivalent) during any 52- week period. Injection of intra -articular steroids is not permitted 
within 8 weeks prior to Week 52. 
Non-steroidal anti -inflammatory drugs (NSAIDs) (including COX -1 or COX -2 inhibitors) 
and acetaminophen/paracetamol Patients on regular use of NSAIDs or paracetamol/acetaminophen should be on stable dose for 
at least 2 weeks before randomization to allow inclusion in the study. 
NSAIDs, low strength opi[INVESTIGATOR_144923]/acetaminophen PRN can be taken during the 
study; however, patients should refrain from any intake during at least the 24 hours before a visit with disease activity assessment.  
After the Week 16 assessments are completed, a change in the NSAID intake regimen is permitted. Any change of the NSAID/paracetamol/acetaminophen treatment during the trial should be recorded on the corresponding eCRF page. 
TNFα inhibitors  
If TNFα inhibitors are chosen as escape treatment for patients considered as inadequ ate 
responders, a [ADDRESS_1236807] study treatment administration. 
[COMPANY_001]  Confidential  Page 49  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 Table 5-1 Prohibited treatment  
Prohibited treatments  Washout period  
(before randomization)  
Etanercept* (until Week 28, if used as escape treatment)  4 weeks  
Infliximab* (until Week 28, if used as escape treatment)  8 weeks  
Adalimumab, golimumab, certolizumab* (until Week 28, if used as 
escape treatment)  10 weeks  
Unstable dose of MTX or sulfasalazine  
(until Week 16)  [ADDRESS_1236808] (except MTX or sulfasalazine)  
(until Week 16)  4 weeks  
Leflunomide  
(until Week 16)  8 weeks  
Leflunomide with Cholestyramine washout  4 weeks  
Unstable dose of NSAIDs (COX1 or COX2 inhibitors)   
(until Week 16)  2 weeks  
Systemic corticosteroids > 10 mg prednisone equivalent**  
(until Week 16)  2 weeks  
Intra-articular steroid injections  
(until Week 16)  4 weeks  
Any biological immunomodulating agents, except those targeting 
TNFα*  No prior exposure  
Any cell -depleting therapi[INVESTIGATOR_90156]- CD20 or 
investigational agents (e.g., CAMPATH, anti -CD4, anti -CD5, anti -
CD3, anti -CD19)  No prior exposure  
Any investigational treatment or participation in any interventional 
trial 4 weeks or 5 half -lives 
(whichever is longer)  
Analgesics other than paracetamol/acetaminophen or low strength 
opi[INVESTIGATOR_232097]  4 weeks  
Live vaccinations  6 weeks  
* These agents fall under the category of biologic immunomodulators and are prohibited medications. 
Administration of these agents requires study treatment discontinuation (see Section 5.5.9).  
** See details about corticosteroid management in Section 5.5.[ADDRESS_1236809] make every effort to determine the primary reason for a patient’s premature discontinuation from the study and record this information on the appropriate Study Phase Completion eCRF.  
[COMPANY_001]  Confidential  Page 50  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 Patients who discontinue study should undergo an end of treatment visit (corresponding to the 
last visit for the patient’s current period of treatment: e.g., Week 24, Week 52, Week 104, Week 
208) at [ADDRESS_1236810]  study treatment and then also return after an additional 8 weeks for a 
final follow -up visit, corresponding to Week F112 or Week F216, respectively ([ADDRESS_1236811] study treatment; see Table 6 -1 and Table 6 -2). The final follow -up visit should be performed 
before any new treatment other than secukinumab is initiated. Study treatment discontinuation 
must also be recorded in IRT. 
For patients who a re lost to follow -up (i.e., those patients whose status is unclear because they 
fail to appear for study visits without stating an intention to withdraw from the study), the 
investigator should show "due diligence" by [CONTACT_884166], e.g., dates of telephone calls, registered letters, etc.  
Patients who are prematurely discontinued from the study will not be replaced. 
[IP_ADDRESS]  Discontinuation of study treatment  
Study treatment must be discontinued if the investigator determines that continuation of study 
treatment would result in a significant safety risk for a patient. The following circumstances require study treatment discontinuation: 
• Withdrawal of informed consent 
• Emergence of the following adverse events: 
a. Any severe or serious adverse event that is not compatible with administration of 
study medication, including adverse events that require treatment with prohibited co-medication  
b. Onset of lymphoproliferative disease or any malignancy except for treated basal cell 
carcinoma, treated actinic keratoses, treated in situ carcinoma of the cervix or non -
invasive malignant colon polyps which are being or have been removed 
c. Life-threatening infection 
d. Any laboratory abnormalities that in the judgment of the invest igator are clinically 
significant and are deemed to place the patient at a safety risk for continuation in the study (A general guidance on clinically notable laboratory values is provided in Appendix 1.) 
e. Pregnancy  
f. Use of  any biologic immunomodulating agent except secukinumab (see Section 5.5.6 for washout periods) 
g. Any protocol deviation that results in a significant risk to the patient’s safety  
In add ition to these requirements for study treatment discontinuation, the investigator should 
discontinue study treatment for a given patient if on balance, he/she thinks that continuation would be detrimental to the patient’s well-being. For patients who were considered inadequate responders as outlined in Section 5.5.6, the investigator should consider discontinuing patients from study treatment who experience a clinically important worsening of disease activity compared to baseline at two consecutive visits after inadequate responder status was confirmed. 
A clinically important worsening will be defined as a worsening of BASDAI ≥ 20% AND ≥ 1 
[COMPANY_001]  Confidential  Page 51  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 unit (0- 10 scale), which represents the minimum clinically important difference ( Pavy et al. 
2005).  
5.5.[ADDRESS_1236812]: 
• Does not want to participate in the study anymore, and • Does not allow further collection of personal data In this situation, the investigator should make a reasonable effort (e.g., telephone, e -mail, letter) 
to understand the primary reason for the subject’s decision to withdraw his/her consent and 
record this information.  
Study treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing.  
Further attempts to contact [CONTACT_109032]-up. 
All efforts should be made to complete the assessments prior to study withdrawal. A final 
evaluation at the time of the subject’s study withd rawal should be made as detailed in the 
assessment table.  
[COMPANY_001]/sponsor will continue to keep and use collected study information (including any data resulting from the analysis of a subject’s samples until their time of withdrawal) according to applic able law.  
For US and Japan: All biological samples not yet analyzed at the time of study withdrawal may still be used for further testing/analysis in accordance with the terms of this protocol and of the informed consent form.  
For EU and RoW: All biologic al samples not yet analyzed at the time of study withdrawal will 
no longer be used, unless permitted by [CONTACT_1289]. They will be stored according to 
applicable legal requirements.  
 
5.5.11  Loss to follow -up 
For patients whose status is unclear because they fai l to appear for study visits without stating 
an intention to withdraw, the investigator should show "due diligence" by [CONTACT_884167], e.g., dates of telephone cal ls, registered letters, etc. A patient should not be formally considered lost 
to follow-up until his/her scheduled end of study visit would have occurred. 
5.5.[ADDRESS_1236813] often, investigational treatment discontinuation and knowledge of the possible treatment assignments are sufficient to treat a study patient who presents with an emergency condition. Emergency treatment code breaks are performed using 
[COMPANY_001]  Confidential  Page 52  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 the IRT. When the investigator contacts the system to break a treatment code for a patient, 
he/she must provide the requested patient identifying information and confirm the necessity to break the treatment code for the patient. The investigator will then receive details of the investigational drug treatment for the specified patient and a fax or email confirming this information. The system will automatically inform the [COMPANY_001] monitor for the site and the Study Team that the code has been broken. 
It is the investigator’s responsibility to ensure that there is a procedure in place to allow access 
to the IRT in case of emergency. The investigator wi ll inform the patient how to contact [CONTACT_5657]/her 
backup in cases of emergency when he/she is unavailable. The investigator will provide protocol number, study treatment  name [CONTACT_90228], subject number, and instructions for 
contact[CONTACT_144957] (or any entity to which it has delegated responsibility for emergency code breaks) to the patient in case an emergency treatment code break is  required at a time when the investigator and backup are unavailable.  
Study medication must be discontinued after emergency unblinding. 
In the case of accidental unblinding, patients will not be replaced by [CONTACT_884168]. 
5.5.[ADDRESS_1236814] completed the  core phase if he/she recei ved a maximum of 
[ADDRESS_1236815] completed the extension phase if he/she has received an 
additional 16 weeks of study treatment and has completed the scheduled study assessments and procedures up to and including Visit F216. 
Information on the patient’s completion or discontinuation of the study and the reason for 
discontinuation of the study will be recorded on the appropriate Study Phase Completion eCRF 
page.  
In any case, the investigator or site staff must contact [CONTACT_786971]’s study completion (Visit F112 for the core  phase /Visit F216 for the extension phase ) 
and/or discontinuation. 
The investigator must provide follow -up medical care for all patients who are prematurely 
withdrawn from the study, or must refer them for appropriate ongoing care. This care may 
include initiating a nother treatment outside of the study as deemed appropriate by [CONTACT_1275]. This treatment may be any non- biologic DMARD. In case of a biologic treatment, 
a waiting period of 3 months before initiating the treatment is recommended.  
5.5.14  Early study termination  
The study can be terminated at any time for any reason by [CONTACT_5343]. Should this be necessary, the patient should be seen as soon as possible and treated as a prematurely withdrawn patient. The investigator may be informed of additional procedures to be followed in order to ensure that adequate consideration is given to the protection of the patient’s interests. The investigator 
[COMPANY_001]  Confidential  Page [ADDRESS_1236816]/Independent Ethics Committee 
(IRBs/IECs) of the early termination of the trial.  
[ADDRESS_1236817] all of the assessments and indicates with an “x” when the visits are 
performed.  
Patients should be seen for all visits on the designated day or as close to it as possible. 
Patients who prematurely discontinue during a specific treatment period should return for the 
final visit within that treatment period ([ADDRESS_1236818] study treatment administration), as well as return for the follow -up visit [ADDRESS_1236819] a duration of up to 10 weeks, during which time the patient 
will sign the informed consent form (ICF), be evaluated for eligibility and sufficient time is 
allowed for potential medication washout, in addition to all other assessments indicated i n Table 
6-1.  
Screening will consist of two consecutive visits. During Screening visit 1, initial assessments 
will be performed as outlined in Table 6 -1. At that visit, the duration of the washout period will 
be determined and Screening visit 2 will be performed as follows: 
• If the washout period is ≤ 4 weeks the investigator should proceed directly to Screening visit 2 on the same day and complete all assessments in the next 4 weeks prior to randomization.  
• If the was hout period is more than [ADDRESS_1236820] study visit, however preferably for a follow up visit F112 for the core phase /Visit F216 
for the extension phase , [ADDRESS_1236821] the patient 
should be recorded in the source documentation. 
[COMPANY_001]  Confidential Page 54  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 Table 6-1 Assessment schedule: C ore phase  
 Screening1 Treatment Period 1  Treatment Period 2  Treatment Period 3  Follow 
up 
Week  SV1        
-10 to 
-4 SV2   ≤ -4 
BSL  
1 
2 
3 
4 
8 
12 
16 
20 
24* 
28 
32 
36 
40 
44 
48 
52* 
  56 & 60  
  64 
  68 & 72  
  76 
  80 & 84  
  88 
  92, 96&100  
  104*  
  F112*  
Optional site visit                     X  X  X  X   
Inclusion/Exclusion criteria2 X X X                          
Relevant medical history/ current 
medical condition2 X X X                          
Prior medication  X X X                          
nr-axSpA assessment and history 
of extra -axial involvement3 X                            
Demography  X                            
MRI (spi[INVESTIGATOR_884126])  X11         X         X        X  
X-Ray of sacroiliac joints  X4                          X  
Cardiovascular medical history    X                          
Smoking history    X                          
Physical Exam   S S S S S S S S S S S S S S S S S S  S  S  S  S S 
Height   X                           

[COMPANY_001]  Confidential Page 55  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
  Screening1 Treatment Period 1  Treatment Period 2  Treatment Period 3  Follow 
up 
Week  SV1        
-10 to 
-4 SV2   
≤ -4 
BSL  
1 
2 
3 
4 
8 
12 
16 
20 
24* 
28 
32 
36 
40 
44 
48 
52* 
  56 & 60  
  64 
  68 & 72  
  76 
  80 & 84  
  88 
  92, 96&100  
  104*  
  F112*  
Weight   X X       X         X        X X 
Vital signs   X X X X X X X X X X X X   X   X  X  X  X  X X 
[COMPANY_003] skin test5 or QuantiFERON 
TB-Gold test   X                           
Chest X -ray or MRI6  S                           
Hematology, blood chemistry, 
urinalysis   X X X X  X X X X  X X   X   X  X  X  X  X X 
Serum pregnancy test   X                           
Hepatitis B, C or HIV serology (only in countries where 
required)**   S                           
Urine pregnancy test    X    X   X  X    X   X  X  X  X  X X 
ECG   X       X         X        X X 
Randomization via IRT    X                          
Responder assessment via IRT            X X X X X X X X           
On-site administration of s.c. 
study treatment by [CONTACT_16625]7   X X X X X X X X X X X X X X X X X X7 X X7 X X7 X X7   
Concomitant medication / non -
drug therapy  X Updated as necessary  

[COMPANY_001]  Confidential Page 56  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
  Screening1 Treatment Period 1  Treatment Period 2  Treatment Period 3  Follow 
up 
Week  SV1        
-10 to 
-4 SV2   
≤ -4 
BSL  
1 
2 
3 
4 
8 
12 
16 
20 
24* 
28 
32 
36 
40 
44 
48 
52* 
  56 & 60  
  64 
  68 & 72  
  76 
  80 & 84  
  88 
  92, 96&100  
  104*  
  F112*  
Adverse events/SAEs (including 
injection site reactions)8 X Update as necessary  
Patient’s global assessment of 
disease activity (VAS)    X X X X X X X X X X X X X X X X X  X  X  X  X X 
Patient’s assessment of back pain 
intensity (VAS)    X X X X X X X X X X X X X X X X X  X  X  X  X X 
BASFI    X X X X X X X X X X X X X X X X X  X  X  X  X X 
BASDAI    X X X X X X X X X X X X X X X X X  X  X  X  X X 
ASQoL    X     X  X  X       X    X    X X 
SF-36 v2   X     X  X  X       X    X    X X 

[COMPANY_001]  Confidential Page 57  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
  Screening1 Treatment Period 1  Treatment Period 2  Treatment Period 3  Follow 
up 
Week  SV1        
-10 to 
-4 SV2   
≤ -4 
BSL  
1 
2 
3 
4 
8 
12 
16 
20 
24* 
28 
32 
36 
40 
44 
48 
52* 
  56 & 60  
  64 
  68 & 72  
  76 
  80 & 84  
  88 
  92, 96&100  
  104*  
  F112*  
High sensitivity C -Reactive 
protein (hsCRP)   X X X X X X X X X X X X X X X X X X  X  X  X  X X 
HLA -B27  X                           
Lipi[INVESTIGATOR_805]9   X     X  X         X        X  
Treatment period 1 completion 
form             X                 
Treatment period 2 completion 
form                    X          
Treatment period 3 completion 
form                            X  

[COMPANY_001]  Confidential Page 58  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
  
S Source data only  
1 If the patient’s washout period ≤ 4 weeks, Screening visit 1 (SV1) and Screening visit 2 (SV2) can be performed on the same d ay.  
[ADDRESS_1236822] X -ray or MRI is required if it was not performed and evaluated within 3 months prior to screening. The X -ray should be performed after it is 
certain the patient meets inclusion/exclusion criteria in order to minimize unnecessary exposure to radiation. The X -ray may be replaced by [CONTACT_750650].  
7 After Week 52, patients able to self-administer can do so at home and don’t have to attend the site at these specified visits  
8 AEs/SAEs occurring after the patient has signed the informed consent must be captured on the appropriate eCRF page.  
[ADDRESS_1236823] 3 months prior to targeted Baseline  
* For all patients who discontinue the study prematurely, the investigator should ensure that the patient completes an end of treatment visit (corresponds 
to the last visit for the patient’s current treatment period) [ADDRESS_1236824] study treatment to complete assessments show n for Week 104, and also 
returns after an additional 8 weeks for a final follow -up visit, F112 ([ADDRESS_1236825] study treatment). The final visit should be performed before any 
new treatment other than secukinumab is initiated.  
All patients that continue into the extension phase will have their first extension phase visit at the last treatment period visit of the core phase (week 104) 
and will skip the follow -up visit F112.  
** Hepatitis B and/or hepatitis C and/or HIV serology testing to be performed during screening period only if required as per local medical practice or local regulations prior to initiation of therapy. These assessments will be documented in source records only and will not be entered into the eCRF  
 

[COMPANY_001]  Confidential Page 59  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 Table 6-2 Assessment schedule: E xtension phase  
Period /Visit name  16-week dose escalation treatment 
period  Continuous treatment period14 EoT
* Follow 
up* 
Week  
[ZIP_CODE] 
108 
112 
116 
120 
124/128/132  
136 
140/144/148  
152 
156/160/164  
168 
172/176/180  
184 
188/192/196  
200 
204 
208 
216 
Optional site visit   X  X  X  X  X  X  X  X   
Obtain informed consent13 X                  
Inclusion/Exclusion criteria  X                  
Physical Exam    X  X  X  X  X  X  X  X X 
Weight                  X  
Vital signs    X  X  X  X  X  X  X  X X 
Randomization in IRT  X                  
Patient’s global assessment of 
disease activity (VAS)    X  X    X    X    X  
Patient’s assessment of back pain 
intensity (VAS)    X  X    X    X    X  
BASFI    X  X    X    X    X  
BASDAI    X  X    X    X    X  
ASQoL    X  X    X    X    X  
SF-36   X  X    X    X    X  

[COMPANY_001]  Confidential Page 60  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 Period /Visit name  16-week dose escalation treatment 
period  Continuous treatment period14 EoT
* Follow 
up* 
Week  
[ZIP_CODE] 
108 
112 
116 
120 
124/128/132  
136 
140/144/148  
152 
156/160/164  
168 
172/176/180  
184 
188/192/196  
200 
204 
208 
216 
High sensitivity C -Reactive 
Protein (hsCRP)    X  X  X  X  X  X  X  X  
Hematology, blood chemistry, 
urinalysis    X  X  X  X  X  X  X  X X 
Serum pregnancy test                  X X 
Urine pregnancy test    X  X  X  X  X  X  X    
On-site administration of s.c. 
study treatment by [CONTACT_16625]15 X X15 X X15 X X15 X X15 X X15 X X15 X X15 X X15   
Concomitant medication / non -
drug therapy  X Update as necessary  
Adverse events/SAEs (including 
injection site reactions)8 X Update as necessary  
8 AEs/SAEs occurring after the patient has signed the informed consent must be captured on the appropriate eCRF page.  
[ADDRESS_1236826] to sign a new ICF for participation in the extension phase  
14 Depending on the timing for each patient, some of these visits might not be conducted and the patient will go directly to the  EoT (End of Treatment) 
visit 
15 Patients able to self -administer can do so at home and don’t have to come to the site at these specified visits  
* For all patients who discontinue the study prematurely, the investigator should ensure that the patient completes an end of  treatment visit Week 208, [ADDRESS_1236827] study treatment to complete assessments shown for Week 208, and also returns after an additional 8 weeks for a final follow -up visit, 
F216 ([ADDRESS_1236828] study treatment). The final visit should be performed before any new treatment other than secukinumab is initiated.  
 

[COMPANY_001]  Confidential  Page [ADDRESS_1236829] 
be notified within 2 days and the reason for not being randomized will be entered on the Screening Phase Disposition eCRF page. In addition, only the following eCRFs should be completed: Demography eCRF, Informed Consent eCRF, Inclusion/Exclusion eCRF, and the 
Adverse event (AE) eCRF should be completed for any Serious Adverse Events (SAEs) that occurred during the screening period. Adverse events that are not SAEs will be followed by [CONTACT_90200]. 
All patients who have signed informed consent and are randomized into the Treatment period 
[ADDRESS_1236830] abnormality occurred prior to the informed consent signature. 
6.2 Patient demographics/other baseline characteristics 
Patient demographic and baseline characteristics data to be collected on all patients and to be recorded in the eCRF include: 
• Date of birth, age, sex, race, ethnicity and source of patient referral  
• Relevant nr -axSpA and general medical history/current medical condition data until the 
start of study treatment, history of extra-axial involvement (uveitis, psoriasis, 
inflammatory bowel disease, dactylitis, enthesitis, peripheral arthritis), date of onset of inflammatory back pain, number of previous DMARDs used, date of diagnosis of nr-axSpA, previous nr-axSpA therapi[INVESTIGATOR_014], cardiovascular medical history and smoking history 
Whenever possible, diagnoses and not symptoms will be recorded here. 
6.[ADDRESS_1236831] eCRF page. 
Drugs administered prior to start of treatment and other drugs continuing or started during the 
study treatment period will be entered in the Prior/Concomitant medications or Significant non-drug therapi[INVESTIGATOR_144924].  
Compliance is expected to be 100%, unless temporary interruption is needed for safety reasons 
as described in Section 5.5.5. Compliance will also be assessed by a [COMPANY_001]/CRO monitor using information provided by [CONTACT_110608]. 
6.4 Efficacy 
• Assessment of SpondyloArthritis International Society criteria (ASAS)  
[COMPANY_001]  Confidential  Page 62  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
•Patie
nt’s global assessment of disease activity (VAS)
•Patient’s assessment of back pain intensity (VAS)
•Bath Ankylosing Spondylitis Functional Index (BASFI)
•Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
•hs
CRP 
• , ASDAS -CRP  response categories
•M
RI of spi[INVESTIGATOR_884126]
•X
-ray of the sacroiliac joints
6.4.1  Assessment of SpondyloArthritis International Society criteria (ASAS)  
The ASAS response measures consist of the following assessment domains ( Sieper et al 2009 ). 
Main ASA S domains: 
1.Patient’s global assessment of disease activity measured on a VAS scale
2. Patient’s assessment of back pain, represented by [CONTACT_90202],
both measured on a VAS scale
3. Function represented by [CONTACT_90203] [ADDRESS_1236832] 2 questions on the 6-question BASDAI  as measured by [CONTACT_884169]: 
5. Spi[INVESTIGATOR_884133]
6. C- reactive protein (acute phase reactant)
[IP_ADDRESS]  ASAS Response Criteria -20% (ASAS20)  
ASAS20 response is defined as an improvement of ≥20% and ≥[ADDRESS_1236833] 
three of the four main domains and no worsening of ≥20% and ≥1 unit on a scale of 10 in the 
remaining domain. 
[IP_ADDRESS]  ASAS Response Criteria -40% (ASAS 40)  
ASAS40 response is defined as an improvement of ≥40% and ≥[ADDRESS_1236834] three of the four main domains and no worsening at all in the remaining domain. [IP_ADDRESS]  ASAS 5/6 improvement criteria  
The ASAS 5/6 improvement criteria is an improvement of ≥20% in at least five of all six 
domains. 

[COMPANY_001]  Confidential  Page 63  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 [IP_ADDRESS]  ASAS partial remission criteria  
The ASAS partial remission criteria are defined as a value not above 2 units in each of the four 
main domains on a scale of 10. 
6.4.2  Patient’s global assessment of disease activity (VAS)  
The patient’s global assessment of disease activity will be performed using a 100 mm visual 
analog scale (VAS) ranging from not severe to very severe, after the question, "How active was your disease on average during the last week?”  
6.4.3  Patient’s assessment of back pain intensity (VAS)  
The patient’s assessment of back pain will be performed using a 100 mm VAS ranging from no pain to unbearable pain, after the question “ Based on your assessment, please indicate what is 
the amount of back pain at any time that you experienced during the last week?” and “Based 
on your assessment, please indicate what is the amount of back pain at night that you experienced during the last week?”  
6.4.4  Bath Ankylosing Spondylitis Functional Index (BASFI)  
The BASFI is a set of [ADDRESS_1236835] 8 questions consider activities related to functional anatomy. The final 2  questions 
assess the patients’ ability to cope with everyday life. A 0 through 10 scale (captured by a 
continuous VAS) is used to answer the questions. The mean of the ten scales gives the BASFI score – a value between 0 and 10. 
6.4.5  Bath Ankylosing Spondylitis Disease Acti vity Index (BASDAI)  
The BASDAI consists of a 0 through 10 scale ([ADDRESS_1236836] 
problem, captured as a continuous VAS), which is used to answer 6 questions pertaining to the 5 major symptoms of AS: 
1. Fatigue  
2. Spi[INVESTIGATOR_18172]  
3. Joint pai n / swelling  
4. Areas of localized tenderness (called enthesitis, or inflammation of tendons and ligaments)  
5. Morning stiffness duration  
6. Morning stiffness severity  
To give each symptom equal weighting, the mean (average) of the two scores relating to 
morning stiffness is taken (questions 5 and 6). The resulting 0 to 10 score is added to the scores from questions 1- 4. The resulting 0 to 50 score is divided by 5 to give a final 0–[ADDRESS_1236837] suboptimal control of disease, and patients with scores of 4 or greater are usually good candidates for either a change in their medical therapy or for enrollment in clinical trials evaluating new drug therapi[INVESTIGATOR_90159]. BASDAI is a quick and simple index taking between 30 seconds and 2 minutes to complete. 
[COMPANY_001]  Confidential  Page 64  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 [IP_ADDRESS]  BASDAI [ADDRESS_1236838] 50% in the BASDAI compared to 
baseline.  
6.4.
8 High sensitivity C -reactive protein (hsCRP)  
This assessment will be performed in order to identify the presence of inflammation, to determine  its severity, and to monitor response to treatment. 
Since the results of this test may unblind study personnel, results from the central lab will be provided for screening and baseline only. The hsCRP results from samples collected during the treatment pe riod will be revealed following database lock only. 
6.4.10   ASDAS -CRP  response categories  
The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a composite index to assess disease activity in AS.  

[COMPANY_001]  Confidential  Page 65  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 The  ASDAS -CRP (Ankylosing S pondylitis Disease Activity Score) will be 
utilized to assess the disease activity status. Parameters used for the ASDAS include spi[INVESTIGATOR_18172] 
(BASDAI question 2), the patient global assessment of disease activity, peripheral pain/swelling (BASDAI question 3), duration of morning stiffness (BASDAI question 6) and C-reactive protein (CRP) in mg/L  (Sieper et al 2009 , 
Lukas et al 2009).  
Disease activity states are inactive disease, moderate disease activity, high disease activity, and 
very high disease activity. The 3 values selected to separate these states were < 1.3 between inactive disease and moderate disease activity, < 2.1 between moderate disease activity and high disease activity, and > 3.5 between high disease activity and very high disease activity. Selected cutoffs for improvement scores were a change ≥ 1.1 unit for “minimal clinically important improvement” and a change ≥ 2.0 uni ts for “major improvement” ( Machado et al 
2011).  
6.
4.12 MRI 
MRIs will be obtained as defined in the schedule of assessments ( Table 6 -1) and according to 
the imaging acquisition guidelines provided by [CONTACT_884170]. The MRI for each 

[COMPANY_001]  Confidential  Page 66  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 patient will include T1 and STIR sequences of the sagittal spi[INVESTIGATOR_050] (cervical, thoracic and lumbar) 
and oblique coronal of the pelvis including both sacroiliac joints. These MRI images should be transferred as anonymized electronic files to the central imaging lab following acquisition. The central imaging lab will conduct independent review for all spi[INVESTIGATOR_884134].  
6.4.13  X- ray 
X-rays will be obtained as defined in the schedule of assessments ( Table 6 -1) and according to 
the imaging acquisition guidelines provided by [CONTACT_884170]. The X -ray requirements 
include  
anterio -posterior view of the pelvis including 
visibility of both sacroiliac joints for modified [LOCATION_001] AS determination. These images should be transferred to the central imaging lab following acquisition. Some X -rays may need 
to be repeated if deemed unevaluable by [CONTACT_9559]. In case of insufficient quality, the center will be advised and trained on any quality issues prior to the repeat X -ray, to keep any repeat 
X-rays to a minimum.  
The central imaging lab will conduct independent review for all spi[INVESTIGATOR_58886] X -rays in 
this trial.  
6.4.[ADDRESS_1236839] X -ray, as well as X -rays of part 
of the thoracic, the cervical and lumbar spi[INVESTIGATOR_884135]. The radiation exposure from these 
procedures is not necessary for medical care but is intended for research purposes only. 
The amount of cumulative annual  radiation in this study is about 3.4 mSv for the combined X-
ray procedures and is based on effective doses for various diagnostic radiological procedures 
reported in literature ( Mettler et al 2008 ). This exposure is comparable to the natural radiation 
an average person receives in one year. The radiation dose between 3 mSv and 50 mSv is considered ‘minimal’ ( Stabin et al 2009). Therefore, the radiation exposure in this study 
involves minimal risk and is necessary to obtain the research information desired. 
6.5 Safety 
• QuantiFERON TB -Gold test or [COMPANY_003] skin test 
• Chest X -ray or MRI 
• Physical examination  
• Vital signs  
• Height and weight 
• Laboratory evaluations  
  
• Electrocardiogram  
• Pregnancy and assessment of fertility  

[COMPANY_001]  Confidential  Page 67  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 • Local tolerability (Injection site reactions)  
• Tolerability of secukinumab 
All blood draws and safety assessments should be done prior to study treatment administration. 
Appropriate safety assessments (e.g., evaluation of AEs and SAEs including injection site reactions) should be repeated after the dose is administered. 
6.5.[ADDRESS_1236840] may participate in the study if further work up (according to local 
practice/guidelines) establishes conclusively that the patient has no evidence of active tuberculosis, or if presence of latent tuberculosis is established then treatment according to local guidelines must have been initiated. 
QuantiFERON TB -Gold test  
A QuantiFERON TB -Gold test is to be performed at the second screening visit and the results 
to be available prior to randomization to determine the patient’s eligibility. The test will be used 
to screen the patient population for latent tuberculosis infection.  
The test will be analyzed by [CONTACT_2237]. Details on the collection, processing and 
shipment of samples and reporting of results by [CONTACT_90209]. 
[COMPANY_003] skin test  
A [COMPANY_003] skin test is to be performed at screening and read before randomization  to determine the 
patient’s eligibility for the trial. The test dose is bioequivalent to [ADDRESS_1236841] superficial layer under the skin. If given correctly, the injection should raise a small wheal of about 5 mm, which resolves within 10-15 minutes.  
Since the reaction (in duration) will take 48-[ADDRESS_1236842] return to the 
investigators’ site within that time for a proper evaluation of the injection site. This will determine whether the patient has had a significant reaction to the [COMPANY_003] test. A reacti on is 
measured in millimeters of induration (hard swelling) at the site. A [COMPANY_003] skin induration ≥5  mm 
(or according to local practice/guidelines) is interpreted as a positive result.  
6.5.[ADDRESS_1236843] X -ray or MRI at screening (or within 3 months prior to screening) is performed to rule 
out the presence of a pulmonary malignancy or infectious process, in particular, tuberculosis. 
6.5.[ADDRESS_1236844] in sitting position. 
If possible, vital signs assessments should be performed by [CONTACT_90208]. 
6.5.5  H eight and weight  
Height in centimeters (cm) and body weight (to the nearest 0.1 kilogram [kg] in indoor clothing) 
(both without shoes) will be measured. 
If possible, body weight assessments should be performed by [CONTACT_884171]. 
6.5.6  Laboratory evaluations  
A central laboratory will be used for analysis of all specimens collected listed below (except 
urinalysis). Details on the collection, shipment of samples and reporting of results by [CONTACT_884172]. For the identification of clinically notable 
values, see Appendix 1. All patients with laboratory tests containing clinically significant 
abnormal values are to be followed until the values return to normal ranges or until a valid 
reason, other than treatment related AE, is defined.  
[IP_ADDRESS]  Hematology  
Hemoglobin, platelet, red blood cell, white blood cell (WBC) and differential white blood cell counts will be measured  at scheduled visits.  
[IP_ADDRESS]  Clinical chemistry  
Serum chemistries will include glucose, urea, creatinine, total bilirubin, AST (SGOT), ALT (SGPT), GGT, alkaline phosphatase, sodium, potassium, bicarbonate, calcium, phosphorus, total protein, albumin, and uric acid.  
[IP_ADDRESS]  Lipid panel  
A lipid profile including High Density Lipoprotein, Low Density Lipoprotein, cholesterol and triglycerides  will be measured from a fasting blood sample. 
A cardiovascular profile including lipoprotein (a), apolipoprotein B, apolipoprotein A -1, and 
adiponectin will be measured from a fasting blood sample. 
[COMPANY_001]  Confidential  Page 69  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 [IP_ADDRESS]  Urinalysis  
Dipsticks will be provided by [CONTACT_250361]. 
The urinalysis results for standard parameters such as protein, glucose, blood and WBCs will be recorded in the appropriate eCRF page.  
  
 
  
 
 
 
 
6.
5.8 Electrocardiogram (ECG)  
A standard [ADDRESS_1236845] be performed on the ECG machines provided for the study. 
All ECGs will be independently reviewed. Instructions for the collection and transmission of 
the ECGs to the independent reviewer will be provided in the ECG investigator manual. 
Clinically relevant abnormalities should be r ecorded on the relevant medical history/Current 
medical conditions eCRF page for the baseline ECG.  Clinically relevant abnormalities noted after the baseline ECG should be reported as AE 
(Section 7.1).  
6.5.[ADDRESS_1236846] (serum 
pregnancy test) performed at the second screening visit and local urine pregnancy tests as indicated in Table [ADDRESS_1236847] requires immediate 
interruption of study drug until serum β -hCG is performed and found to be negative. 

[COMPANY_001]  Confidential  Page 70  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 6.5.10  Local tole rability (Injection site reactions)  
The local tolerability at the site of s.c. injection of the study treatment will be assessed in case 
of any local reaction, until this has disappeared.  
The assessment of pain, redness, swelling, induration, hemorrhage and itching will be 
performed by a physician and will be recorded on the Adverse Events eCRF, including the severity (mild, moderate, severe) and the duration. 
6.5.[ADDRESS_1236848] for this indication/patient population.  
The safety measures used in this study are reliable and relevant standard measures for a biologic 
in nr-axSpA.  
The safety assessments selected are standard and adequate for this indication/patient population.  
6.6 Other assessments  
• Health -related Quality of Life  
•  
• HLA-B27 
•  
•  
•  
6.6.[ADDRESS_1236849] of nr -axSpA on various aspects of patient's health- related quality of life (QoL) will 
be assessed by [CONTACT_858416]: 
• SF-36 
• ASQoL  
  
  
  
All questionnaires will be available, where possible, in the local languages of the participating 
countries. 
All questionnaires will be completed at the scheduled study visit prior to the patient seeing the 
investigator for any other clinical assessment or evaluation. The patient should be given sufficient instruction, space, time and privacy to complete the questionnaires. The study coordinator should check each questionnaire for completeness and encourage the patient to complete any missing responses. Guidelines for administering the PRO questionnaires can be 

[COMPANY_001]  Confidential  Page 71  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 found in Appendix 8. A detailed training manual relating to the administrative procedures of 
the questionnaires will be provided to the sites. 
Complet ed questionnaires will be reviewed and examined by [CONTACT_093], before the clinical 
examination, for responses that may indicate potential adverse events (AEs) or serious adverse 
events (SAEs). The investigator should review not only the responses to the questions in the questionnaires but also for any unsolicited comments written by [CONTACT_102]. If AEs or SAEs are confirmed, then the physician must record the events as per instructions given in App endix [ADDRESS_1236850] 
time a questionnaire  is administered.  
[IP_ADDRESS]  Medical Outcome Short Form Health Survey (SF -36) Version 2 (Acute 
Form)  
The SF -36 is a widely used and extensively studied instrument to measure health- related quality 
of life among healthy patients and patients with acute and chronic conditions. It consists of eight subscales that can be scored individually: Physical Functioning, Role -Physical, Bodily Pain, 
General Health, Vitality, Social Functioning, Role -Emotional, and Mental Health ( Ware and 
Sherbourne 1992). Two overall summary scores, the Physical Component Summary and the 
Mental Component Summary also can be computed ( McHorney et al 1993 ). The SF -36 has 
proven useful in monitoring general and specific populations, comparing the relative burden of different disease, differentiating the health benefits produced by [CONTACT_506001], and in screening individual patients. 
The purpose of the SF -36 in this study is to assess the health- related QoL of patients. Given the 
acute nature of this disease, version 2, with a 1-week recall period, will be used in this study.  The use of the SF -36, especially the SF -36 physical component summary (PCS), in patients 
with nr -axSpA can be supported. While SF -[ADDRESS_1236851] and known-groups validity as well as good correlations with clinical outcomes in nr-
axSpA. 
[IP_ADDRESS]  Ankylosing Spondylitis Quality  of Life (ASQoL)  
The ASQoL is a self -administered questionnaire designed to assess health- related quality of life 
in adult patients with Ankylosing Spondylitis. The ASQoL contains 18 items with a 
dichotomous yes/no response option. A single point is assigned for each "yes" response and no points for each "no" response resulting in overall scores that range from 0 (least severity) to 18 (highest severity). As such, lower score indicate better quality of life. Items include an assessment of mobility/energy, s elf-care and mood/emotion. The recall period is "at the 
moment," and the measure requires approximately 6 minutes to complete. 
The purpose of the ASQoL is to assess the disease specific QoL of patients in this study.  
[COMPANY_001]  Confidential  Page 72  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 

[COMPANY_001]  Confidential  Page 73  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 6.6.3  HLA- B27 
A blood sample to analyze Human Leukocyte Antigen- B27 (HLA -B27) will be obtained from 
all patients at screening . 
Details on the collection, handling and shipment of the sample to the central laboratory will be 
provided to investigators in the laboratory ma nual.  

[COMPANY_001]  Confidential  Page [ADDRESS_1236852] medical occurrence (i.e., any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a patient or clinical investigation subject after providing written informed consent  for participation in the study. 
Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product. 
The occurrence of adverse events should be sought by [CONTACT_105]- directive questioning of the patient 
at each visit during the study. Adverse events also may be detected when they are volunteered 
by [CONTACT_24479], laboratory test, or other assessments.  
Abnormal laboratory values or test results constitute adverse events only if t hey fulfill at least 
one of the following criteria: 
• they induce clinical signs or symptoms,  

[COMPANY_001]  Confidential  Page 76  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 • they are considered clinically significant,  
• they require therapy.  
Clinically significant abnormal laboratory values or test results should be identified through a 
review of values outside of normal ranges/clinically notable ranges, significant changes from baseline or the previous visit, or values which are considered to be non- typi[INVESTIGATOR_90160]. Investigators have the responsibility for managing the safety of individual patient and identifying adverse events. Alert ranges for labs and other test abnormalities are included in Appendix 1. 
Adverse events should be recorded in the AE eCRF under the signs, symptoms, or diagnosis 
associated with them, accompanied by [CONTACT_6644]. 
• the severity grade  
• mild: usually transient in nature and generally not interfering with normal activities  
• moderate: sufficiently discomforting to i nterfere with normal activities  
• severe: prevents normal activities  
• its relationship to the study treatment (no/yes)  
• its duration (start and end dates), or if the event is ongoing, an outcome of not 
recovered/not resolved should be reported. 
• whether it cons titutes a serious adverse event (SAE)  
• action taken regarding study treatment 
• whether other medication or therapi[INVESTIGATOR_95254] (concomitant medication/non- drug therapy) 
• its outcome (not recovered/not resolved; recovered/resolved; recovering/resolving, recovered/resolved with sequelae; fatal; or unknown) 
Once an adverse event is detected, it should be followed until its resolution or until it is judged to be permanent, and assessment should be made at each visit (or more frequently, if necessary) of any changes in severity, the suspected relationship to the study drug, the interventions 
required to treat it, and the outcome. 
Information about common side effects already known about the investigational drug can be 
found in the IB or will be communicated between IB updates in the form of Investigator Notifications. This information will be included in the patient informed consent and should be discussed with the patient during the study as needed. 
The investigator should also instruct each patient to report any new adverse event (beyond the 
protocol observation period) that the patient, or the patient’s personal physician, believes might reasonably be related to study treatment. This information should be recorded in the investigator’s source documents, however, if the AE meets the criteria of an SAE, it must be reported to [COMPANY_001]. 
[COMPANY_001]  Confidential  Page 77  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 7.2 Serious adverse events 
7.2.1  Definition of SAE  
An SAE is defined as any adverse event (appearance of (or worsening of any pre -existing) 
undesirable sign(s), symptom(s) or  medical conditions(s) which meets any one of the following 
criteria:  
• is fatal or life -threatening  
• results in persistent or significant disability/incapacity  
• constitutes a congenital anomaly/birth defect 
• requires inpatient hospi[INVESTIGATOR_1081], unless hospi[INVESTIGATOR_062]: 
• routine treatment or monitoring of the studied indication, not associated with any 
deterioration in condition  
• elective or pre- planned treatment for a pre -existing condition that is unrelated to t he 
indication under study and has not worsened since signing the informed consent 
• treatment on an emergency outpatient basis for an event not fulfilling any of the definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_063]  
• social reasons and  respi[INVESTIGATOR_064]’s 
general condition 
• is medically significant, i.e. defined as an event that jeopardizes the patient or may require medical or surgical intervention. 
All malignant neoplasms will be assessed a s serious under “medically significant” if other 
seriousness criteria are not met.  
Life-threatening in the context of a SAE refers to a reaction in which the patient was at risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetically might have caused death if more severe (see Annex IV, ICH -E2D Guideline). 
Medical and scientific judgment should be exercised in deciding whether other situations should be considered serious reactions, such as important medical events that might not be immediately life threatening or result in death or hospi[INVESTIGATOR_76593]. Examples of such events are intensive treatment in an emergency r oom or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_6536] (see Annex IV, ICH-E2D Guideline). 
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.  
All AEs (serious and non- serious) are captured on the e CRF, SAEs also require individual 
reporting to Drug Safety and Epi[INVESTIGATOR_623] (DS&E) as per Section 7.2.2. 
[COMPANY_001]  Confidential  Page [ADDRESS_1236853] be reported to [COMPANY_001]/CRO within 24 hours of learning of its occurrence. 
Any SAEs experienced after this period should only be reported to [COMPANY_001]/CRO if the 
investigator suspects a causal relationship to study treatment. 
Recurrent epi[INVESTIGATOR_1841], complications, or progression of the initial SAE must be reported as follow -
up to the original epi[INVESTIGATOR_1865], regardless of when the event occurs. This report must be submitted 
within 24 hours of the investigator receiving the follow -up information. An SAE that is 
considered completely unrelated to a previously reported one should be reported separately as a new event.  
Information about all SAEs (either initial or follow -up information) is collected and recorded 
in English on the paper Serious Adverse Event Report Form or the electronic Serious Adverse Event Form within the EDC system (where available). The Investigator must assess the relationship to each specific component of the study treatment (if the study treatment consists of several components). 
SAEs (initial and follow -up) that are recorded on the paper  SAE form should be faxed within 
24 hours of awareness of the SAE to the local [COMPANY_001]/CRO Drug Safety and Epi[INVESTIGATOR_31908]. The telephone and fax number of the contact [CONTACT_146537]&E, specific to the site, are listed in th e investigator folder provided to each site. The original 
copy of the SAE Report Form and the fax confirmation sheet must be kept with the case report form documentation at the study site. Follow -up information should be provided using a new 
paper SAE Repo rt Form stating that this is a follow -up to a previously reported SAE. 
SAEs (initial and follow -up) that are recorded electronically in the EDC system should be 
submitted  within 24 hours of awareness of the SAE or changes to an existing SAE. Detailed 
instructions regarding the submission process and requirements for signature [CONTACT_884193]. 
Follow- up information provided should describe whether the event has resolved or continues, 
if and how it was treated, whether the treatment code was broken or not and whether the patient 
continued or withdrew from study participation. Each re -occurrence, complication, or 
progression of the original event should be reported as a follow -up to that event regardless of 
when it occurs. 
If the SAE is not previously documented in the IB or Package Insert (new occurrence) and is 
thought to be related to the investigational treatment a Drug Safety and Epi[INVESTIGATOR_187869]. [COMPANY_001]/CRO may need to issue an Investigator Notification (IN) to inform all investigators involved in any study with the same investigational treatment that this SAE has been reported. Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) will be collected and reported to the competent authorities and relevant ethics committees in accordance with Directive 2001/20/EC or as per national regulatory requirements in participating countries. 
[COMPANY_001]  Confidential  Page [ADDRESS_1236854] of blocking IL -17A on the kidney. All patients with laboratory tests containing 
clinically significant abnormal values (see Appendix 1 for notable laboratory values) are to be 
followed until the values return to normal ranges or until a valid re ason, other than treatment 
related AE, is defined. Standard renal function tests (blood urea nitrogen, serum creatinine) will be obtained at regular intervals, but special measures for renal safety monitoring are not planned. 
7.[ADDRESS_1236855] be reported to 
[COMPANY_001]/CRO within 24 hours of learning of its occurrence. The pregnancy should be followed up to determine outcome, including spontaneous or voluntary termination, details of the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal and/or newborn complications. The study drug must be discontinued, though the patient may stay in the study, if she wishes to do so. All assessments that are considered as a risk during pre gnancy 
must not be performed. The patient may continue all other protocol assessments. 
Pregnancy must be recorded on a Pharmacovigilance Pregnancy Form and reported by [CONTACT_884173]/CRO Drug Safety and Epi[INVESTIGATOR_066]. Pregnancy follow- up should be recorded on the same form and should include an assessment of the 
possible relationship to the [COMPANY_001]/CRO study drug of any pregnancy outcome. Any SAE experienced during pregnancy must be reported on the SAE Report Form. 
8 Data re view and database management  
The study originally used two data collection systems, eSource and OC/RDC. The systems were chosen according to the countries and only one system was in place in each site. Due to the 
discontinuation of the eSource system, all sites using eSource will switch to OC/RDC and this will be the only data capture system in the study moving forward. All collected data from eSource will be provided to the sites for documentation and will be included in OC/RDC. 
[COMPANY_001]  Confidential  Page 80  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 8.1 Site monitoring 
Before stud y initiation, at a site initiation visit or at an investigator’s meeting, a [COMPANY_001] 
representative will review the protocol and data capture tools with the investigators and their staff. During the study, [COMPANY_001] employs several methods of ensuring protocol and GCP compliance and the quality/integrity of the sites’ data. The field monitor will visit the site to check the completeness of patient records, the accuracy of entries on the eCRFs, the adherence to the protocol and to Good Clinical Practice, the progress of enrollment, and to ensure that study treatment is being stored, dispensed, and accounted for according to specifications. Key study personnel must be available to assist the field monitor during these visits. Continuous remote monitoring of eac h site’s data may be performed by a centralized [COMPANY_001] CRA 
organization. Additionally, a central analytics organization may analyze data & identify risks & trends for site operational parameters, and provide reports to [COMPANY_001] Clinical Teams to assist with trial oversight.  
The investigator must maintain source documents for each patient in the study, consisting of case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information in the eCRF must be traceable to the source documents in the 
patient's file. The investigator must also keep the original informed consent form signed by [CONTACT_102] (a signed copy is given to the patient). 
The investigator must give the monitor access to all relevant source records.  [COMPANY_001] 
monitoring standards require full verification for the presence of informed consent, adherence to the inclusion/exclusion criteria, documentation of SAEs, and of data that will be used for all primary variables.  No information in source documents about the identity of the patients will 
be disclosed.  
8.2 Data collection 
This study originally incorporated technology (eSource) to capture source document s and 
source data electronically, consistent with FDA guidance ( CDER 2013) regarding electronic 
source and regulations related to the maintenance of adequate patient case histories (21CFR 
312.62 (b)), but this was discontinued during the conduct of the study.   
Designated investigator staff will enter the data required by [CONTACT_109051]/RDC 
system. Designated investigator site staff will not be given access to the system until they have been trained.  
Autom atic validation procedures within the system check for data discrepancies during and 
after data entry and, by [CONTACT_105273], allow the data to be confirmed 
or corrected online by [CONTACT_105274]. The Investiga tor must certify that 
the data entered into the electronic Case Report Forms  are complete and accurate. After 
database lock, the investigator will receive copi[INVESTIGATOR_314192].  
8.3 Database management and quality control 
[COMPANY_001]/CRO staff review the data entered into the eCRFs by [CONTACT_884174] [ADDRESS_1236856], which employs the Anatomical Therapeutic Chemical classification system. 
Concomitant procedures, non- drug therapi[INVESTIGATOR_90162] (MedDRA) terminology.  
Laboratory samples will be processed centrally and the resu lts will be sent electronically to 
[COMPANY_001] /CRO.  
ECG readings will be processed centrally and the results will be sent electronically to [COMPANY_001]/CRO.  
Randomization codes and data about all study drug(s) dispensed to the patient will be tracked using an IRT. The system will be supplied by a vendor, who will also manage the database. The database will be sent electronically to [COMPANY_001] /CRO.  
Each occurrence of a code break via IRT will be reported to the clinical team and monitor. The code break functionality will remain available until study shut down or upon request of [COMPANY_001].  
The occurrence of relevant protocol deviations will be determined. After these actions have 
been completed and the database has been declared to be complete and accurate, it will be locked and the treatment codes will be unblinded and made available for data analysis. Any changes to the database after that time can only be made after written agreement by [CONTACT_109053].  
8.[ADDRESS_1236857] of the trial as applicable.  
Details regarding t he adjudication process will be available in the relevant secukinumab 
Adjudication Committee charter.  

[COMPANY_001]  Confidential  Page 82  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 9 Data analysis 
Summary statistics for continuous variables will generally include the number of patient s (N), 
minimum, lower quartile, mean, median, upper quartile, and maximum. For categorical or binary variables, the number and percent of patient s in each category will be presented. P -values 
presented will be two -sided unless otherwise specified.  
Data analyses will be presented by [CONTACT_1570] . Efficacy and safety data for Treatment  
Period 1 and Treatment Period 2 will be presented by [CONTACT_716] t hree treatment groups. 
Patient s may be included in more than one treatment group for some analyses (e.g.,  exposure-
adjusted adverse events over the entire treatment period).  
• Secukinumab 150 mg with loading regimen 
• Secukinumab 150 mg with no loading regimen 
• Placebo  
Note that the treatment groups above for a patient  may differ depending on the time period of 
the analysis and whether one assesses the patient  for efficacy or safety (see Section 9.1  for 
details). Data may be presented by a combination of the ‘original’ and ‘switch’ treatment groups. These treatment groups represent the treatment combinations the patient s experience 
over the course of the entire trial (e.g., placebo patients who are reassigned to 150 mg secukinumab). 
9.1 Analysis sets  
The following analysis sets will be used in this trial: 
Randomized set:  The randomized set will be defined as all patient s who were randomized. 
Unless otherwise specified, mis -randomized patient s (mis -randomized in IRT) will be excluded 
from the randomized set.  Full analysis set (FAS) : The FAS will be comprised of all analyzabl e patient s from the 
randomized set to whom study treatment has been assigned. Following the intent -to-treat 
principle, patient s will be evaluated according to the treatment assigned to at randomizati on, 
but actual stratum.  
Safety set : The safety set includes all patients who took at least one dose of study treatment 
during the treatment period. Patients will be evaluated according to treatment received. 
9.2 Patient demographics and other baseline characteristics  
Demographics and baseline characteristics 
The following common background and demographic variables will be summarized:   
• Gender, age, race, ethnicity, weight, height, and BMI. 
Baseline disease characteristics will also be summarized for the following variables:  
• Patient’s global assessment of disease activity and other ASAS components, hsCRP (mg/L 
and >ULN) ,  prior use (yes/no) of TNF -alpha inhibitors, use (yes/no) and 
separate dose of MTX (mg/week), sulfasalazine (g/day) and systemic corticosteroids (mg/day) at randomization, time since first diagnosis of inflammatory back pain and nr -

[COMPANY_001]  Confidential  Page 83  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 axSpA (years), modified [LOCATION_001] criteria for AS, HLA -B27,  total back pain 
(VAS), nocturnal back pain (VAS), total BASDAI score, spi[INVESTIGATOR_18172] (BASDAI question #2) and BASMI components (all seven in original units), presence of SIJ inflammation by [CONTACT_884175] ( CRP+/MRI+, CRP+/MRI -, CRP -/MRI+ ). 
Medical history  
A history of nr-axSpA with focus on previous extra -articular involvement and past therapi[INVESTIGATOR_884136]-axSpA will be o btained  and summarized by [CONTACT_1570]. Any other significant prior 
or active medical condition at the time of signing informed consent will be recorded and coded using the MedDRA dictionary. These medical conditions will be summarized by [CONTACT_884176].  
To establish a baseline level of cardiovascular risk, the number and percentage of patient s with 
pre-solicited cardiovascular risk factors will be summarized by [CONTACT_1570]. The number 
of cardiovascular risk factors tha t each patient  has will also be summarized by [CONTACT_1570]. 
If it is unknown whether or not a patient  currently or previously experienced a specific 
cardiovascular risk factor, it will be assumed that cardiovascular risk factor did not occur for that pa tient. 
9.3 Treatments 
Study treatment  
The analysis of study treatment data will be based on the safety set. The number of visits with active and placebo injections received will be presented by [CONTACT_1570].  
The duration of exposure to study treatment will  also be summarized by [CONTACT_1570]. In 
addition, the number and percentage of patient s with cumulative exposure levels (e.g., any 
exposure, ≥ 1 week, ≥ 2 weeks, ≥ 4 weeks, ≥ 8 weeks, etc.) will be presented. 
Prior and concomitant medication  
Prior and c oncomitant medications will be summarized in separate tables by [CONTACT_1570].  
Prior medications are defined as treatments taken and stopped prior to first dose of study 
treatment. Any medication given at least once between the day of first dose of study treatment 
and within [ADDRESS_1236858] dose  will be a concomitant medication, including those which were 
started pre -baseline and continued into the period where study treatment is administered. 
Medications will be presented in alphabetical order, by [CONTACT_884177] 
(ATC) codes and grouped by [CONTACT_121975]. Tables will show the overall number and percentage of patient s receiving at least one treatment of a particular ATC code and at least one 
treatment in a particular anatomi cal main group. 
Significant prior and concomitant non- drug therapi[INVESTIGATOR_471715]. 
The number and percentage of patient s receiving prior and concomitant nr-axSpA therapy will 
be presented by [CONTACT_144971][INVESTIGATOR_144930] (primary lack 
of efficacy, secondary lack of efficacy, lack of tolerability, other) and the total duration of 

[COMPANY_001]  Confidential  Page 84  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 exposure to nr -axSpA therapi[INVESTIGATOR_144931].  
 use will be summarized.  
9.4 Analysis of the primary variable(s) 
Details of the testing strategy including primary and secondary endpoints are provided in 
Section 9.5. 
9.4.1  Variable(s)  
Primary endpoint for analysis plan A 
The primary efficacy variable is response to treatment according to the ASAS40  criteria at 
Week 16  in TNF  naïve patients . The analysis of the primary variable will be based on the FAS 
patient s. 
Primary endpoint for analysis plan B 
The primary efficacy variable is response to treatment according to the ASAS40  criteria at 
Week 52 in TNF  naïve patients . The analysis of the primary variable will be based on the FAS 
patient s. 
9.4.2  Statistical model, hypothesis, and method of analysis  
Primary endpoint for analysis plan A 
The statistical hypothesis for ASAS40  being tested is that there is no difference in the proportion 
of TNF naïve patient s fulfilling the ASAS40 criteria at Week 16 in secukinumab with loading  
regimen versus placebo regimen. 
Let p j denote the proportion of ASAS40  responders at Week 16 in TNF n aïve patients  for 
treatment regimens j , j=0, 1, where  
• 0 corresponds to placebo regimen, 
• 1 corresponds to secukinumab 150 mg with loading regimen,  
In statistical terms, H 1: p1 = p 0, HA1: p1 ≠ p 0, i.e. 
H1: secukinumab [ADDRESS_1236859] to ASAS40 
response in TNF naïve patients  at Week 16  
The primary analysis will be conducted via logistic regression with treatment and  stratification 
factor  (CRP+/MRI+, CRP+/MRI -, CRP -/MRI+ ) as factors and weight as a covariate. Odds 
ratios and 95% CI will be presented comparing secukinumab regimen to placebo. 
Primary endpoint for analysis plan B 
The statistical hypothesis for ASAS40  being tested is that there is no difference in the proportion 
of TNF naïve patient s fulfilling the ASAS40  criteria (and did not escape) at Week 52  in 
secukinumab without loading regimen versus placebo regimen. Let p
j denote the proportion of ASAS40  responders at Week 52 in TNF naïve  patients  for 
treatment regimens j , j=0, 1, where  
• 0 corresponds to placebo regimen, 

[COMPANY_001]  Confidential  Page 85  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 • 1 corresponds to secukinumab 150 mg without loading regimen , 
In statistical terms, H 1: p1 = p 0, HA1: p1 ≠ p 0, i.e. 
H1: secukinumab [ADDRESS_1236860] to 
ASAS40 response in TNF naïve patients  at Week 52 
The primary analysis will be conducted via logistic regression with treatment and  stratification 
factor ( CRP+/MRI+, CRP+/MRI -, CRP -/MRI+ ) as factors and weight as a covariate. Odds 
ratios and 95% CI will be presented comparing secukinumab regimen to placebo. 
9.4.3  Handling of missing values/censoring/discontinuations  
Missing data for ASAS20/40 response and other binary efficacy variables (e.g., ASAS5/6, etc.) 
for data up to W eek 52 will be handled as follows: 
1. Patie nts who drop out of the trial for any reason will be considered as non-responders 
from the time they drop out through Week [ADDRESS_1236861] the required data to compute responses (e.g., ASAS 
components) at baseline and at the specific time point will be classified as non -responders 
at the specific time  point.   
Patients who are unblinded will be considered non- responders from the time of unblinding up 
to Week 52. The primary analysis will use non-responder imputation.  
Continuous variables (e.g., ASAS components) with the exception of MRI endpoints , will be 
analyzed using a mixed- effects model repeated measures (MMRM) which is valid under the 
missing at random (MAR) assumption. As such, single -point imputation of missing data will 
not be performed (e.g., LOCF). For analyses of these parameters, if all post -baseline values are 
missing then these missing values will not be imputed and this patient  will be removed from 
the analysis of the corresponding variable, i.e., it might be that the number of patient s providing 
data to an analysis is smaller than the number of patient s in the FAS. 
For SI joint edema on MRI a multiple imputation approach will be applied to handle missing 
data.  
Data post treatment switch  decision (see Section 5.5.6) 
In general, data for patients where a decision was made to switch treatment will be handled in the following fashion up to Week 52:   
• For binary endpoints, patients will be considered non-responders after switching. This will 
be done for all treatment regi mens in order to minimize bias for between- treatment 
comparisons. However, the actual response rates will also be summarized without considering the patients as non-responders as they provide insight into the long- term 
response profile within each treatment regimen.   
• For continuous endpoints (ASQoL and SI joint edema score on MRI) , a composite 
estimand strategy will be applied and data after switch will be set to the worst possible outcome. Rank-based analysis will be used for hypothesis testing.  
• If applic able, difference in trimmed means estimate will be used to summarize  the 
treatment effect estimate for the continuous composite endpoint 
[COMPANY_001]  Confidential  Page 86  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 • For continuous endpoints the actual observed values after switch will be also summarized  
with descriptive statistics  
• A supplementary estimand principal stratum strategy might be used to quantify treatment 
effect in population of subjects who would adhere in case randomized  to secukinumab 
•  
9.4.[ADDRESS_1236862]. 
In order to determine the robustness of the logistic regression model used for the primary 
analysis, ASAS40 response in TNF naïve  patients at Week 16 and Week 52 will also be 
evaluated using a non -parametric regression ( Koch et al 1998) model with the same independent 
variables as the logistic regression model. 
The impact of missing data on the analysis results of ASAS40 in TNF naï ve patients  will be 
assessed as well by [CONTACT_884178]. These may include, but are not limited to: 
• Multiple imputation  
• Observed based on randomized treatment (based on patients providing data at a specific 
visit regardless of current treatment, i.e. also using data collected after switch decision point).  
• Tippi[INVESTIGATOR_18275] 
9.5 Analysis of secondary variables  
9.5.1  Secondary efficacy variables  
Secondary endpoints for analysis plan A  
The secondar y efficacy variables and the method for adjusting for multiplicity are described 
below. Secondary efficacy variables will be analyzed using the FAS population. 
ASAS 40 at Week 16  
The proportion of patients meeting the response criteria will be evaluated using a logistic 
regression model with treatment group , stratification factor  (CRP+/MRI+, CRP+/MRI -, CRP -
/MRI+ ) and TNF- α status as factors  and weight as a covariate.  
ASAS 5/6 at Week 16  
The proportion of patients meeting the response criteria will be evaluated using a logistic regression model with treatment group , stratification factor  (CRP+/MRI+, CRP+/MRI -, CRP -
/MRI+ ) and TNF- α status as factors  and weight as a covariate.  
[COMPANY_001]  Confidential  Page 87  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 BASDAI at Week  16 
Between -treatment differences in the change from baseline in BASDAI will be evaluated using 
MMRM with treatment group , stratification factor ( CRP+/MRI+, CRP+/MRI -, CRP -/MRI+ ), 
TNF -α status, and analysis visit  as factors and baseline BASDAI score and weight as continuous 
covariates. Treatment by [CONTACT_884179]. An unstructured covariance structure will be assumed for the model. The significance of the treatment  effect for secukinumab regimens  at 
different analysis visits will be determined from the pairwise comparisons performed between secukinumab regimens and placebo at the appropriate analysis visits. 
BASDAI50 at Week 16 
The proportion of patients meeting the  response criteria will be evaluated using a logistic 
regression model with treatment group , stratification factor  (CRP+/MRI+, CRP+/MRI -, CRP -
/MRI+ ) and TNF- α status as factors  and baseline weight and BASDAI score as covariates. 
hsCRP at Week [ADDRESS_1236863] that the data are not 
normally distributed ( Huffman et al 2006), analysis will be performed on the log
e ratio of the 
treatment value vs baseline value (calculated by [CONTACT_319690] -baseline value by [CONTACT_750668] e transformation) to normalize the distribution of hsCRP at each 
analysis visit. Between -treatment differences in the change in hsCRP relative to baseline will 
be evaluated using MMRM with treatment group, stratification factor ( CRP+/MRI+, 
CRP+/MRI -, CRP -/MRI+),  TNF -α status, and analysis visit as factors and log e baseline hsCRP 
and weight as continuous covariates. Treatment by [CONTACT_750669] e baseline hsCRP by 
[CONTACT_884180]. An unstructured covariance structure will be assumed for the model. The significance of the secukinumab treatment effect for secukinumab regimens at different analysis visits will be determined from the pairwise 
comparisons performed between secukinumab regimens and placebo at the appropriate analysis visits. The estimate and the 2 -sided 95% confidence intervals obtained from the model will be 
back transformed to the ori ginal scale.  
SF-36 PCS at Week 16 
See Section 9.5.4. 
ASQoL  at Week 16  
See Section 9.5.4. ASAS20  at Week 16  
The proportion of patients meeting the response criteria will be evaluated using a logistic 
regression model with treatment group , stratification factor  (CRP+/MRI+, CRP+/MRI -, CRP -
/MRI+ ) and TNF- α status as factors  and weight as a covariate.  
[COMPANY_001]  Confidential  Page 88  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 BAS FI at Week 16  
Between -treatment differences in the change from baseline in BAS FI will be evaluated using 
MMRM with treatment group , stratification factor ( CRP+/MRI+, CRP+/MRI -, CRP -/MRI+ ), 
TNF -α status, and analysis visit  as factors and baseline BAS FI score and weight as continuous 
covar iates. Treatment by [CONTACT_884181]. An unstructured covariance structure will be 
assumed for the model. The significance of the treatment  effect for secukinumab r egimens  at 
different analysis visits will be determined from the pairwise comparisons performed between secukinumab regimens and placebo at the appropriate analysis visits. 
SI joint edema on MRI  at Week 16  
The change from baseline to Week 16 in inflammatio n measured by [CONTACT_884182] a n analysis of covariance ( ANCOVA) model with treatment group, 
stratification factor ( CRP+/MRI+, CRP+/MRI -, CRP -/MRI+ ) and TNF -α status  as factor s, and 
weight and baseline inflammation score as covariates .  
Supportive analysis for SI joint edema on MRI will be performed as follows: 
• Using a non- parametric ANCOVA model on multiple imputation data  
• Using an ANCOVA model where instead of multiple imputation missing data is handled 
by [CONTACT_884183] (B OCF ) 
ASAS partial r emission at Week 16 
Response at Week 16 to ASAS partial remission will be evaluated using a logistic regression model with treatment, stratification factor ( CRP+/MRI+, CRP+/MRI -, CRP -/MRI+ ) and TNF-
α status as factors and weight as a covariate.  
Testing strategy for analysis plan A  
The following null hypotheses will be included in the testing strategy, and type -I-error will be 
set such that a family -wise type-I- error of 5% is kept:  
Primary objective:  
H
1: secukinumab 150 mg (with load)  is not different to placebo regimen with respect to 
ASAS40 response in TNF naïve patients  at Week 16  
Secondary objectives: 
H2: secukinumab 150 mg (with load)  is not different to placebo regimen with respect to 
ASAS 40 resp onse at Week 16 
H3: secukinumab 150 mg (with load)  is not different to placebo regimen with respect to 
ASAS 5/6 response at Week 16 H
4: secukinumab 150 mg (with load)  is not different to placebo regimen with respect to 
change from baseline in total BASDAI at Week 16  
H5: secukinumab 150 mg (with load)  is not different to placebo regimen with respect to 
BASDAI50 at Week 16 
[COMPANY_001]  Confidential  Page 89  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 H6: secukinumab 150 mg (with load)  is not different to placebo regimen with respect to 
change from baseline in hsCRP  at Week 16  
H7: secukinumab 150 mg (with load)  is not different to placebo regimen with respect to 
change from baseline in BASFI  at Week 16  
H8: secukinumab 150 mg (with load)  is not different to placebo regimen with respect to 
change from screening in SI joint edema on M RI at Week 16  
H9: secukinumab 150 mg ( with load)  is not different to placebo regimen with respect to 
ASAS2 0 at Week 16  
H10: secukinumab 150 mg (with load)  is not different to placebo regimen with respect to 
change from baseline in SF- 36 PCS at Week 16  
H11: secukinumab 150 mg (with load)  is not different to placebo regimen with respect to 
change from baseline in ASQoL  at Week 16  
H12: secukinumab 150 mg (with load)  is not different to placebo regimen with respect to 
ASAS partial remission  at Week 16  
H13: secukinumab 150 mg ( without load) is not different to placebo regimen with respect to 
ASAS 40 response in TNF naïve patients  at Week 16  
H14: secukinumab 150 mg (with out load) is not different to placebo regimen with respect to 
ASAS 40 response at Week 16  
H15: secukinumab 150 mg ( without load) is not different to placebo regimen with respect to 
ASAS 5/6 response at Week 16  
H16: secukinumab 150 mg (with out load) is not different to placebo regimen with respect to 
change from baseline in total BASDAI  at Week 16  
H17: secukinumab 150 mg ( without load) is not different to placebo regimen with respect to 
BASDAI50  at Week 16  
H18: secukinumab 150 mg (with out load) is not different to placebo regimen with respect to 
change from baseline in hsCRP  at Week 16  
H19: secukinumab 150 mg ( without load) is not different to placebo regimen with respect to 
change from baseline in BASFI  at Week 16  
H20: secukinumab 150 mg (with out load) is not different to placebo regimen with respect to 
change from screening in SI joint edem a on MRI at Week 16  
H21: secukinumab 150 mg (with out load) is not different to placebo regimen with respect to 
ASAS2 0 at Week 16  
H22: secukinumab 150 mg (with out load) is not different to placebo regimen with respect to 
change from baseline in SF-36 PCS at Week 16  
H23: secukinumab 150 mg (with out load) is not different to placebo regimen with respect to 
change from baseline in ASQoL  at Week 16  
H24: secukinumab 150 mg (with out load) is not different to placebo regimen with respect to 
ASAS partial remission  at Week 16  
[COMPANY_001]  Confidential  Page 90  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 Figure 9-1 Testing strategy for analysis plan A  
 
The family -wise error will be set to α=5% and it will be controlled with the proposed sequential 
testing strategy  as described in Figure 9-1. T he primary hypothesi s (H 1) for the primary 
objective (ASAS 40 in TNF naïve  at Week 16) for secukinumab with load regimen versus 
placebo will be tested at α -level.  If the  hypothesi s H1 is rejected then the whole α will be passed 
to the next hypothesi s (H2) which will be tested at α-level.  This procedure will continue 
(pending rejection of the null hypotheses) until H 12 is rejected . If H 12 is rejected then the full  α-
level is passed on to the testing sequence of se cukinumab without load which can now be tested 
at 5% level  sequentially in a similar way . 
Of note, in the description above, rejection of a hypothesis refers to rejection of the two-sided hypothesis; however the level of a rejected hypothesis is only passed on according to the sequence for the test of another hypothesis if the treatment effect is in favor of secukinumab. 
Secondary endpoints for analysis plan B  
The secondary efficacy variables and the method for adjusting for multiplicity are described below. Secondary efficacy variables will be analyzed using the FAS population. 

[COMPANY_001]  Confidential  Page 91  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 ASAS40  at Week 52 
The proportion of patients meeting the response criteria will be evaluated using a logistic 
regression model with treatment group, stratification factor  (CRP+/MRI+, CRP+/MRI -, CRP -
/MRI+) and TNF -α status as factors  and weight as a covariate.  
ASAS40  at Week 16  
The proportion of patients meeting the response criteria will be evaluated using a logistic regression model with treatment group , stratification factor  (CRP+/MRI+, CRP+/MRI -, CRP -
/MRI+ ) and TNF- α status as factors  and weight as a covariate.  
ASAS 5/6 at Week 16  
The proportion of patients meeting the response criteria will be evaluated using a logistic regression model with treatment group , stratification factor  (CRP+/MRI+, CRP+/MRI -, CRP -
/MRI+ ) and TNF- α status as f actors  and weight as a covariate.  
ASAS20  at Week 16  
The proportion of patients meeting the response criteria will be evaluated using a logistic regression model with treatment group , stratification factor  (CRP+/MRI+, CRP+/MRI -, CRP -
/MRI+ ) and TNF- α status as factors  and weight as a covariate.  
BASDAI at Week 16  
Between -treatment differences in the change from baseline in BASDAI will be evaluated using 
MMRM with treatment group , stratification factor ( CRP+/MRI+, CRP+/MRI -, CRP -/MRI+ ), 
TNF -α status, and analys is visit  as factors and baseline BASDAI score and weight as continuous 
covariates. Treatment by [CONTACT_884184]. An unstructured covariance structure will be assumed for the model. The significance of the treatment  effect for secukinumab regimens  at 
different analysis visits will be determined from the pairwise comparisons performed between secukinumab regimens and placebo at the appropriate analysis visits.   
SF-[ADDRESS_1236864]  (principal stratum) estimand may be presented as supplementary estimand 
for treatment effect in population adhering to treatment in case of randomized to secukinumab.  
SI joint edema on MRI  at Week 16  
The change from baseline to Week 16 in inflammation measured by [CONTACT_884182] a n ANCOVA model wi th treatment group, stratification factor 
(CRP+/MRI+, CRP+/MRI -, CRP -/MRI+ ) and TNF -α status  as factor s, and weight and baseline 
inflammation score as covariates .  
Supportive analysis for SI joint edema on MRI will be performed as follows: 
• Using a non- parametric ANCOVA model on multiple imputation data  
• Using an ANCOVA model where instead of multiple imputation missing data is handled 
by [CONTACT_884185] [ADDRESS_1236865]  (principal stratum) estimand may be presented as supplementary estimand 
for treatment effect in population adhering to treatment  in case of randomized to secukinumab.  
hsCRP at Week [ADDRESS_1236866] that the data are not 
normally distributed ( Huffman et al 2006), analysis will be per formed on the log e ratio of the 
treatment value vs baseline value (calculated by [CONTACT_319690] -baseline value by [CONTACT_750668] e transformation) to normalize the distribution of hsCRP at each 
analysis visit. Between -treatm ent differences in the change in hsCRP relative to baseline will 
be evaluated using MMRM with treatment group, stratification factor ( CRP+/MRI+, 
CRP+/MRI -, CRP -/MRI+),  TNF -α status, and analysis visit as factors and log e baseline hsCRP 
and weight as continuous covariates. Treatment by [CONTACT_750669] e baseline hsCRP by 
[CONTACT_884180]. An unstructured covariance structure will be assumed for the model. The significance of the secukinumab treatme nt effect 
for secukinumab regimens at different analysis visits will be determined from the pairwise comparisons performed between secukinumab regimens and placebo at the appropriate analysis visits. The estimate and the 2 -sided 95% confidence intervals obtained from the model will be 
back transformed to the original scale.  
BAS FI at Week 16  
Between -treatment differences in the change from baseline in BAS FI will be evaluated using 
MMRM with treatment group , stratification factor ( CRP+/MRI+, CRP+/MRI -, CRP -/MRI+), 
TNF -α status, and analysis visit  as factors and baseline BAS FI score and weight as continuous 
[COMPANY_001]  Confidential  Page [ADDRESS_1236867] for secukinumab regimens  at 
different analysis visits will be determined from the pairwise comparisons performed between 
secukinumab regimens and placebo at the appropr iate analysis visits.  
BASDAI50 at Week 16 and Week 52  
The proportion of patients meeting the response criteria will be evaluated using a logistic regression model with treatment group , stratification factor  (CRP+/MRI+, CRP+/MRI -, CRP -
/MRI+ ) and TNF- α statu s as factors  and baseline weight and BASDAI score as covariates. 
ASDAS-CRP inactive disease at Week 52  
Response at Week 52 to ASAS  partial remission  will be evaluated using a logistic regression 
model with treatment, stratification factor  (CRP+/MRI+, CRP+/ MRI -, CRP -/MRI+ ) and TNF-
α status as factors and baseline weight and ASDAS -CRP score as covariate s. 
Testing strategy for analysis plan B  
The following null hypotheses will be included in the testing strategy, and type -I-error will be 
set such that a family -wise type-I- error of 5% is kept:  
Primary objective:  
H
1: secukinumab 150 mg (with out load) is not different to placebo regimen with respect to 
ASAS40 in TNF naïve at Week 52 
Secondary objectives: H
2: secukinumab 150 mg (with out load) is not different  to placebo regimen with respect to 
ASAS40 at Week 52 H
3: secukinumab 150 mg ( without load) is not different to placebo regimen with respect to 
ASAS 40 at Week 16  
H4: secukinumab 150 mg (with load)  is not different to placebo regimen with respect to 
ASAS40 in TNF naïve at Week 52 H
5: secukinumab 150 mg (with load)  is not different to placebo regimen with respect to 
ASAS40 at Week 52 H
6: secukinumab 150 mg (with load)  is not different to placebo regimen with respect to 
ASAS40 at Week 16 H
7: secukinumab 150 mg (with out load) is not different to placebo regimen with respect to 
change from baseline in total BASDAI at Week 16  
H8: secukinumab 150 mg (with out load) is not different to placebo regimen with respect to 
BASDAI50 at Week 16 H
9: secukinumab 150 mg (with out load) is not different to placebo regimen with respect to 
BASDAI50 at Week 52 
[COMPANY_001]  Confidential  Page 94  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 H10: secukinumab 150 mg ( without load) is not different to placebo regimen with r espect to 
change from baseline in hsCRP  at Week 16  
H11: secukinumab 150 mg (with out load) is not different to placebo regimen with respect to 
change from baseline in SF- 36 PCS at Week 16  
H12: secukinumab 150 mg (with out load) is not different to placebo re gimen with respect to 
change from baseline in ASQoL  at Week 16  
H13: secukinumab 150 mg (with out load) is not different to placebo regimen with respect to 
ASAS5/6 at Week 16  
H14: secukinumab 150 mg (with out load) is not different to placebo regimen with respect to 
ASAS20  at Week 16  
H15: secukinumab 150 mg (with out load) is not different to placebo regimen with respect to 
change from baseline in BASFI  at Week 16  
H16: secukinumab 150 mg ( without load) is not differen t to placebo regimen with respect to 
change from screening in SI joint edema on MRI at Week 16 
H17: secukinumab 150 mg (with out load) is not different to placebo regimen with respect to 
ASDAS -CRP ID  at Week 52 
H18: secukinumab 150 mg (with out load) is not different to placebo regimen with respect to 
change from baseline in ASQoL  at Week 52 
H19: secukinumab 150 mg (with out load) is not different to placebo regimen with respect to 
change from screening in SI joint edema on MRI at Week 52 H
20: secukinumab 150 mg (with load)  is not different to placebo regimen with respect to 
change from baseline in total BASDAI at Week 16  
H21: secukinumab 150 mg (with load)  is not different to placebo regimen with respect to 
BASDAI50 at Week 16 H
22: secukinumab 150 mg (with load)  is not different to placebo regimen with respect to 
BASDAI50 at Week 52 H
23: secukinumab 150 mg (with load)  is not different to placebo regimen with respect to 
change from baseline in hsCRP  at Week 16  
H24: secukinumab 150 mg (with load)  is not different to placebo regimen with respect to 
change from baseline in SF- 36 PCS at Week 16  
H25: secukinumab 150 mg (with load)  is not different to placebo regimen with respect to 
change from baseline in ASQoL  at Week 16  
H26: secukinumab 150 mg (with load) is not different to placebo regimen with respect to 
ASAS5/6 at Week 16  
H27: secukinumab 150 mg (with load)  is not different to placebo regimen with respect to 
ASAS20  at Week 16  
H28: secukinumab 150 mg (with load)  is not different to placebo regimen w ith respect to 
change from baseline in BASFI  at Week 16  
[COMPANY_001]  Confidential  Page 95  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 H29: secukinumab 150 mg (with load)  is not different to placebo regimen with respect to 
change from screening in SI joint edema on MRI at Week 16 
H30: secukinumab 150 mg (with load)  is not different t o placebo regimen with respect to 
ASDAS -CRP ID  at Week 52 
H31: secukinumab 150 mg (with load)  is not different to placebo regimen with respect to 
change from baseline in ASQoL  at Week 52 
H32: secukinumab 150 mg (with load)  is not different to placebo regimen with respect to 
change from screening in SI joint edema on MRI at Week 52 
Figure 9-2 Testing strategy for analysis plan B  
 
The family -wise error will be set to α=5% and it will be controlled with the proposed sequential  
testing strategy  as described in  Figure 9-2. The primary hypothesi s (H1) for the primary 
objective (ASAS 40 in TNF naïve  at Week 52) for secukinumab without load regimen versus 
placebo will be tested at α -level. If the  hypothesis H 1 is rejected then the whole α will be passed 

[COMPANY_001]  Confidential  Page 96  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 to the next hypothesi s (H2) which will be tested at α-level.  This procedure will continue 
(pending rejection of the null hypotheses) until H 32 is rejected .  
Of note, in the description above, rejection of a hypothesis refers to rejection of the two-sided 
hypothesis; however the level of a rejected hypothesis is only passed on according to the graphical procedure for the test of another hypothesis if the treatment effect is in favor of secukinumab. 

[COMPANY_001]  Confidential  Page 97  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 

[COMPANY_001]  Confidential  Page 98  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
  
9.
5.3 Safety variables  
Adverse events  
Treatment  emergent adverse events ( i.e. events started after the first dose of study treatment or 
events present prior to the first dose of study treatment but increased in severity based on preferred term  and on or before last dose + 84 days ) will be summarized.  
Adverse events will be summarized by [CONTACT_1601], for each treatment group, the number and percentage of patient s having any AE, having an AE in each primary system organ class and 
having each individual AE (preferred term). Summaries will also be presented for AEs by [CONTACT_201092]. If a patient  reported more than one adverse event 
with the same preferred term, the adverse event with the greatest severity will be presented. If 
a patient  reported more than one adverse event within the same primary system organ class, the 
patient  will be counted only once with the greatest severity at the  system organ class level, 
where applicable.  
These summaries may be presented separately by [CONTACT_884186], e.g., Week 1 -20 and 
entire treatment period.  
As appropriate, the incidence of AEs will be presented per 100 patient  years of exposure.  
Separate summaries will be provided for death, serious adverse event, adverse events leading 
to discontinuation and adverse events leading to dose adjustment. A graphical display of relative frequencies within system organ classes and relative risks, as 
appropriate, will be presented. 
When adjudication is required of major cardiovascular events, a listing  of those types of events 
as reported by [CONTACT_250368]. Non-treatment emergent AEs will be provided in listings. 
Laboratory data  
The summary of laboratory evaluations will be presented for three groups of laboratory tests 
(hematology, serum chemistry and urinalysis). Descriptive summary statistics for the change from baseline to each study visit will be present ed. These descriptive summaries will be 
presented by [CONTACT_109057], laboratory test and treatment group. Change from baseline will only be summarized for patient s with both baseline and post baseline.  
For each parameter, the maximum change from baseline within each study period will be evaluated analogously.  

[COMPANY_001]  Confidential  Page 99  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 In addition, shift tables will be provided for all parameters to compare a patient ’s baseline 
laboratory evaluation relative to the visit’s observed value. For the shift tables, the normal 
laboratory ranges will be used to evaluate whether a particular laboratory test value was normal, low, or high for each visit value relative to whether or not the baseline value was normal, low, or high. These summaries will be presented by [CONTACT_884187]. Shifts will 
be presented by [CONTACT_250369]- baseline.  
 
 
Vital signs  
Analysis of the vital sign measurements using summary statistics for the change from baselin e 
for each post -baseline visit will be performed. These descriptive summaries will be presented 
by [CONTACT_37297]. Change from baseline will only be summarized for patient s 
with both baseline and post- baseline values.  
ECG  
Summary statistics  will be presented for ECG variables by [CONTACT_3232]. Qualitative 
changes will be summarized.  
9.5.4  Health -related Quality of Life  
Health -related Quality of Life assessments will be evaluated based on FAS unless otherwise 
specified.  
SF-36 
The follow ing variables will be evaluated:  
• SF-36 domain scores (based on a scale of 0-100). 
• SF-36 PCS and MCS scores (norm- based scores).  
• SF-36 PCS and MCS responder (improvement of ≥  2.5 points, Lubeck 2004) 
For the change in SF -36 summary scores (PCS and MCS), between -treatment differences will 
be evaluated using MMRM. Treatment group, stratification factor ( CRP+/MRI+, CRP+/MRI -, 
CRP -/MRI+ ), TNF -α status and analysis visit will be included as categorical factors and 
baseline SF -36 score (PCS or MCS) and weight as continuous covariates. Treatment by [CONTACT_884188] -36 score (PCS or MCS) by [CONTACT_884189]. An unstructured covariance structure will be assumed for the model. Pairwise comparisons will be performed between secukinumab regimens and placebo and/or 
secukinumab at appropriate analysis visits. 
In the responder analyses, treatment groups will be compared with respect to response to 
treatment using a logistic regression model with treatment, stratification factor ( CRP+/MRI+, 
CRP+/MRI -, CRP -/MRI+ ), TNF -α status as factor s and baseline SF -36 score ( PCS or MCS) 
and weight as covariates. Odds ratios and 95% CI will be presented for appropriate treatment comparisons. 

[COMPANY_001]  Confidential  Page 100  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 The SF -36 domain scores will be summarized by [CONTACT_3148].  
ASQoL  
For the change in ASQoL scores, between -treatment differences in the change in ASQoL scores  
will be eva luated using MMRM. Treatment group, stratification factor ( CRP+/MRI+, 
CRP+/MRI -, CRP -/MRI+ ), TNF -α status and analysis visit be used as categorical factors and 
baseline ASQoL score and weight as continuous covariates. Treatment by [CONTACT_884190]. An 
unstructured covariance structure will be assumed for the model. The significance of the treatment effects for secukinumab regimens at different analysis visits will be  determined from 
the pairwise comparisons performed between secukinumab regimens and placebo and/or secukinumab at the appropriate analysis visits. 

[COMPANY_001]  Confidential  Page 101  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 

[COMPANY_001]  Confidential  Page 102  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 9.
5.8 PK/PD  
Not applicable.  
9.[ADDRESS_1236868] completed the assessments  associated with 
the primary endpoint (Week 16), no adjustment will be made to the type I  error rate for this 
analysis.  
Subsequent to the primary endpoint analysis, an analysis of the full double -blind treatment 
period (up to Week 52) will also be performed  after all patient s have completed the Week [ADDRESS_1236869] completed the assessments  associated with 
the primary endpoint (Week 52), no adjustment will be made to the type I error  rate for this 
analysis.  Based on enrollment, it is estimated that approximately 70% of pa tients will have 
completed the Week 52 assessments at the time of the database lock for W eek 24 (analys is plan 
A). An interim analysis may be conducted at that time f or analysis plan B using an Obrien-
Fleming spending function to control the type I error. The results of the interim analysis will 
not affect the study conduct; i.e., all patients will continue to be treated according to the current study design and a blinded study team will oversee the trial conduct to prevent bias until the Week 52 database lock. Performing the interim analysis is dependent on health authority 
feedback and further details will be included in the statistical analysis plan, which will be finalized before Week 24 database lock . 
9.7 Sample size calculation  
In a study of an anti -TNF agent i n the same indication of similar design ( Landewé et al 2014 ) 
an ASAS40 response rate of 47.1% for active treatment and 16% for placebo was observed at Week 12 ; however, this trial had a limited number of TNF -IR patients  and a meta -analysis (MA) 
from unpublished studies  with secukinumab in AS indicates  that the placebo rates observed in 
recent AS studies may be higher. Hence, assumptions are based on the result of active treatment 

[COMPANY_001]  Confidential  Page 103  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 from th is TNF -inhibitor study in nr-axSpA (but adjusted for the expected inclusion of TNF -IR 
patients ) and with placebo response rates taken from the secukinumab MA. This MA included 
approximately 25% TNF -IR patients , and the ASAS40 response rate in the 150 mg dose for 
TNF -IR was 76% of the response in the  TNF naïve group. Assuming 20% of randomized 
patients will be TNF -IR and have  the same TNF -IR vs. TNF naïve response ratio  as seen in  the 
MA (76%), the estimate  for the entire population is 44.8% (i.e. 47.1%*0.8 + 47.1%*0.2*0.76)  
for secukinumab and 25.9% for placebo. ASAS40 in TNF naïve patients only is assumed to be 
47.1% for secukinumab and 27.9% for placebo. 
At Week 16, response rates for the secukinumab 150 mg s.c. regimens with loading and without 
loading are assumed to be the same.  
Primary endpoint for analysis plan A  
An overall type I error (2 -sided) 5% will be used to control type I error. Since the hierarchy is 
sequential starting with secukinumab with load tested versus placebo the full type I error will 
be utilized  for each comparison. 
Table 9-1 Summary of power for binary primary endpoint  
Endpoint  Placebo 
Response  
Rate  Secukinumab with load Secukinumab without load 
Response   
Rate  Power 
N=18 5/arm Response  
Rate  Power 
N=18 5/arm 
ASAS40 TNF 
naïve at Week 
16 27.9% 47.1% 91% 47.1%  91% 
Based on these assumptions including 185 patients per arm would give 91 % power to reject a 
hypothesis of equal response rate based on Fisher’s exact test. 
Primary endpoint for analysis plan B  
An overall type I error (2 -sided) 5% will be used to control type I error. Since the hierarchy is 
sequential starting with secukinumab without load tested versus placebo the full type I error 
will be utilized  for each comparison. 
Based on an assumption that the ASAS40 TNF naïve  response rate at Week 16 will be 4 7.1% 
for secukinumab and 27.9% for placebo , that 80% of secukinumab patients and 65% of placebo 
patients will retain their response status from Week 16, and that 10% of secu kinumab patients 
and 5% of placebo patients will be new responders at  Week 52, the ASAS40 response rate at 
Week 52 based on non- responder imputation can be estimated as 43.0% and 21.7%, 
respectively , resulting in a power of 97% to reject an hypothesis of e qual response rate at the 
5% level.  
[COMPANY_001]  Confidential  Page 104  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 Table 9-2 Summary of power for binary primary endpoint  
Endpoint  Placebo 
Response  
Rate  Secukinumab with load Secukinumab without Loading  
Response   
Rate  Power 
N=18 5/arm Response  
Rate  Power 
N=18 5/arm 
ASAS40 TNF 
naïve at Week 
52 21.7% 43.0% 97% 43.0% 97% 
9.8 Power for analysis of secondary variables 
Secondary  endpoints for analysis plan A  
In Table 9 -3 the power for rejecting each of the binary secondary hypotheses at Week 16 is 
presented based on Fisher’s exact test with a 2 -sided 5% type I error rate  and 185 patients per 
group assuming the response rates without load are  the same as for with load . 
Table 9-3 Power for binary secondary variables at Week 16 
Endpoint  Placebo 
Response  
Rate  Secukinumab with load Secukinumab without load 
Response   
Rate  Power 
N=18 5/arm Response  
Rate  Power 
N=18 5/arm 
ASAS40  25.9% 44.8%  96% 44.8%  96% 
ASAS5/6  24.3% 45.0% 98% 45.0% 98% 
BASDAI50  19.4% 45.4% 99% 45.4% 99% 
ASAS20  43.7% 61.1% 90% 61.1% 90% 
ASAS PR1 8.7% 21.9% 93% 21.9% 93% 
Source:  Active from  R Landewé et al 2014 (Week 12 result, 400 mg Q4W) adjusted for TNF -IR and Placebo from a meta-
analysis of  unpublished [COMPANY_001] AS studies ( CAIN457F2314 and CAIN457F2320) . Calculations based on Fisher’s exact test 
(nQuery 7.0 PTT2- 1) 
1Week  16 response for TNF naïve  patients assumed 25% for secukinumab and 10% for placebo which were then adjusted for 
20% TNF -IR. 
In Table [ADDRESS_1236870] deviation 
(SD). Following the assumption for response variable s the change from baseline was adjusted 
for inclusion of TNF -IR patients but with unchanged SD. The change from baseline without 
load is assumed the same as for with  load. 
Table 9-4 Power for continuous secondary variables at Week 16  
Endpoint  Common 
SD Placebo 
Mean  Secukinumab                     
with load Secukinumab                    
without load 
Mean  Power 
N=185/arm  Mean  Power 
N=185/arm  
BASDAI1 2.3 -1.75 -3.30 99% -3.30 99% 
hsCRP2 0.867 0.095 -0.544 99% -0.544 99% 
BASFI1 2.1 -1.37 -2.20 96% -2.20 96% 
MRI SI joint 
edema3 2.17 -0.17 -1.30 99% -1.30 99% 
SF-36 PCS4 7.15 3.67 6.32 94% 6.32 94% 
ASQoL4 4.55 -2.32 -4.10 96% -4.10 96% 
SD=standard deviation. Result is mean change from baseline with CRP in log scale.  
[COMPANY_001]  Confidential  Page 105  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 1 Active from R Landewé et al 2014  (Week 12 result, 400 mg Q4W)  adjusted for TNF -IR and  Placebo from a meta -analysis of 
unpublished AS studies ( CAIN457F2314 and C AIN457F2320) . 
2 Meta- analysis of unpublished [COMPANY_001] AS studies (C AIN457F2314 and CAIN457F2320)  
3 [COMPANY_001]  AS study (AIN457F2305) 
4 Meta- analysis of [COMPANY_001] AS studies  (CAIN457F2310 and CAIN457F2320)  
Calculations based on two -sample t -test (nQuery 7.0 MTT0 -1) 
Secondary  endpoint s for analysis plan B  
Response rates for  load and without load at Weeks 16 and 52 are assumed to be the same.  
Table 9-5 Power for binary secondary variables  
Endpoint  Placebo 
Response  Rate  Secukinumab with load Secukinumab without load 
Response   
Rate  Power 
N=18 5/arm Response  
Rate  Power 
N=18 5/arm 
ASAS40 wk52  20.5% 41.4% 99% 41.4% 99% 
ASAS40 wk16  25.9%  44.8%  96% 44.8%  96% 
BASDAI50 wk16  19.4% 45.4% 99% 45.4% 99% 
BASDAI50 wk52  16.6% 41.8% 99% 41.8% 99% 
ASAS5/6 wk16  24.3% 45.0% 98% 45.0% 98% 
ASAS20 wk16  43.7% 61.1% 90% 61.1% 90% 
ASDAS ID wk521 10.2% 25.3% 96% 25.3% 96% 
Week 16  
Source:  Active from  R Landewé et al 2014 (Week 12 result, 400 mg Q4W) adjusted for TNF -IR and Placebo from a meta-
analysis of  unpublished [COMPANY_001] AS studies ( CAIN457F2314 and C AIN457F2320) . 
Week 52  
Estimates from Week 16 were adjusted for assumed response retention.  
1 Week 16  response  for TNF naïve patients assumed 25% for secukinumab and 10% for placebo which were then adjusted for 
20% TNF -IR and assumed response retention.  
ASDAS ID = ASDAS CRP Inactive Disease (ASDAS -CRP score <  1.3) 
Calculations based on Fisher’s exact test (nQuery 7.0 PTT2 -1) 
Table 9-6 Power for continuous secondary variables  
Endpoint  Common 
SD Placebo 
Mean  Secukinumab with 
load Secukinumab without 
load 
Mean  Power 
N=185/arm  Mean  Power 
N=185/arm  
BASDAI  wk161 2.30 -1.75 -3.30 99% -3.30 99% 
hsCRP  wk162 0.867 0.095 -0.544 99% -0.544 99% 
SF-36 PCS wk163 7.15 3.67 6.32 94% 6.32 94% 
BASFI wk161 2.10 -1.37 -2.20 96% -2.20 96% 
MRI SI joint edema wk164 2.17 -0.17 -1.30 99% -1.30 99% 
ASQoL  wk163 4.55 -2.32 -4.10 96% -4.10 96% 
SD=standard deviation. Result is mean change from baseline with CRP in log scale.  
Week 16  
1Active from R Landewé et al 2014 (Week 12 result, 400 mg Q4W)  adjusted for TNF -IR and Placebo from a meta- analysis of 
unpublished [COMPANY_001] AS studies (CAIN457F2314 and CAIN457F2320) . 
2Meta- analysis of unpublished [COMPANY_001] AS studies (CAIN457F2314 and CAIN457F2320)  
3Meta- analysis of [COMPANY_001] AS studies (C AIN457F2310 and CAIN457F2320)  
4[COMPANY_001]  AS study ( CAIN457F2305).  
Calculations based on two -sample t -test (nQuery 7.0 MTT0 -1) 
[COMPANY_001]  Confidential  Page [ADDRESS_1236871] (ASQoL 96% and MRI SI joint edema 99%). If escape rates are 
similar in both treatment arms the power  will decrease if  overall escape rate is increasing , 
whereas the power will remain the same or increase if escape rates are different between 
treatment arms.   
9.9 Analysis of extension phase 
The analysis extension phase data will be exploratory in nature and mainly reported by 
[CONTACT_9086] , applying the same principles as in core phase data analysis.  
Statistical models may be applied to produce confidence intervals for treatment summaries, but 
no formal statistical inference will be done.  
Data analyses will be presented by [CONTACT_6660]. Treatment groups for core phase 
responders are  as follows: 
• Secukinumab 150 mg blinded 
• Secukinumab 300 mg blinded 
and for core phase non-responders: 
• Secukinumab 300 mg open- label  
The following analysis sets will be used in the extension phase: 
Full analysis set (FAS) : The FAS will be comprised of all subjects enrolled in the extension 
phase.  
Safety set: The safety set includes all subjects enrolled in the extension phase and who took at 
least 1 dose of study treatment during the extension phase 
Total sample size for extension phase is not pre -specified.  It is estimated that approximately 
70% of subjects enrolled in the core phase will enter the extension phase, which is equivalent 
to about 380 subjects. Around 305 subjects are estimated to be core phase responders and will be in the randomized  group and around 75 subjects are expected to be core phase non-
responders and will enter the open -label treatment group. 
10 Ethical considerations  
10.1 Regulatory and ethical compliance  
This clinical study was designed and shall be implemented and reported in accordance with the 
ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local regulations (including European Directive 2001/20/EC, US CFR 21, and Japanese Ministry of Health, Labor, and Welfare), and with the ethical principles laid down in the Declaration of Helsinki.  
[COMPANY_001]  Confidential  Page 107  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 10.2 Informed consent procedures  
Eligible patients may only be included in the study after providing written (witnessed, where required by [CONTACT_6617]), IRB/IEC -approved informed consent, or, if incapable of doing 
so, after such consent has been provided by a legally acceptable representative(s) of the patient. In cases where the patient’s representative gives consent, the patient should be informed about the study to the extent possible given his/her understanding. If the patient is capable of doing so, he/she should indicate assent by [CONTACT_90218] a separate assent form. Informed consent must be obtained before conducting any study- specific procedures (i.e. all of the procedures described in the protocol). The process of 
obtaining informed consent should be documented in the patient source documents.  
[COMPANY_001] will provide to investigators in a separate document a proposed informed consent form 
that complies with the ICH GCP guideline and regulatory requirements and is considered appropriate for this study. Any changes to the proposed consent form suggested by [CONTACT_90219]/IEC, and a copy of th e 
approved version must be provided to the [COMPANY_001] monitor after IRB/IEC approval. 
Women of child bearing potential should be informed that taking the study treatment may 
involve unknown risks to the fetus if pregnancy were to occur during the study and a gree that 
in order to participate in the study they must adhere to the contraception requirement for the entire study or longer if required by [CONTACT_109016] (e.g. 20 weeks in EU). If there is any question that the patient will not reliably comply, they should not be entered in the study. 
  
 
 
 
 
In the event that [COMPANY_001] wants to perform testing on the samples that are not described in this 
protocol, additional Institutional Review Board and/or Ethics Committee approval will be obtained. 
10.3 Responsibilities of the investigator and IRB/IEC 
Before initiating a trial, the investigator/institution should obtain approval/favorable opi[INVESTIGATOR_30757]/Independent Ethics Committee (IRB/IEC) for the trial protocol, written informed consent form, consent form updates, patient recruitment procedures (e.g., advertisements) and any other written information to be provided to patients. Prior to study start, the investigator is required to sign a protocol signature [CONTACT_5389]/her agreement to conduct the study in accordance with these documents and all of the instructions and procedures found in this protocol and to give access to all relevant data and records to [COMPANY_001] monitors, auditors, [COMPANY_001] Quality Assurance representatives, designated agents of [COMPANY_001], IRBs/IECs, and regulatory authorities as required. If an inspection of the clinical site is requested by a regulatory authority, the investigator must inform [COMPANY_001] immediately that this reque st has been made.  

[COMPANY_001]  Confidential  Page 108  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 10.4 Publication of study protocol and results 
[COMPANY_001] assures that the key design elements of this protocol will be posted in a publicly accessible database such as clinicaltrials.gov. In addition, upon study completion and finalization of the study report the results of this trial will be either submitted for publication and/or posted in a publicly accessible database of clinical trial results.  
[ADDRESS_1236872] be 
considered a protocol amendment, and unless such an amendment is agreed upon by [CONTACT_6669]/IEC and health authorities, where required, it cannot be implemented. All significant protocol deviations will be recorded and reported in the CSR. 
11.[ADDRESS_1236873] be approved by [CONTACT_5343], Health Authorities where required, and the IRB/IEC prior to implementation. Only amendments th at are intended to eliminate an apparent immediate hazard 
to patients may be implemented immediately provided the Health Authorities are subsequently notified by [CONTACT_6670]/IEC is notified. Notwithstanding the need for approval of formal protocol amendments, the investigator is expected to take any immediate action required for the safety of any patient included in this study, even if this action represents a deviation from the protocol. In such cases, the reporting requirement s identified in 
Section [ADDRESS_1236874]  
Baraliakos X and Braun J (2011) Spondyloarthritides. Best Pract Res Clin Rheumatol ; 
25:825-42. 
Baraliakos X, Braun J, Laurent D, et al (2011) Interleukin-17A blockade with secukinumab 
reduces spi[INVESTIGATOR_884137] 6, as detected by [CONTACT_19243].  Arthritis Rheum; 63:S972. 
Baraliakos X, Listing J, Brandt J, et al (2005) Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther; 7:
 R439-R444. 
 

[COMPANY_001]  Confidential  Page 109  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 Callhoff J, Sieper J, Weib A,et al (2014) Efficacy of TNFα blockers in patients with 
ankylosing spondylitis and non-radiographic a xial spondyloarthritis: a meta -analysis. Ann 
Rheum Dis; 0:1 -8 
 
 
 
 
Dougados M, van der Heijde D, Sieper J, et al (2013) Safety and Efficacy Of Etanercept In Early Non-Radiographic Axial Spondyloarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial At [ADDRESS_1236875] Number 1516. ACR 2013 
Dougados M, van der Heijde D, Sieper J, et al (2014) Symptomatic efficacy of etanercept and 
its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis – a multicenter, randomized, double-blind, placebo- controlled trial.  Arthritis Rheum; 
66:2091-2102. 
EMA guidance document: 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC5
00003424.pdf 
 
 
 
Huffman KM, Samsa GP, Slentz CA, et al (2006) Response of high- sensitivity C -reactive 
protein to exercise training in an at-risk population. Am Heart J; 152:793-800. 
Koch GG, Tangen CM, Jung JW, et al (1998) Issues for covariance analysis of dichotomous 
and ordered categorical data from randomized clinical trials and non- parametric strategies for 
addressing them. Statist Med; 17:1863-92. 
Landewé R, Braun J, Deodhar A, et al (2014) Efficacy of certolizumab pegol on signs and 
symptoms of axial spondyloarthritis including ankylosing spondylitis: 24- week results of a 
double-blind randomized placebo-controlled Phase 3 study. Ann Rheum Dis; 73:39-47. 
Langley RG, Elewski BE, Lebwohl M, et al (2014) Secukinumab in plaque psoriasis–results 
of two phase 3 trials. N Engl J Med; 371(4):326–38. 
Lubeck DP (2004) Patient-reported outcomes and their role in the assessment of rheumatoid 
arthritis. Pharmacoeconomics; [ADDRESS_1236876] 1:27-38. 
Lukas C, Landewé R, Sieper J, et al (2009) Development of an ASAS- endorsed disease 
activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis; 68:18-24. Machado P, Landewé R, Lie E, et al (2011) Ankylosing Spondylitis Disease Activity Score 
(ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis; 70:47-53. 
McHorney CA, Ware JE and Raczek AE C (1992) The MOS 36-Item Short- Form Health 
Survey (SF-36). Medical Care; 31: 247-263. 

[COMPANY_001]  Confidential  Page 110  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 Mease PJ, McInnes IB, Kirkham B, et al  (2015) Secukinumab inhibition of interleukin-17A in 
patients with psoriatic arthritis. N Engl J Med; 373(14):1329-39. 
Mettler FA, Huda W, Yoshizumi TT, et al (2008) Effective doses in Radiology and 
Diagnostic Nuclear Medicine – A catalog. Radiology; 248:254-63. 
Pavy S, Brophy S, Calin A (2005) Establishment of the minimum clinically important 
difference for the Bath Ankylosing Spondylitis In dices - A prospective study. J Rheumatol; 
32:80-5. 
Poddubnyy D, Rudwaleit M, Haibel H, et al (2011) Rates and predictors of radiographic 
sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis; 70:1369-74. 
Robinson PC, Wordsworth BP, Reveille JD, et al (2013) Axial spondyloarthritis: a new 
disease entity, not necessarily early ankylosing spondylitis. Ann Rheum Dis; 72:162-4. 
Rudwaleit M, Landewé R, van der Heijde D, et al (2009) The development of Assessment of 
SpondyloA rthritis international Society classification criteria for axial spondyloarthritis (part 
I): classification of paper patients by [CONTACT_18430][INVESTIGATOR_884138]. Ann 
Rheum Dis; 68:770-76. 
Sieper J, Rudwaleit M, Baraliakos X, et al (2009) The Assessment of SpondyloArthritis 
international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis; [ADDRESS_1236877] 2:1-44. 
Sieper J (2012) Developments in therapi[INVESTIGATOR_884139]. Nat Rev Rheumatol; 8:280-
87. 
Sieper J, Kivitz AJ, Van Tubergen AM, et al. (2012) Rapid improvements in patient reported 
outcomes with certolizumab pegol in patients with axial spondyloarthritis, including 
ankylosing spondylitis and non-radiographic axial spondyloarthritis: [ADDRESS_1236878] Number 558. ACR 2012 
Sieper J and van der Heijde D (2013) Nonradiographic Axial Spondyloarthritis - New 
Definition of an Old Disease? Arthritis Rheum; 65:543-51. 
Sieper J, van der Heijde D, Dougados M, et al (2013) Efficacy and safety of adalimumab in 
patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY -1). Ann Rheum Dis; 72:815-22. 
Song IH, Hermann KG, Haibel H, et al (2011) Effects of etane rcept versus sulfasalazine in 
early axial spondyloarthritis on active inflammatory lesions as detected by [CONTACT_28760]-body MRI (ESTHER): a 48 -week randomized controlled trial. Ann Rheum Dis; 70:590-96. 
Song IH, Weib A, Hermann KG, et al (2013) Similar response r ates in patients with 
ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial. Ann Rheum Dis; 72:823 -25. 
Stabin M, Marcus C, Siegel J (2009) New tool for nuclear medicine patient release calculations. J Nucl Med; 50:14N. 
US Department of Health and Human Services, Food and Drug Administration, Center for 
Drug Evaluation and Research (CDER) (2013) Guidance for Industry – Electronic Source 
Data in Clinical Investigations.  
[COMPANY_001]  Confidential  Page 111  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 van der Heijde D, Landewé R, Baraliakos X, et al (2008a) Radiographic findings following 
two years of infliximab therapy in patients with Ankylosing Spondylitis. Arthritis Rheum; 
58:3063-70. 
van der Heijde D, Landewé R, Einstein S, et al (2008b) Radiographic progression of 
Ankylosing Spondylitis after up to two years of treatment with etanercept. Arthritis Rheum; 58:1324-31. 
van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of the diagnostic criteria for 
ankylosing spondylitis - A proposal for modification of the [LOCATION_001] criteria. Arthritis 
Rheum; 27:361-8. 
van Tubergen A, Black PM, Coteur G (2015) Are patient-reported outcome instruments for 
ankylosing spondylitis fit for purpose for the axial spondyloarthritis patient? A qualitative and psychometric analysis. Rheumatology; EPub  
Wallis D, Haroon N, Ayearst R, et al (2013) Ankylosing Spondylitis and Nonradiographic 
Axial Spondyloarthritis: Part of a Common Spectrum or Distinct Diseases? J Rheumatol; 40:2038-41. 
Ware JE and Donald Sherbourne C (1992) The MOS 36-Item Short-Form Health Survey (SF-
36). Medical Care; 30: 473-483. 
 
13 Appendices  
13.1 Appendix 1: Clinically notable laboratory values  
The following criteria will be used to define expanded limits and notable abnormalities of key 
laboratory tests. 
Clinically notable values will be forwarded to [COMPANY_001]/CRO at the same time that they are sent 
to investigators. Any action based on these laboratory values should be discussed with [COMPANY_001]/CRO personnel. 

[COMPANY_001]  Confidential  Page 112  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 Table 13 -1 Safety Analyses: Expanded Limits and Notable Criteria  
 Final Harmonization  
Laboratory Variable  Notable Criteria  
Standard Units  SI Units  
LIVER FUNCTION AND RELATED VARIABLES  
SGOT (AST)  >[ADDRESS_1236879]  >[ADDRESS_1236880]  
SGPT (ALT)  >[ADDRESS_1236881]  >[ADDRESS_1236882]  
Bilirubin  >[ADDRESS_1236883]  >[ADDRESS_1236884]  
Alkaline phosphatase  >2.[ADDRESS_1236885]  >2.[ADDRESS_1236886]  
RENAL FUNCTION, METABOLIC AND ELECTROLYTE VARIABLES  
Creatinine (serum)  >[ADDRESS_1236887]  >[ADDRESS_1236888]  
HEMATOLOGY VARIABLES  
Hemoglobin  20 g/L decrease from baseline  
Platelet Count  <100x10E9/L  
White blood cell count  <0.[ADDRESS_1236889]  
Neutrophils  <0.[ADDRESS_1236890]  
 

[COMPANY_001]  Confidential  Page 113  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 

[COMPANY_001]  Confidential  Page 114  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 13.3 Appendix 3: Modified [LOCATION_001] criteria 
According to Exclusion Criteria 1, patients must not have below described radiological changes  
Clinical criteria:  
• Low back pain and stiffness for more than [ADDRESS_1236891].  
• Limitation of motion of the lumbar spi[INVESTIGATOR_750618]. 
• Limitation of chest ex pansion relative to normal values correlated for age and sex. 
Radiological criterion:  
• Sacroiliitis grade ≥2 bilaterally or grade 3–[ADDRESS_1236892] one clinical criterion.  

[COMPANY_001]  Confidential  Page 115  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 13.4 Appendix 4: ASAS Classification Criteria for Axial 
Spondyloarthritis (axSpA) 
In patients with ≥ 3 months back pain and age at onset <45 years:  
 
Sacroiliitis on imaging*  
plus 
 ≥ 1 SpA feature  OR HLA-B27  
plus  
≥ 2 other SpA features  
*Sacroiliitis on imaging:  
• Active (acute) inflammation 
on MRI highly suggestive of sacroiliitis associated with SpA 
• Definite radiographic sacroiliitis according to the 
modified NY criteria  SpA features:  
• Inflammatory back pain 
• Arthritis  
• Enthesitis (heel)  
• Uveitis  
• Dactylitis  
• Psoriasis 
• Crohn’s / colitis  
• Good respons to NSAIDs 
• Family history for SpA 
• HLA-B27 
• Elevated CRP   
13.5 Appendix 5: Assessment of SpondyloArthritis International 
Society criteria (ASAS) 
The ASAS response measures consist of the following assessment domains ( Sieper et al 2009 ). 
Main ASAS domains: 
1. Patient’s global assessment of disease activity measured on a VAS scale  
2. Patient’s assessment of back pain, represented by [CONTACT_90202], 
both measured on a VAS scale  
3. Function represented by [CONTACT_90203] [ADDRESS_1236893] 2 questions on the 6-question BASDAI as measured by [CONTACT_750652]: 
5. Spi[INVESTIGATOR_884133] 
6. C-reactive protein (acute phase reactant)  
13.5.1  Bath Ankylosing Spondylitis Functional Index (BASFI)  
The BASFI is a set of [ADDRESS_1236894] 8 questions consider activities related to functional anatomy. The final 2 questions 
[COMPANY_001]  Confidential  Page 116  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 assess the patients’ ability to cope with everyday life. A 10 cm visual analog scale is used to 
answer the questions. The mean of the ten scales gives the BASFI score – a value between 0 
and 10. 
13.5.2  Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)  
The BASDAI consists of a 0 through 10 scale ([ADDRESS_1236895] 
problem, captured as a continuous VAS), which is used to answer 6 questions pertaining to the 5 major symptoms of AS: 
1. How wou ld you describe the overall level of fatigue/tiredness you have experienced? 
2. How would you describe the overall level of AS neck, back or hip pain you have had? 
3. How would you describe the overall level of pain/swelling in joints other than neck, back, 
hips you have had? 
4. How would you describe the overall level of discomfort you have had from any areas tender to touch or pressure? 
5. How would you describe the overall level of morning stiffness you have had from the time you wake up?  
6. How long does your morning stiffness last from the time you wake up? 
To give each symptom equal weighting, the mean (average) of the two scores relating to morning stiffness (questions 5 and 6) is taken. The mean of questions 5 and 6 is added to the scores from questions 1- 4. The resulting 0 to 50 score is divided by 5 to give a final 0 – [ADDRESS_1236896] suboptimal control of disease, and patients with scores  of 4 or greater are usually good candidates for either a change in their medical therapy 
or for enrollment in clinical trials evaluating new drug therapi[INVESTIGATOR_884140]. BASDAI is a quick and simple index (taking between 30 seconds and 2 minutes to complete).  

[COMPANY_001]  Confidential  Page 117  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 13.6 Appendix 6: Definition of Sacroiliitis on MRI 
An MRI will be considered positive for sacroili itis (active inflammatory lesions, “positive 
MRI”, MRI+) if the following characteristics are evident ( Sieper et al 2009 ): 
• The presence of definite subchondral bone marrow oedema/osteitis highly suggestive of sacroi liitis is mandatory.  
• The presence of synovitis, capsulitis, or enthesitis only without concomitant subchondral bone marrow oedema/osteitis is compatible with sacroliitis but not sufficient for making a diagnosis of active sacroliitis.  
• Amount of signal required: if there is one signal (lesion) only, this should be present on at least two slices. If there is more than one signal on a single slice, one slice may be enough. 

[COMPANY_001]  Confidential  Page 118  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 13.8 Appendix 8: Guidelines for administering the questionnaires for 
patient reported outcomes 
Before trial start  
Study coordinators should familiarize themselves with the PRO questionnaire(s) in the trial and identify any items where a patient’s response might highlight issues of potential concern. 
For e xample, one question in the SF -36 asks ‘How much of the time in the past [ADDRESS_1236897] 
you felt downhearted and blue?’ If a patient responds ‘most or all of the time’, then the study 
coordinator should inform the study investigator. 
Before completion  
1. Patie nts should be provided with the correct questionnaire at the appropriate visits and in 
the appropriate language 
2. Patients should have adequate space and time to complete the forms 
3. Questionnaire should be administered before the clinical examination 

[COMPANY_001]  Confidential  Page 119  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 During completion  
1. Administrator may clarify the questions but should not influence the response 
2. Only one response for each question 
3. Also see “Addressing Problems and Concerns” 
After completion  
1. Check for completeness and not for content* 
2. Check for multiple responses that were made in error  
*However, any response which may directly impact or reflect the patient’s medical condition 
(e.g., noting of depression) should be communicated by [CONTACT_144978]). 
Addressing problems and concerns 
Occasionally a patient may have concerns or questions about the questionnaires administered. 
Guidance related to some of the most common concerns and questions are given below. 
The patient does not want to complete the questionnaire(s)  
Tell the patient that completion of the questionnaire(s) is voluntary. The goal is to better 
understand the physical, mental and social health problems of patients. Emphasize that such information is as important as any other medical information and that the questionnaire(s ) is 
simple to complete. Suggest that the questionnaire(s) may be different from anything the respondent has filled in the past. If the patient still declines, retrieve the questionnaires. Record the reason for the decline and thank the patient. 
The patien t is too ill or weak to complete the questionnaire(s)  
In these instances, the coordinator may obtain patient responses by [CONTACT_90222], followed by [CONTACT_144979], and entering the patient’s response. No help should be provided to the patient by [CONTACT_884191]. The coordinator should not influence patient responses. The study coordinator cannot translate the question into simpler language and has to be read verbatim. 
The patient wants someone else to complete the questionnaire(s)  
In no case should the coordinator or anyone other than the patient provide responses to the 
questions. Unless specified in the study protocol, proxy data are not an acceptable substitute for 
patient sel f-report. Patients should be discouraged from asking a family member or friend for 
help in completing a questionnaire. 
The patient does not want to finish completing the questionnaire(s)  
If non -completion is a result of the patient having trouble understanding particular items, ask 
the patient to explain the difficulty. Re -read the question for them verbatim  but do not rephrase 
the question. If the respondent is still unable to complete the questionnaire, accept it as 
incomplete. Thank the patient. 
[COMPANY_001]  Confidential  Page 120  
Amended Protocol Version v02 Clean  Protocol No. CAIN457H2315 
 
 The pati ent is concerned that someone will look at his/her responses  
Emphasize that all responses are to be kept confidential. Point out that their names do not appear 
anywhere on the questionnaire, so that their results will be linked with an ID number and not their name. Tell the patient that his/her answers will be pooled with other patients’ answers and 
that they will be analyzed as a group rather than as individuals. Tell the patient that completed forms are not routinely shared with treating staff and that their responses will only be seen by [CONTACT_10825] (to check for completeness) and by [CONTACT_093]. Any response which may directly impact on or reflect their medical condition (e.g., noting of severe depression) will be communicated by [CONTACT_884192].  
The patient asks the meaning of a question/item  
While completing the questionnaire, some patients might ask the meaning of specific items so that they can better understand and respond. If this happens, assist the patient by [CONTACT_250374]. If the patient asks to interpret the meaning of an item, do not try to explain it, but suggest that he/she use his/her own interpretation of the question. Patients should answer the questions based on what they think the questions mean. 
General information about all questionnaire(s):  
All questionnaires have to be completed by [CONTACT_811515]. The questionnaires should be completed by [CONTACT_90227] a quiet area free from disturbance, and before any visit assessments. Patients should receive no help from family members; if questions cannot be answered alone (due to problems with reading or understanding), then the doctor or nurse should read the questions and record the patient’s responses without influencing their answers. The information provided is strictly confidential and will be treated as such. If a patient has missed a question or given more than one response per question, then this should be brought to patient. Incomplete questions should not be accepted without first encouraging the patient to complete unanswered questions. 
The investigator must complete the patient/visit information on the electronic device and ensure 
that the center number, patient’s number and initials are identical to the Case Record Form. As there are no source data for this questionnaire, the data queries will be restricted to patient/visit information. 